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 Endocrine disrupting chemicals (EDCs) are compounds in the environment that 
interfere with hormone systems in the body. I investigated if gestational exposure to a 
known class of EDCs, polychlorinated biphenyls (PCBs), resulted in life long alterations 
in neuroendocrine function. My overall hypothesis was that prenatal PCB exposure 
would cause molecular and cellular changes to the developing hypothalamus that would 
manifest across development through differences in hypothalamic gene expression, 
molecular epigenetic modifications, and corresponding effects on sexual development. 
To perform this work, I characterized changes in gene expression in two regions of the 
hypothalamus required for reproductive function throughout the life cycle and measured 
changes in somatic markers associated with reproductive physiology and development. 
This approach allowed me to relate specific neuroendocrine changes back to altered 
reproductive function. First, I present normative data showing gene and hormone changes 
throughout development in male and female rats to use as a basis of comparison for my 
further studies on EDCs. Second, I investigated how gestational exposure to PCBs on 
 viii 
embryonic day 16 and 18 affected development of the hypothalamus through adulthood 
and caused corresponding changes in physiological functions. PCBs altered estrous 
cyclicity in females and delayed the timing of puberty in males. Developmental changes 
in gene expression were associated with sex, age and region of the hypothalamus. As a 
whole, the data suggested that gestational exposure to PCBs altered a network of 
hypothalamic genes and was associated with altered reproductive physiology. Finally, I 
extended my study farther along the life cycle to investigate if gestational exposure to 
PCBs altered the timing of reproductive aging in male and female rats. Few effects in 
males were observed. However, females exposed to PCBs had lower serum 
concentrations of LH on proestrus, and altered expression of numerous genes in the 
hypothalamus. These changes in gene expression were specific to the females’ cycle 
status and the results provided novel insight into the molecular mechanisms underlying 
reproductive aging. Taken together, my dissertation resulted in a comprehensive profile 
of both normal hypothalamic developmental changes, as well as providing insight into 
endocrine disruption of hypothalamic gene networks from birth through aging. 
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Introduction to neuroendocrine systems 
Vertebrates have two systems responsible for communication in the body: the 
nervous system and the endocrine system. The brain is not only the major regulatory 
element for both, but also a mediator between the two systems. The brain coordinates 
inputs from the environment with hormonal outputs from the endocrine system via the 
autonomic nervous system. Endocrine glands in the body are innervated by the autonomic 
nervous system, which controls glandular function in two ways: 1) by regulating blood 
flow into the gland or 2) by regulating the release of hormones from the gland. The 
hypothalamus, located at the base of the brain, is especially important for regulation of 
endocrine function as it serves as an interface between the nervous system and endocrine 
systems, and these endocrine functions that receive a driving input from the brain are 
called “neuroendocrine”. There are two types of neuroendocrine outputs that are involved 
in the control of homeostatic processes. One of these outputs involves the release of 
peptide hormones, specifically vasopressin or oxytocin, from neurons that originate in the 
hypothalamus and terminate at a bloodstream located in the posterior pituitary gland. The 
second neuroendocrine output involves the release of peptide hormones collectively called 




hypothalamus. This vasculature, called the portal capillary system, transports the 
hypothalamic peptides to the anterior pituitary gland, where they bind to specific pituitary 
receptors, a process that in turn results in the synthesis and release of secondary hormones. 
The anterior pituitary hormones then act at peripheral endocrine target glands to cause the 
release of tertiary hormones that affect various functions throughout the body. Along with 
these actions, tertiary endocrine hormones can exert negative feedback onto hypothalamic 
neurons or their inputs to suppress or modify the release of the initial hypothalamic 
hormones. Although all neuroendocrine systems exhibit negative feedback regulation, the 
reproductive hypothalamic-pituitary-gonadal (HPG) system of females has the unique 
ability to exert a positive feedback signal just prior to the time of ovulation (Gore and JL, 
2003).  
Endocrine hormones are essential for the normal development and function of the 
central nervous system (CNS). The prenatal and early postnatal period is particularly 
important in this regard as exposure to hormones during early development results in the 
normal organization and facilitation of many behaviors in the adult organism. Each axis of 
the neuroendocrine system is sensitive to organization at this time as evidenced by the fact 
that disruption of glucocorticoids (Mirescu and Gould, 2004; Mirescu et al., 2004), thyroid 
hormone (Ambrogini et al., 2005; Koibuchi et al., 1999) (Reviewed in (Schantz et al., 
2001)) and sex steroid hormones (Reviewed (Wilson and Davies, 2007)) in the perinatal 
period result in long – term effects on brain function and behavior in the adult. The role of 




responsiveness to hormonal feedback, makes it an important organ to consider when 
studying endocrine disrupting chemicals (EDCs).  
Endocrine-disrupting chemicals (EDCs) are “exogenous chemicals, or mixture of 
chemicals, that interferes with any aspect of hormone action” (Zoeller et al., 2012). 
Disruptions of hormone levels, their receptors or their actions in the brain through 
exposure to EDCs are not only disruptive to the structure and function of the brain itself 
but also to the regulation of hormones downstream from the brain. The mechanisms of 
endocrine disruption are diverse and complex; in the nervous system they probably 
involve actions through hormone receptors, the enzymes involved in the biosynthesis and 
degradation of hormones, and other aspects of hormone regulation. In addition, EDCs can 
be overtly neurotoxic through actions independent (or in addition to) hormone receptors, 
such as through actions neurotransmitter receptors, transporters and biosynthesis. 
The discovery that the synthetic estrogen diethylstilbesterol (DES) can cause 
gynecological cancers and reproductive tract abnormalities in the daughters of mothers 
who took the drug during pregnancy was a landmark finding that demonstrated endocrine 
disruption in humans. It is now recognized that along with effects on the reproductive 
system, EDCs can disrupt numerous hormonal systems in the body including stress, 
thyroid, growth, and other metabolic hormones. This work will focus primarily on 
estrogenic EDCs and their effects on the mammalian brain in vivo. For information 
regarding other hormonal systems refer to the following reviews on thyroid (Zoeller, 
2005); glucocorticoids (Moritz et al., 2005; Schantz et al., 2001); and androgens (Kelce 




effects of EDCs occurs through the two nuclear estrogen receptors, ERα and ERβ, both of 
which are abundant in brain, but which may be differentially affected by EDCs. There are 
also non-nuclear estrogen receptors that may be affected by EDCs. While there are 
numerous families of extensively studied estrogenic endocrine disruptors including, but 
not limited to phytoestrogens, organochlorine pesticides and plasticizers such as bisphenyl 
A, this work will focus on a class of prototypical endocrine disrupting chemicals called 
polychlorinated biphenyls (PCBs). 
Overview of Polychlorinated biphenyls (PCBs) 
 PCBs are synthetic compounds that were manufactured in the United States from 
the 1930’s through 1970’s. They are categorized into two groups, coplanar and non-
coplanar, as per their molecular structure, and they exist in various states of chlorination. 
These structural features affect the ability of PCBs to bind to various hormone and 
neurotransmitter receptors and to act as agonists, antagonists, or mixed 
agonists/antagonists. Although banned in the 1970’s, PCBs are environmentally persistent 
and widely dispersed throughout the globe, including in regions where PCBs were never 
used (e.g., the Arctic) due to populations of animals exposed to PCBs in industrial regions 
that migrate to non-industrial regions and enter the food chain. Additionally, PCBs are 
promiscuous compounds in that they exert actions on multiple classes of neurotransmitter 
and hormonal targets that are not always predictable. Some non-coplanar PCBs affect 
neurotransmitter systems (dopamine, serotonin, acetylcholine). In this way they may 
indirectly affect neuroendocrine functions. Other PCBs (usually coplanar) interact directly 




(Meserve et al., 1992; Schantz et al., 2001)) and sex steroid hormone levels. To make 
matters even more complicated, PCBs are both estrogenic and antiestrogenic as well 
antiandrogenic, an effect that is usually based on the structure of the specific congener 
(Reviewed in (Schantz and Widholm, 2001)). Finally, some “dioxin-like” PCBs may 
interact with orphan receptors such as the aryl hydrocarbon receptor (AhR; Reviewed in 
(Denison and Nagy, 2003)); this makes an understanding of PCB actions even more 
difficult since the endogenous ligand of the AhR is not currently known. It is this diversity 
of interactions that make the PCB compounds such an interesting subject for endocrine 
studies and a potentially dangerous compound for human exposure.  
PCBs actions in the brain during fetal and early postnatal development 
The development of the brain begins in embryonic life and continues through 
puberty into adulthood. Neural development is a carefully regulated sequence of events 
that is controlled by several factors including genes, neurotransmitters, growth factors, 
hormones, and their interactions. Disruption of any one of these events by EDCs can have 
permanent effects on brain morphology and function, resulting in changes to physiology 
and behavior. To follow is a brief summary of the importance of normal pre- and early 
postnatal exposures to steroid hormones, to be followed by how early exposures to EDCs 
can disrupt these processes. 
BRAIN DEVELOPMENT, SEXUAL DIFFERENTIATION, AND THE ROLE OF STEROID 
HORMONES 
The brain is sexually dimorphic, meaning that there are distinct differences in 




permanent and determined during a critical period of sexual differentiation, largely 
through exposures to sex steroid hormones in fetal development or shortly after birth. In 
male mammals, much of sexual differentiation of the brain occurs via activation of the 
fetal testis to release the testicular hormone testosterone. Testosterone and its metabolite, 
estradiol, are responsible for sexual differentiation of the male brain through the actions of 
the metabolic enzyme aromatase, which converts testosterone to estradiol. The brain is an 
organ that has particularly high levels of aromatase, and together with the brain’s high 
expression of both androgen and estrogen receptors, both endogenous and exogenous 
hormones may significantly impact neural function. Under normal developmental 
circumstances, early exposure to gonadal steroids lays the groundwork for the male 
physiology and behavior in the organism; the absence of such exposure results in a female 
phenotype (Reviewed in (Simerly, 1998; Wilson and Davies, 2007)).  
The mechanisms for these effects of steroids in the nervous system are beginning 
to be understood. Steroid hormones, acting as transcription factors, determine which genes 
will be expressed in certain areas of the brain. Additionally, hormones may affect sexual 
differentiation at the cellular level by determining the brain’s capacity to express sex 
steroid hormone receptors in a region and sex specific manner (Simerly, 1998) and cause 
other neurobiological changes such as dendrite outgrowth and synaptogenesis (Reviewed 
in (Matsumoto, 1991; Palanza et al., 1999)). In addition, structural effects of steroids, via 
apoptosis, have been observed in some areas of the brain. This is known to be a factor in 
the development of several sexually dimorphic nuclei in which hormones play an 




these processes determines whether a brain region is masculinized, de-masculinized, 
feminized, or de-feminized, depending upon the sex and the type of exposure. For 
example, testosterone decreases cell death in three sexually dimorphic regions: the spinal 
nucleus of the bulbocavernosus (SNB) in male rats involved in penile erection (Johansen 
et al., 2004); the sexually dimorphic nucleus of the preoptic area (SDN-POA), thought to 
be involved in masculine sexual behavior in rats (Davis et al., 1996a); and the bed nucleus 
of the stria terminalis (BNST), involved in reproductive physiology and behavior and in 
affective behavior pathways (Reviewed in (Simerly, 2002)). On the other hand, 
testosterone increases cell death in the anteroventral periventricular nucleus (AVPV) 
(Reviewed in (Forger, 2006)) thought to regulate preovulatory GnRH release (Wiegand 
and Terasawa, 1982). Several of these aforementioned processes are not mediated by 
testosterone acting on its androgen receptor, but rather, by the metabolism of testosterone 
to estradiol and subsequent actions on estrogen receptors. Several relevant points need to 
be addressed in this regard. First, these early “organizational” effects of sex steroid 
hormones are necessary for the appropriate expression of sex-typical dimorphic behaviors 
later in life including reproductive behaviors such as the lordosis reflex in female rodents 
and mounting behavior in males. These latter behaviors require appropriate exposure to 
steroid hormones not only prenatally in the organizational period, but also pubertally, and 
the manifestation of these behaviors after puberty is referred to as the “activational” 
effects of steroid hormones. Second, early sex hormone exposure organizes other 
dimorphic non-reproductive behaviors such as infant play, aggression, learning, 




The fact that sex steroid hormones play a large role in normal sexual 
differentiation of the brain make early exposure to estrogenic/antiestrogenic and 
androgenic EDCs a potent dysregulator of brain function from genes to behavior. Notably, 
hormonal levels involved in controlling such events are extremely low (1 part per trillion) 
and the fetus is exceptionally sensitive to even the slightest shift in the hormonal milieu. 
Therefore, even the slightest imbalance can have exponential effects (Colbert et al., 1997). 
Because the events of early development are relatively well understood, and the 
developing fetus/neonate is especially sensitive to alterations in hormonal concentrations it 
is not surprising that many of the studies focusing on effects of EDCs on the brain 
examine their role in early development. To follow is such a discussion of the effects of 
PCB exposure in this period, a field often referred to as the “fetal (or developmental) basis 
of adult disease” (Reviewed in (Barker, 2003)). 
PCB EXPOSURE DURING EARLY BRAIN DEVELOPMENT 
The estrogenic nature of PCBs has been known for decades. Exposure to these 
compounds during critical periods in development is especially detrimental to wildlife 
(Ferguson et al., 2000). Additionally, PCBs are lipophilic and so have the potential to 
bioaccumulate in adipose tissue. This is of particular concern when PCBs accumulate in 
tissues of pre-reproductive or reproductive females, because these compounds can be 
transferred to the developing offspring, either via the placenta or postnatally via lactation. 
Therefore, it is not surprising that many of the laboratory experiments examining the role 




term effects on estrogen responsive genes, cellular processes, structural alterations and 
behaviors.  
Gene Expression, Protein Expression and Brain Morphology 
Numerous studies have shown that PCBs can have long-term effects on gene 
expression throughout the body after developmental exposure (Desaulniers et al., 2005; 
Desaulniers et al., 2009; Shimada et al., 2010). Studies from our laboratory showed that 
young adult rats exposed to Aroclor 1221 (A1221) (a mixture of lightly chlorinated PCB 
congeners) during development displayed altered sexually dimorphic expression of key 
genes and proteins involved in reproductive function in the AVPV, a sexually brain 
dimorphic region involved in the control of female ovulation (Dickerson et al., 2011b; 
Salama et al., 2003). Other studies focusing on aromatase activity have found that 
gestational exposure to a mixture of PCBs decrease aromatase activity in the 
hypothalamus of male pups (Hany et al., 1999). Additionally, PCBs may act on 
neurotransmitter systems in the brain, as gestational exposure to A1254 has been shown to 
alter dopamine (Seegal et al., 2005), acetylcholine (Corey et al., 1996; Juarez de Ku et al., 
1994) and serotonin (Morse et al., 1996) systems throughout the adult brain.  
The consequences of EDCs altering protein expression and enzymatic activity 
during development include potentially profound neurodevelopmental effects throughout 
the brain. The effects of PCBs exposure on structural (non-sexually dimorphic) changes 
have been observed throughout the brain and are associated with locomotor (Nguon et al., 
2005; Roegge et al., 2004) and cognitive (Seegal et al., 1994) deficits in adults exposed to 




Reproductive Physiology and Behavior 
Several studies from our laboratory and others have shown that gestational 
exposure to PCBs alters reproductive physiology. Lyche et al (2004), reported that 
PCB153, but not PCB126, decreased prepubertal LH concentrations, delayed puberty and 
resulted in higher progesterone concentrations during ovulation (luteal phase) in 9 month 
old female goats exposed during gestation and lactation (Lyche et al., 2004). Additionally, 
Hany et al. (Hany et al., 1999) found that treatment with a reconstituted mixture of PCBs 
throughout gestation resulted in a decrease in serum testosterone levels in adult male rats. 
Studies from our laboratory have found that serum progesterone and testosterone were 
decreased in adult males exposed to A1221 (Dickerson et al., 2011b) and serum LH was 
increased on estrus in adult females (Steinberg et al., 2008). A1221 has also been shown 
to alter the timing of puberty in males and females (Dickerson et al., 2011b; Gellert, 
1978b), eye opening, estrous cyclicity (Dickerson et al., 2011b) and may advance 
reproductive senescence in females (Gellert, 1978b; Gellert and Wilson, 1979). While 
further investigation is necessary to determine the mechanisms these effects, it is clear that 
gestational exposure to PCBs results in long-term alterations in reproductive physiology.  
These physiological effects may manifest in altered reproductive behavior and 
reduced fertility. For example, neonatal exposure to A1254 reduces sexual receptivity 
(lordosis quotient) while A1221 has no effect (Chung et al., 2001). However, when 
treatment includes pre and postnatal exposure, A1254 decreases sexual motivation and 




These data suggest that timing of exposure is an extremely important parameter to 
consider when analyzing the effects of EDCs on sexual behavior.  
PCBs also alter sexually dimorphic behaviors. For example, when rats are 
exposure to a reconstituted mixture that is similar to that found in human breast milk an 
increase in sweet preference in males was observed. This sexually dimorphic behavior is 
usually increased in females, suggesting that gestational and lactational exposure can 
feminize sexually dimorphic behaviors in adult rats (Hany et al., 1999; Kaya et al., 2002). 
CONCLUSIONS 
Taken together, these data suggest that perinatal exposure to PCBs have 
consequences throughout the brain and these effects are, in many cases, persistent. 
However, it is difficult to interpret these results further as the studies discussed differ in 
many experimental parameters (i.e., dose, age and duration of exposure, nature of 
compound, etc.). The few conclusions that can be made suggest that PCBs have effects on 
neurotransmitter release and metabolism, reproductive function and alter normal 
development (both somatic and cognitive). Further studies are needed to conclusively 
determine how early exposure to PCBs affect brain development and function.  
To address this I designed 3 experiments to determine if gestational exposure to 
PCBs results in sex and age specific effects on the reproductive neuroendocrine axis. 
Chapter 1 provides a description of gene expression profiles in the hypothalamus 
throughout postnatal development (neonatal period – adulthood) in untreated male and 
female rats as well as characterizes changes in sex steroid hormones in the same animals. 




neuroendocrine genes and serum hormone changes, something that was lacking in the 
current literature. This also enabled me to investigate sex and age specific relationships in 
these endpoints and identify novel interactions not previously reported (Walker et al., 
2012). Chapter 2 investigated if gestational exposure to PCBs disrupts development of two 
hypothalamic nuclei necessary for reproductive function in males and females as well as 
identifies functional outcomes of exposure to EDCs. I addressed this by characterizing 
gene expression changes in the hypothalamus in siblings exposed to PCBs in utero and 
relating those to the alterations in reproductive function and physiology, such as the 
altered timing of puberty and estrous cyclicity in males and females respectively. Chapter 
3 expands this study into the paradigm of reproductive aging by relating gene expression 
changes observed in the hypothalamus to the peripheral manifestations of reproductive 
senescence. Taken together, these experiments provide a comprehensive profile of 
neuroendocrine gene expression throughout the life cycle as well as identifying those 
brain regions, genes and hormonal changes that are associated with reproductive 
transitions and may be sensitive to disruption by gestational exposure to EDCs. Finally, I 
was able to identify novel targets of EDCs and determine important players in 





Profiles of Neuroendocrine Gene Expression Throughout Postnatal 
Development in Female and Male Rats  
Significant portions of this chapter were published previously in: Walker DM, Kirson D, 
Perez LF and Gore AC (2012) Molecular Profiling of Postnatal Development of the 
Preoptic Area and Mediobasal Hypothalamus in Female and Male Rats, Biology of 
Reproduction, Oct 3 (Epub ahead of print). 
Contribution of Authors: DMW and ACG contributed equally to this work, DK helped 
with statistical analysis, LFP provided technical assistance. 
Abstract  
Reproductive function is highly dynamic during postnatal developmental. Here, we 
performed molecular profiling of gene expression patterns in the hypothalamus of 
developing male and female rats to identify which genes are sexually dimorphic, to gain 
insight into a more complex network of hypothalamic genes, and to ascertain dynamic 
changes in their relationships with one another and with sex steroid hormones during 
development. Using a low-density PCR platform, we quantified mRNA levels in preoptic 
area (POA) and medial basal hypothalamus (MBH), and assayed circulating estradiol, 
testosterone, progesterone at six ages from birth through adulthood. Numerous genes 
underwent developmental change, particularly postnatal increases, decreases, or 
peaks/plateaus at puberty. Surprisingly, there were few sex differences; only Esr1, Kiss1 
and Tac2 were dimorphic (higher in females). Cluster analysis of gene expression revealed 




measurements showed few sex differences in developmental profiles of estradiol; higher 
levels in progesterone only after P30; and a developmental pattern of testosterone with a 
nadir at P30 followed by a dramatic increase through P60 (males only). Furthermore, 
bionetwork analysis revealed that hypothalamic gene expression profiles and their 
relationships to hormones undergo dynamic developmental changes that differ 
considerably from adults. These data underscore the importance of developmental stage in 
considering effects of hormones on the regulation of neuroendocrine genes in the 
hypothalamus. Moreover, the finding that few neuroendocrine genes are sexually 
dimorphic highlights the need to consider postnatal development from a network approach 
that allows assessment of interactions and patterns of expression. 
INTRODUCTION 
For an individual to be able to reproduce, its reproductive system must be in 
synchrony with favorable external stimuli and internal factors that permit and even 
optimize reproductive success. For example, serum hormone levels and patterns of 
release, adequate nutritional status, and physiological and psychological maturity affect 
reproductive capacity, as do light cycles, seasonal variations, and immune function 
(Ebling, 2005). Of all of the body’s systems, the reproductive system is one of the most 
highly dynamic in the context of the life cycle, with reproductive competence not being 
attained until after a complex and often protracted postnatal developmental and pubertal 
process has occurred. Much of this coordination is orchestrated through a hypothalamic 
neural and glial network that converges upon the gonadotropin-releasing hormone 




example, the onset of puberty is initiated by an increase in the pulsatile release of GnRH 
from these neurons, but GnRH neurons are already mature at birth. This has led to the 
hypothesis that neural and glial inputs to GnRH neurons are responsible for initially 
clamping GnRH release at low levels prepubertally, then enabling pulsatile GnRH release 
to increase postnatally through the progression of puberty (Ojeda et al., 2010c; Terasawa 
and Fernandez, 2001).  
The hypothalamus is structurally and functionally sexually dimorphic (Gorski et 
al., 1980), something that plays out as sex differences in GnRH release, hypothalamic 
neural functioning, and reproductive behavior. Sexual differentiation of the hypothalamus 
is strongly influenced by differential exposure of male and female brains to sex steroid 
hormones in early life (Wilson and Davies, 2007). However, GnRH neurons themselves 
do not express most sex steroid hormone receptors (Hrabovszky et al., 2001; 
Wintermantel et al., 2006). Therefore, effects of developmental steroids on this neural 
network are mediated by afferent inputs to GnRH neurons. Excitatory inputs thought to 
regulate GnRH include kisspeptin (Kiss1), neurokinin B (Tac2) and glutamate, whereas 
inhibitory inputs include the opioid, dynorphin (Colledge et al., 2010; Ojeda et al., 2010b). 
GABA exerts both excitatory and inhibitory influences and this balance may contribute to 
developmental regulation of GnRH (Herbison and Moenter, 2011). Transcription factors 
that activate or repress gene expression also play a key role (Ojeda et al., 2010b). 
Nevertheless, it remains unclear how these and other factors interact to result in the 




There is considerable literature on how peripheral sex hormones, especially 
estradiol and testosterone, regulate gene expression in the hypothalamus. Most of this 
work was conducted in adults, using models of castration and/or hormone treatments 
(Guerra-Araiza et al., 2002; Handa et al., 1996; Lauber et al., 1991a; Lustig et al., 1989; 
McAbee and DonCarlos, 1999b; Navarro et al., 2004; Navarro et al., 2009; Navarro et al., 
2011b; Simerly and Young, 1991; Smith et al., 2006; Tessier et al., 2000; Yuri and 
Kawata, 1991). A separate body of work has addressed how circulating serum hormones 
are involved during sexual differentiation of the brain during early life (Wilson and 
Davies, 2007). However, there is surprisingly little research on the relationship between 
hormones and gene expression throughout postnatal development in an intact model 
(Walker et al., 2009). Considering that the brain remains sensitive to steroid hormones 
postnatally (Sisk and Foster, 2004), during which time there are large changes in both 
hormone and neurotransmitter release, this is an important gap in research. 
While previous studies have measured gene expression in the hypothalamus, and 
characterized circulating hormones, much of this work has been cross-sectional, used few 
ages, did not compare the sexes, or studied one or a few genes. The literature for 
individual genes and hormones varies widely due to these experimental differences. Thus, 
our goal was to provide a more unified perspective on hormones, gene expression, and 
developmental sex differences through quantification of 48 hypothalamic genes and 
assaying serum concentrations of sex steroid hormones in male and female animals across 




MATERIALS AND METHODS 
Animals 
 All animal protocols were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals and approved by The University of Texas at Austin 
Institutional Animal Use and Care Committee. Sex differences in neuroendocrine gene 
expression and serum hormone concentrations were investigated throughout postnatal 
development on postnatal days (P) 1, 5, 15, 30, 45, and 60. Sprague-Dawley rats were 
purchased from Harlan Laboratories (Houston, TX) and impregnated in house. Dams were 
allowed to give birth and on the day after birth (P1) litter composition and birth weights 
were recorded. The study was designed to distribute male and female littermates across as 
many different ages as possible. For earlier time points (P1, 5), two same-sex siblings 
were pooled to ensure enough RNA and serum for all assays. For later time points (P15, 
30, 45, 60) individual rats were used. At P1 and P5, samples from 2 littermates were 
pooled to get a targeted N=8 (see figures for final numbers). A total of 10 litters were used 
to achieve this number. Pups were weaned on P21 and housed in same-sex groups (2-3 per 
cage) with food and water provided ad libitum, at a constant temperature (21- 22 C) with a 
partially reversed light cycle (lights on at 2300h). A secondary sex characteristic of the 
onset of puberty was monitored daily (preputial separation in males and vaginal opening 
in females). After vaginal opening, females were subjected to daily vaginal smears. 
Tissue Collection and Storage 
 Rats were euthanized by rapid decapitation between 10:30 and 11:30 h. 




cytology. Brains were removed and the preoptic area (POA) and medial basal 
hypothalamus (MBH) were dissected using standard brain landmarks as described 
(Dickerson et al., 2008; Jakubowski et al., 1991) and snap frozen on dry ice. Trunk bloods 
were collected, allowed to clot, and serum was separated via centrifugation (1500 X g for 
5 min). Tissues and serum were stored at -80C until use.  
RNA Extraction 
 RNA was extracted from frozen POA and MBH tissues using an in-house double 
detergent lysis buffer system (Jakubowski et al., 1991). Samples were homogenized using 
a 22-gauge needle and 1cc syringe, cytoplasmic RNA was treated with proteinase K, 
extracted with phenol chloroform, and precipitated in ethanol. Resuspended RNA was 
treated with 1 U of TURBO DNase (Applied Biosystems Inc., Foster City, CA) to rid 
samples of genomic DNA. All samples were run on a Bioanalyzer 2100 (Agilent 
Technologies, Santa Clara, CA) to assess RNA purity, integrity and concentration. 
Taqman  Microfluidic Real-time PCR Cards 
 Samples were run on custom-designed microfluidic 48-gene PCR cards (Applied 
Biosystems Inc, Foster City, CA), with specific gene assays chosen based on a priori 
hypotheses and published reports on their importance in neuroendocrine function, timing 
of puberty, steroid hormone responsiveness, and sex differences (46 genes of interest and 
2 housekeeping genes; a complete list is provided in Supplemental Table 3.1). Because it 
is a Taqman PCR-based card, it does not require further PCR validation (which would be 
redundant). Nevertheless, we have previously validated this assay by comparing it with 




identical samples run by the two methods (Walker et al., 2009). Inter- and intra-sample 
variability on the cards is low (Walker et al., 2009) and we have since been using single 
samples because of the high cost of the assay together with its very low variability in our 
hands. Cytoplasmic RNA (2µg) was converted to cDNA using a high capacity cDNA 
reverse transcription kit (Applied Biosystems, Foster City CA) according to 
manufacturer’s protocol. Product was stored at -20 until use at which time samples were 
diluted 1:10 before PCR reactions were conducted. 
 Real-time RT-PCR was carried out on an ABI 7900 using Taqman Universal 
Mastermix (Applied Biosystems, Foster City CA) and the following run parameters: 50C 
for 2 minutes, 95C for 10 minutes, 45 cycles of 94.5C for 30 seconds and 59.7C for 1 
minute. Relative expression was determined for each sample using the comparative Ct 
Method (Livak and Schmittgen, 2001; Pfaffl, 2001; Schmittgen and Livak, 2008). 
Samples were normalized to Gapdh as described previously (Gore et al., 2011; Walker et 
al., 2009) and calibrated to the median delta-Ct of the group with the lowest expression to 
determine fold-change in expression for each gene. 
Serum hormone assays 
 Serum hormone concentrations were measured using radioimmunoassay (RIA) for 
estradiol (E2), progesterone (P4) and testosterone (T) (Beckman Coulter, Webster, TX) 
according to the manufacturer’s recommended protocols. Samples were run in duplicate if 
possible. For the youngest animals (P1 and 5) serum was pooled when necessary to ensure 
there was sufficient serum for all assays. Samples having a CV of 10% or greater were 




sample dropped, P4 = 2 samples dropped). In a few cases, there was not enough serum to 
run all serum hormones for the P1 animals so serum from other P1 animals was used for 
the testosterone and estradiol assays to maintain sample size as close to n=8 as possible.  
For the estradiol assay, two assays were run with assay sensitivity of 2.2 pg/ml and 
intra-assay variability of 4.22% (14 samples) and 4.06% (90 samples). Inter-assay 
variability was 11.49%. For the testosterone assay, two assays were run with assay 
sensitivity of 0.08 ng/ml and intra-assay variability of 2.47% (88 sample) and 3.2% (27 
samples). Inter-assay variability was 36.86%. While the inter-assay variability is high, 
each assay had representatives from each age and sex and there was not a significant 
difference between the two runs in serum concentrations obtained, and group data show 
small standard error bars suggesting that the variability did not affect the validity of serum 
results. These testosterone levels were also in line with those reported previously in our 
laboratory (Walker et al., 2009) and others (Dohler and Wuttke, 1975). For the 
progesterone assay, one assay was run with assay sensitivity of 0.12 ng/ml and intra-assay 
variability of 2.96%. 
Statistics 
For gene expression data, statistics were performed using relative expression for 
each sample. Multiple regression analysis was conducted using PASW software (IBM, 
Armonk NY) to compare each endpoint (genes and hormones) using age and sex as 
independent variables. For those endpoints where a significant main effect of age or a sex 
by age interaction was observed a Tukey-Kramer post hoc analysis was performed to 




for multiple regression, data were transformed (natural log or square root) and reanalyzed. 
In a few cases, transformed data did not meet assumptions for statistical analysis by 
multiple regression. In those cases, data were analyzed using a Kruskal-Wallis test 
followed by Mann-Whitney test between each group. For hormone concentrations an 
effect was considered significant at p<0.05. For gene expression data a Benjamini and 
Hochberg False-Discovery Rate correction (Benjamini and Hochberg, 1995; Benjamini 
and Hochberg, 2000) was used to correct our p-values in order to account for the large 
number of variables measured. Gene expression data were tested for outliers using the z-
score of the residuals from the initial regression. A data point was considered an outlier if 
the residual was greater than 2.5 standard deviations from initial line of best fit.  For 
hormone concentrations, data were tested for outliers using the Grubbs’ outlier test. 
Confirmed outliers were excluded from final analysis. 
To examine possible relationships between gene expression and serum hormones 
throughout development, data were analyzed using a bootstrap technique (Efron and 
Tibshirani, 1993). Briefly, original paired data was resampled with replacement for 1000 
repetitions, and Pearson's correlation coefficient was computed on each of these new 
bootstrapped data sets to build a distribution of coefficients. Significance of Pearson's 
correlation coefficient for each gene/gene or gene/hormone interaction was determined 
from the bootstrapped distributions. Only those correlation coefficients that survived a 
Benjamini and Hochberg False Discovery Rate (Benjamini and Hochberg, 1995; 




bootstrap and subsequent analyses were performed using Matlab (The Mathworks, Natick 
MA) software. 
Hierarchical cluster analysis and heatmaps were performed using Multiple 
Experiment Viewer V4.8.1 (TM4.org) and clusters were validated using R statistical 
packages.  
RESULTS 
Sex Differences in Developmental Profiles of Neuroendocrine Genes in the POA and 
MBH 
Expression of 48 genes was measured by real-time RT-PCR throughout 
development in the POA and MBH of females and males using the Taqman low-density 
array. Of these, only 3 genes exhibited any sexual dimorphism, with a significant age by 
sex effect for Esr1 and Kiss1 in the POA (Figure 1.1A, C), and main effects of sex for 
Esr1, Kiss1, and Tac2 in the MBH.  
In the POA, Esr1 expression was significantly greater (~3-fold) in females than males 
early in development (P1 – P15; p<0.05), a difference that disappeared after adolescence 
(P30 – P60; Figure 1.1A). Additionally, a significant main effect of age was found for 
Esr1 expression, with developmental decreases in both female and male POA, albeit a 
much smaller magnitude of change in males. Kiss1 mRNA (Figure 1.1C) expression was 
also sexually dimorphic in the POA, with significantly greater expression (~3-fold) in 
females when compared to males from P30 – P45 (p<0.01). Additionally, age related 
increases were observed for Kiss1 in both males and females, (~30-fold increase in 




expression in the POA (Figure 1.1E) demonstrated a significant age-related increase, but 
no sex difference. Post-hoc analysis revealed a significant increase (~5-fold) in expression 
from P1 – P15 followed by another significant 2-fold increase from P30 – P45 (p<0.01) in 
both sexes.  
In the MBH, there were significant main effects of sex (p<0.001) and age 
(p<0.001) for Esr1, Kiss1 and Tac2 (Figure 1.1B, D, F) but no significant interactions. 
Esr1 expression was greater in developing females than males, with significant increases 
from P1 – P15 (~2-fold). Kiss1 (Figure 1.1D) expression increased significantly from P1 – 
P15 (~2-fold) and P5 – P30 (~3-fold) in males and females. Females had significantly 
greater Kiss1 expression than males, especially early in postnatal life. There was a trend 
for an interaction of sex and age (p=0.02); however, this effect did not survive a false-
discovery rate correction. Finally, Tac2 (Figure 1.1F) expression was greater in females 
than males (p<0.001) and expression increased ~3-fold from P5 – P15 in both sexes.  
Developmental Changes in Neuroendocrine Gene Expression in the POA and MBH 
 The real-time PCR array contains 2 internal controls for normalization: Gapdh, and 
18s. Both controls displayed small (~20%) but significant age related changes. Therefore, 
we took a conservative approach: only genes that survived a false discovery rate 
correction and displayed greater than a 2-fold change in expression were included for 
further analysis. (This was also taken into consideration in the gene analysis described 
above for Esr1, Kiss1 and Tac2.) In the POA and MBH, 31 and 29 genes, respectively, 
met these criteria. In order to maintain consistency with past publications that used the 




2009). For graphic purposes, genes were categorized into related functional groups (Figure 
1.2). Because no sex differences were observed, data were collapsed across the sexes for 
graphing and analysis. Of those genes undergoing substantial developmental change, the 
most common patterns were a developmental decrease or developmental increase through 
puberty, with regional differences for a subset of genes. 
 In order to determine the relationships among specific genes across postnatal 
development, hierarchical cluster analysis was conducted using MeV 4.8.1 and validated 
using R statistical packages. Clustergrams were constructed using MeV 4.8.1 software 
(Figure 1.3) for each brain region and sex using the correlation coefficients to express 
similarity and the average linkage method. Validated clusters are indicated in red. In 
general, the genes clustered into two broad groups identified from inspection of 
developmental profiles (Figures 1.1 and 1.2): those that decreased from P1 and those that 
increased from P1. Clusters by sex and age reveal sex differences in the POA (Figure 
1.3A) from P30 to P60 that were not observed in the MBH (Figure 1.3B). In the POA 
(Figure 1.3A), males and females clustered together from P1 to P15, but from P30 to P60 
the sexes segregated into two separate clusters. In the MBH (Figure 1.3B), females and 
males clustered together by age from P1 through P60 indicating that while there were few 
sex differences in the expression patterns of gene expression, there were sex differences in 
the correlation of genes in the POA but not the MBH. 
Sex Differences in the Developmental Profiles of Serum Hormone Concentrations 
  Serum concentrations of estradiol (Figure 1.4A), testosterone (Figure 1.4B) and 




gene expression. In both sexes, estradiol concentrations were significantly greater on P15 
when compared to any other time point (p<0.05) but there were no sex differences. In 
males, testosterone exhibited a nadir at P30, followed by a dramatic increase to P60. 
Mann-Whitney post-hoc analysis revealed that concentrations were significantly greater in 
males when compared to females on all days but P30. In females, serum testosterone was 
significantly greater on P15 when compared to all other days. Finally, serum testosterone 
was significantly greater on P60 in males than all other ages, regardless of sex (p< 0.05). 
For progesterone, significant age by sex interactions as well as significant main effects of 
age and sex (p<0.001), were detected. Progesterone concentrations were identical in males 
and females from P1 to P30. From P45 to P60, progesterone levels were significantly 
greater in females than males, as well as all other ages in both males and females (p < 
0.01).  
Integration of genes and hormones as developmental networks 
  To examine the relationship between gonadal hormones and hypothalamic gene 
expression throughout development we used the network analysis platform Cytoscape 
(Cline et al., 2007; Kohl et al., 2011; Yeung et al., 2008) to generate networks based on 
significant Pearson correlation coefficients between hormones and relative gene 
expression in each brain region. Data were first collapsed across the sexes for each age in 
each region to identify relationships that change throughout postnatal development 
regardless of sex (Figures 1.5 and 1.6). In order to display the networks in a legible format 




1.6. For information regarding changes on P1 and P5 in the POA and MBH please see 
(Walker et al., 2012).  
 In the POA, the highest number of significant correlations was detected on P1 
(data not shown) and P30 (Figure 1.5B). On P15, there were a number of negative 
correlations, many of them with sex steroid hormones and their receptors, an effect not 
observed on other ages. From P30 to P60 in the POA, the majority of the correlations were 
positive. Finally on P60, Gnrh1 was negatively correlated with 7 genes; four are growth 
factors or their receptors, two are associated with neurotransmitters (Gabbr2 and Grin2c), 
and one is the steroidogenic enzyme, aromatase p450 (Cyp19a1). In the MBH, there were 
more correlations on P5 (data not shown) than on any other day. Additionally on P15, 
Pdyn was negatively correlated with a number of genes, and on P45 Hsd17b2 was 
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Figure 1.1: Expression of three sexually dimorphic genes is shown in the POA & MBH 
Data are presented for postnatal days (P) 1, 5, 15, 30, 45, & 60) in males (solid lines) and 
females (dotted lines). Data are expressed as fold-change in relative expression, with the 
age/sex having the lowest expression level set at 1.0. Esr1 and Kiss1 had a significant 
interaction of age and sex in the POA (p<0.001), and there were significant main effects of 
age (p<0.001) and sex (p<0.001) in MBH. Tac2 was sexually dimorphic in the MBH only 
(p<0.001), and underwent a significant developmental increase in both regions (p<0.001). 
Significant sex differences for each age are indicated by *. Numbers of rats here and in 
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Figure 1.2: Developmental profiles of non-sexually dimorphic genes in the POA & MBH. 
 
Data are shown 
combined for males 
and females, as there 
were no sex 
differences, and results 
are displayed as 
relative fold-change. 
Genes were graphed as 
functional groups. In 
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Figure 1.3: Hierarchical cluster analysis of gene expression in the POA and MBH 
Analysis was conducted using the correlation coefficients to express similarity and the 
average linkage method was conducted using the Multiple Experiment Viewer V4.8.1 
(TM4.org), and clusters were validated using R statistical packages to reveal genes that 
grouped by expression patterns in the POA (A) and MBH (B). Data are displayed as 
highest expression in yellow and lowest expression in blue and validated clusters are 
indicated in red brackets for genes (to the left of the clustergrams) and for sex and age 
(above the clustergrams). For both POA and MBH, genes clustered into two general 
expression patterns; those increasing from P1 (bottom) or decreasing from P1 (top). In the 
POA, males and females clustered together by age from P1 to P15. However, from P30 to 
P60 the females and males clustered within the sexes. In the MBH, males and females 






Figure 1.4: Serum hormone changes throughout development in male and female rats. 
Serum estradiol (A), testosterone (B) and progesterone (C) concentrations are shown in 
male (solid line) and female (dotted line) rats throughout postnatal development. Serum 
estradiol (A) changed significantly in males and females throughout postnatal 
development (p<0.001) and was highest on P15 in both sexes. Serum testosterone (B) 
changed significantly with age (p<0.001). In males, serum T dropped to a nadir on P30 
and then increased into adulthood whereas in females, serum T peaked at P15 (p<0.05). 
Serum progesterone had significant changes by age (p<0.001); sex (p<0.001) and a 
significant interaction of sex and age (p<0.001). In both sexes, serum P4 increased until 
P30 but diverged thereafter, with levels falling in males and increasing in females. * 
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Figure 1.5: Networks of gene and hormone correlations in the POA. 
Data are shown for those developmental days with the greatest change (P15, 30, 45 and 
60). Positive correlations are indicated as blue solid lines and negative correlations are 
indicated as red dotted lines. Thirteen specific genes and hormones are indicated by the 
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Figure 1.6: Networks of gene and hormone correlations in the MBH. 
Data are shown for those developmental days with the greatest change (P15, 30, 45 and 
60). Positive correlations are indicated as blue solid lines and negative correlations are 
indicated as red dotted lines. Thirteen specific genes and hormones are indicated by the 
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Table 1.1 Abundance of the genes on the Taqman real-time PCR array in the POA. 
To compare abundance of each gene, the average relative expression for each gene was 
determined by using the lowest expressed genes on the plate as a calibrator and calculating 
relative expression for all genes for each animal in the study. Differences in abundance of 
the genes in the POA are sorted from lowest (green) to highest (red) in abundance. The 
original p-value is listed and those genes that survived a False-discovery rate correction 
are indicated in bold. For those genes for which non-parametric analysis was conducted, a 
p-value could not be obtained for sex by age interactions (indicated by N/A). 
Supplemental*Table*1.*Relative*expression*of*neuroendocrine*genes*in*the*POA*(left)*and*MBH*(right)
POA MBH
Gene*Name Gene Symbol Average Age Sex Age X Sex Gene*Name Gene Symbol Average Age  Sex Age X Sex
cytochrome P450, family 17, subfamily A, polypeptide 1 Cyp17a1 4.02 <**0.001 0.476 0.654 cytochrome P450, family 17, subfamily A, polypeptide 1 Cyp17a1 2.57 <0.001 0.171 0.334
hydroxysteroid (17-beta) dehydrogenase 2 Hsd17b2 8.37 <**0.001 0.951 0.913 hydroxysteroid (17-beta) dehydrogenase 2 Hsd17b2 5.41 <0.001 0.145 0.918
gonadotropin-releasing hormone receptor Gnrhr 38.10 <**0.001 0.037 0.808 gonadotropin-releasing hormone receptor Gnrhr 23.05 <0.001 0.553 0.548
vitamin D receptor Vdr 62.14 <**0.001 0.281 0.815 vitamin D receptor Vdr 41.72 <0.001 0.2 0.151
hydroxysteroid (17-beta) dehydrogenase 1 Hsd17b1 136.92 <**0.001 0.061 0.126 hydroxysteroid (17-beta) dehydrogenase 1 Hsd17b1 83.09 <0.001 0.978 0.224
hydroxysteroid (17-beta) dehydrogenase 3 Hsd17b3 157.05 <**0.001 0.019 0.274 cytochrome P450, family 1, subfamily B, polypeptide 1 Cyp1b1 90.85 0.001 0.806 N/A
KiSS-1 metastasis-suppressor Kiss1 266.38 <**0.001 <**0.001 <**0.001 hydroxysteroid (17-beta) dehydrogenase 3 Hsd17b3 167.81 <0.001 0.474 N/A
cytochrome P450, family 1, subfamily B, polypeptide 1 Cyp1b1 328.01 0.003 0.351 0.654 gonadotropin-releasing hormone 1 Gnrh1 208.05 <0.001 0.989 0.428
estrogen receptor 2 Esr2 620.04 0.006 0.879 0.328 estrogen receptor 2 Esr2 274.03 0.004 0.021 0.122
aryl hydrocarbon receptor Ahr 638.38 <**0.001 0.571 0.658 aryl hydrocarbon receptor Ahr 376.03 <0.001 0.996 N/A
KiSS-1 receptor Kiss1r 1228.81 <**0.001 0.975 N/A cytochrome P450, family 19, subfamily A, polypeptide 1 Cyp19a 378.29 <0.001 0.265 N/A
cytochrome P450, family 19, subfamily A, polypeptide 1 Cyp19a 1304.59 <**0.001 0.01 0.627 KiSS-1 metastasis-suppressor Kiss1 549.55 <0.001 <0.001 0.02
brain-derived neurotrophic factor Bdnf 1317.43 <**0.001 0.849 0.95 KiSS-1 receptor Kiss1r 580.63 <0.001 0.616 0.664
estrogen receptor 1 Esr1 1614.99 <**0.001 <**0.001 <**0.001 estrogen receptor 1 Esr1 705.93 <0.001 <0.001 0.334
androgen receptor Ar 1923.49 <**0.001 0.407 0.948 androgen receptor Ar 1626.38 <0.001 0.067 0.689
G protein-coupled estrogen receptor 1 Gper 2367.39 <**0.001 0.221 0.294 G protein-coupled estrogen receptor 1 Gper 1632.56 <0.001 0.273 0.177
progesterone receptor Pgr 3084.07 <**0.001 0.377 0.215 brain-derived neurotrophic factor Bdnf 1702.74 0.001 0.346 0.141
glutamate receptor, ionotropic, N-methyl D-aspartate 2C Grin2c 3710.58 <**0.001 0.718 0.595 progesterone receptor Pgr 2061.15 <0.001 0.39 0.223
steroid sulfatase Sts 3896.34 <**0.001 0.126 0.495 steroid sulfatase Sts 2294.53 <0.001 0.437 0.963
gonadotropin-releasing hormone 1 Gnrh1 4132.63 <**0.001 0.018 0.442 aryl hydrocarbon receptor nuclear translocator Arnt 2851.35 <0.001 0.151 0.891
steroid-5-alpha-reductase Srd5a1 4864.10 <**0.001 0.683 0.447 insulin-like growth factor 1 Igf1 2918.35 <0.001 0.143 0.438
hydroxysteroid (17-beta) dehydrogenase 8 Hsd17b8 5036.75 0.468 0.944 0.264 glutamate receptor, ionotropic, N-methyl D-aspartate 2C Grin2c 3031.44 <0.001 0.381 N/A
aryl hydrocarbon receptor nuclear translocator Arnt 5052.37 <**0.001 0.404 0.3 transforming growth factor, beta 1 Tgfb1 3136.11 <0.001 0.497 0.382
transforming growth factor, beta 1 Tgfb1 5129.44 <**0.001 0.604 0.752 steroid-5-alpha-reductase Srd5a1 3413.19 <0.001 0.706 0.448
insulin-like growth factor 1 Igf1 5342.64 <**0.001 0.889 0.838 tachykinin 2/neuronkinin b Tac2 3642.77 <0.001 <0.001 0.257
galanin prepropeptide Gal 6425.92 <**0.001 0.896 0.416 hydroxysteroid (17-beta) dehydrogenase 8 Hsd17b8 3964.84 0.003 0.73 N/A
transforming growth factor, alpha Tgfa 7565.17 <**0.001 0.628 0.155 transforming growth factor, alpha Tgfa 4133.47 <0.001 0.167 0.503
tachykinin 2/neuronkinin b Tac2 8689.02 <**0.001 0.31 0.35 glutamate receptor, ionotropic, N-methyl D-aspartate 2A Grin2a 4257.73 <0.001 0.45 N/A
glutamate receptor, ionotropic, N-methyl D-aspartate 2A Grin2a 8887.78 <**0.001 0.625 0.192 glutamate receptor, ionotropic, AMPA 3 Gria3 5575.57 <0.001 0.094 0.339
uncoupling protein 2 Ucp2 11400.67 <**0.001 0.436 0.102 insulin-like growth factor 1 receptor Igf1r 6829.86 <0.001 0.055 0.634
glutamate receptor, ionotropic, AMPA 3 Gria3 13549.35 <**0.001 0.075 0.331 glutamate receptor, ionotropic, kainate 2 Grik2 9545.89 <0.001 0.885 0.215
insulin-like growth factor 1 receptor Igf1r 14080.70 <**0.001 0.221 0.494 uncoupling protein 2 Ucp2 10079.10 <0.001 0.434 0.093
glutamate receptor, ionotropic, kainate 2 Grik2 15752.70 <**0.001 0.415 0.491 galanin prepropeptide Gal 11745.90 <0.001 0.019 0.459
prodynorphin Pdyn 22599.81 <**0.001 0.767 0.752 glutamate receptor, ionotropic, N-methyl D-aspartate 2D Grin2d 12219.98 <0.001 0.822 N/A
glutamate receptor, ionotropic, N-methyl D-aspartate 2D Grin2d 22673.04 <**0.001 0.654 0.123 gamma-aminobutyric acid (GABA) B receptor, 1 Gabbr1 14683.43 <0.001 0.134 0.607
gamma-aminobutyric acid (GABA) B receptor, 1 Gabbr1 23348.65 <**0.001 0.131 0.664 glutamate receptor, ionotropic, N-methyl D-aspartate 2B Grin2b 17799.08 <0.001 0.907 0.632
solute carrier family 17 member 6 Slc17a6 27005.37 <**0.001 0.464 0.45 prodynorphin Pdyn 18002.06 <0.001 0.778 0.721
signal transducer and activator of transcription 5B Sta5b 32038.25 0.008 0.776 0.618 gamma-aminobutyric acid (GABA) B receptor, 2 Gabbr2 18292.57 0.012 0.343 0.226
glutamate receptor, ionotropic, N-methyl D-aspartate 2B Grin2b 33098.07 <**0.001 0.171 0.183 signal transducer and activator of transcription 5B Stat5b 20893.90 0.007 0.144 0.458
gamma-aminobutyric acid (GABA) B receptor, 2 Gabbr2 44716.49 0.012 0.278 0.265 glutamate receptor, ionotropic, AMPA 1 Gria1 26192.21 <0.001 0.213 0.668
glutamate receptor, ionotropic, AMPA 1 Gria1 48646.20 <**0.001 0.692 0.577 solute carrier family 17 member 6 Slc17a6 36264.58 <0.001 0.462 N/A
glutamate receptor, ionotropic, N-methyl D-aspartate 1 Grin1 79806.02 0.008 0.956 0.872 glutamate receptor, ionotropic, AMPA 2 Gria2 43672.21 <0.001 0.307 0.84
glutamate receptor, ionotropic, AMPA 2 Gria2 99445.15 <**0.001 0.38 0.901 glutamate receptor, ionotropic, N-methyl D-aspartate 1 Grin1 51638.93 <0.001 0.487 N/A
progesterone receptor membrane component 1 Pgrmc1 217005.91 <**0.001 0.034 0.481 progesterone receptor membrane component 1 Pgrmc1 131080.27 <0.001 0.009 0.234
A complete list of the 48 genes on the Taqman real-time PCR array is shown. To compare abundance for each gene in the 
different brain regions, the average relative expression for each gene was determined by using the lowest expressed gene on the 
plate as a calibrator and calculating relative expression of all genes for each animal in the study. Differences in abundance of the 
different genes in the two hypothalamic regions are sorted from lowest to highest abundance. The 2 housekeeping genes are not 
shown (Gapdh and 18s). The original p-value obtained from the analysis investigating developmental changes is listed for each 
gene nd independent variable/interaction with those surviving a F lse-Discovery Rate correction indicated in bold. Two g nes 
that did not amplify are not shown (Slc17a1 and Hsd3b). For those genes for which non-parametric analysis was conducted, a p-





Table 1.2 Abundance of the genes on the Taqman real-time PCR array in the MBH. 
To compare abundance of each gene, the average relative expression for each gene was 
determined by using the lowest expressed genes on the plate as a calibrator and calculating 
relative expression for all genes for each animal in the study. Differences in abundance of 
the genes in the MBH are sorted from lowest (green) to highest (red) in abundance. The 
original p-value is listed and those genes that survived a False-discovery rate correction 
are indicated in bold. For those genes for which non-parametric analysis was conducted, a 
p-value could not be obtained for sex by age interactions (indicated by N/A). 
Supplemental*Table*1.*Relative*expression*of*neuroendocrine*genes*in*the*POA*(left)*and*MBH*(right)
POA MBH
Gene*Name Gene Symbol Average Age Sex Age X Sex Gene*Name Gene Symbol Average Age  Sex Age X Sex
cytochrome P450, family 17, subfamily A, polypeptide 1 Cyp17a1 4.02 <**0.001 0.476 0.654 cytochrome P450, family 17, subfamily A, polypeptide 1 Cyp17a1 2.57 <0.001 0.171 0.334
hydroxysteroid (17-beta) dehydrogenase 2 Hsd17b2 8.37 <**0.001 0.951 0.913 hydroxysteroid (17-beta) dehydrogenase 2 Hsd17b2 5.41 <0.001 0.145 0.918
gonadotropin-releasing hormone receptor Gnrhr 38.10 <**0.001 0.037 0.808 gonadotropin-releasing hormone receptor Gnrhr 23.05 <0.001 0.553 0.548
vitamin D receptor Vdr 62.14 <**0.001 0.281 0.815 vitamin D receptor Vdr 41.72 <0.001 0.2 0.151
hydroxysteroid (17-beta) dehydrogenase 1 Hsd17b1 136.92 <**0.001 0.061 0.126 hydroxysteroid (17-beta) dehydrogenase 1 Hsd17b1 83.09 <0.001 0.978 0.224
hydroxysteroid (17-beta) dehydrogenase 3 Hsd17b3 157.05 <**0.001 0.019 0.274 cytochrome P450, family 1, subfamily B, polypeptide 1 Cyp1b1 90.85 0.001 0.806 N/A
KiSS-1 metastasis-suppressor Kiss1 266.38 <**0.001 <**0.001 <**0.001 hydroxysteroid (17-beta) dehydrogenase 3 Hsd17b3 167.81 <0.001 0.474 N/A
cytochrome P450, family 1, subfamily B, polypeptide 1 Cyp1b1 328.01 0.003 0.351 0.654 gonadotropin-releasing hormone 1 Gnrh1 208.05 <0.001 0.989 0.428
estrogen receptor 2 Esr2 620.04 0.006 0.879 0.328 estrogen receptor 2 Esr2 274.03 0.004 0.021 0.122
aryl hydrocarbon receptor Ahr 638.38 <**0.001 0.571 0.658 aryl hydrocarbon receptor Ahr 376.03 <0.001 0.996 N/A
KiSS-1 receptor Kiss1r 1228.81 <**0.001 0.975 N/A cytochrome P450, family 19, subfamily A, polypeptide 1 Cyp19a 378.29 <0.001 0.265 N/A
cytochrome P450, family 19, subfamily A, polypeptide 1 Cyp19a 1304.59 <**0.001 0.01 0.627 KiSS-1 metastasis-suppressor Kiss1 549.55 <0.001 <0.001 0.02
brain-derived neurotrophic factor Bdnf 1317.43 <**0.001 0.849 0.95 KiSS-1 receptor Kiss1r 580.63 <0.001 0.616 0.664
estrogen receptor 1 Esr1 1614.99 <**0.001 <**0.001 <**0.001 estrogen receptor 1 Esr1 705.93 <0.001 <0.001 0.334
androgen receptor Ar 1923.49 <**0.001 0.407 0.948 androgen receptor Ar 1626.38 <0.001 0.067 0.689
G protein-coupled estrogen receptor 1 Gper 2367.39 <**0.001 0.221 0.294 G protein-coupled estrogen receptor 1 Gper 1632.56 <0.001 0.273 0.177
progesterone receptor Pgr 3084.07 <**0.001 0.377 0.215 brain-derived neurotrophic factor Bdnf 1702.74 0.001 0.346 0.141
glutamate receptor, ionotropic, N-methyl D-aspartate 2C Grin2c 3710.58 <**0.001 0.718 0.595 progesterone receptor Pgr 2061.15 <0.001 0.39 0.223
steroid sulfatase Sts 3896.34 <**0.001 0.126 0.495 steroid sulfatase Sts 2294.53 <0.001 0.437 0.963
gonadotropin-releasing hormone 1 Gnrh1 4132.63 <**0.001 0.018 0.442 aryl hydrocarbon receptor nuclear translocator Arnt 2851.35 <0.001 0.151 0.891
steroid-5-alpha-reductase Srd5a1 4864.10 <**0.001 0.683 0.447 insulin-like growth factor 1 Igf1 2918.35 <0.001 0.143 0.438
hydroxysteroid (17-beta) dehydrogenase 8 Hsd17b8 5036.75 0.468 0.944 0.264 glutamate receptor, ionotropic, N-methyl D-aspartate 2C Grin2c 3031.44 <0.001 0.381 N/A
aryl hydrocarbon receptor nuclear translocator Arnt 5052.37 <**0.001 0.404 0.3 transforming growth factor, beta 1 Tgfb1 3136.11 <0.001 0.497 0.382
transforming growth factor, beta 1 Tgfb1 5129.44 <**0.001 0.604 0.752 steroid-5-alpha-reductase Srd5a1 3413.19 <0.001 0.706 0.448
insulin-like growth factor 1 Igf1 5342.64 <**0.001 0.889 0.838 tachykinin 2/neuronkinin b Tac2 3642.77 <0.001 <0.001 0.257
galanin prepropeptide Gal 6425.92 <**0.001 0.896 0.416 hydroxysteroid (17-beta) dehydrogenase 8 Hsd17b8 3964.84 0.003 0.73 N/A
transforming growth factor, alpha Tgfa 7565.17 <**0.001 0.628 0.155 transforming growth factor, alpha Tgfa 4133.47 <0.001 0.167 0.503
tachykinin 2/neuronkinin b Tac2 8689.02 <**0.001 0.31 0.35 glutamate receptor, ionotropic, N-methyl D-aspartate 2A Grin2a 4257.73 <0.001 0.45 N/A
glutamate receptor, ionotropic, N-methyl D-aspartate 2A Grin2a 8887.78 <**0.001 0.625 0.192 glutamate receptor, ionotropic, AMPA 3 Gria3 5575.57 <0.001 0.094 0.339
uncoupling protein 2 Ucp2 11400.67 <**0.001 0.436 0.102 insulin-like growth factor 1 receptor Igf1r 6829.86 <0.001 0.055 0.634
glutamate receptor, ionotropic, AMPA 3 Gria3 13549.35 <**0.001 0.075 0.331 glutamate receptor, ionotropic, kainate 2 Grik2 9545.89 <0.001 0.885 0.215
insulin-like growth factor 1 receptor Igf1r 14080.70 <**0.001 0.221 0.494 uncoupling protein 2 Ucp2 10079.10 <0.001 0.434 0.093
glutamate receptor, ionotropic, kainate 2 Grik2 15752.70 <**0.001 0.415 0.491 galanin prepropeptide Gal 11745.90 <0.001 0.019 0.459
prodynorphin Pdyn 22599.81 <**0.001 0.767 0.752 glutamate receptor, ionotropic, N-methyl D-aspartate 2D Grin2d 12219.98 <0.001 0.822 N/A
glutamate receptor, ionotropic, N-methyl D-aspartate 2D Grin2d 22673.04 <**0.001 0.654 0.123 gamma-aminobutyric acid (GABA) B receptor, 1 Gabbr1 14683.43 <0.001 0.134 0.607
gamma-aminobutyric acid (GABA) B receptor, 1 Gabbr1 23348.65 <**0.001 0.131 0.664 glutamate receptor, ionotropic, N-methyl D-aspartate 2B Grin2b 17799.08 <0.001 0.907 0.632
solute carrier family 17 member 6 Slc17a6 27005.37 <**0.001 0.464 0.45 prodynorphin Pdyn 18002.06 <0.001 0.778 0.721
signal transducer and activator of transcription 5B Sta5b 32038.25 0.008 0.776 0.618 gamma-aminobutyric acid (GABA) B receptor, 2 Gabbr2 18292.57 0.012 0.343 0.226
glutamate receptor, ionotropic, N-methyl D-aspartate 2B Grin2b 33098.07 <**0.001 0.171 0.183 signal transducer and activator of transcription 5B Stat5b 20893.90 0.007 0.144 0.458
gamma-aminobutyric acid (GABA) B receptor, 2 Gabbr2 44716.49 0.012 0.278 0.265 glutamate receptor, ionotropic, AMPA 1 Gria1 26192.21 <0.001 0.213 0.668
glutamate receptor, ionotropic, AMPA 1 Gria1 48646.20 <**0.001 0.692 0.577 solute carrier family 17 member 6 Slc17a6 36264.58 <0.001 0.462 N/A
glutamate receptor, ionotropic, N-methyl D-aspartate 1 Grin1 79806.02 0.008 0.956 0.872 glutamate receptor, ionotropic, AMPA 2 Gria2 43672.21 <0.001 0.307 0.84
glutamate receptor, ionotropic, AMPA 2 Gria2 99445.15 <**0.001 0.38 0.901 glutamate receptor, ionotropic, N-methyl D-aspartate 1 Grin1 51638.93 <0.001 0.487 N/A
progesterone receptor membrane component 1 Pgrmc1 217005.91 <**0.001 0.034 0.481 progesterone receptor membrane component 1 Pgrmc1 131080.27 <0.001 0.009 0.234
A complete list of the 48 genes on the Taqman real-time PCR array is shown. To compare abundance for each gene in the 
different brain regions, the average relative expression for each gene was determined by using the lowest expressed gene on the 
plate as a calibrator and calculating relative expression of all genes for each animal in the study. Differences in abundance of the 
different genes in the two hypothalamic regions are sorted from lowest to highest abundance. The 2 housekeeping genes are not 
shown (Gapdh and 18s). The original p-value obtained from the analysis investigating developmental changes is listed for each 
gene and independent variable/interaction with those surviving a False-Discovery Rate correction indicated in bold. Two genes 
that did not amplify are not shown (Slc17a1 and Hsd3b). For those genes for which non-parametric analysis was conducted, a p-





 In the current study, we profiled a network of neuroendocrine-related 
hypothalamic genes and serum hormones in the context of postnatal development of the 
two sexes. Our results revealed novel relationships and surprisingly few sex differences, 
leading us to believe that the developing hypothalamus has very different hormone-
dependent and -independent properties from those in adults. A number of published 
studies have identified sex differences in gene expression (Cao and Patisaul, 2011; 
DonCarlos and Handa, 1994; Kurian et al., 2010b; McAbee and Doncarlos, 1999a, b; 
Poling et al., 2012; Takumi et al., 2011) protein expression (MacLusky et al., 1979; 
Yokosuka et al., 1997) and epigenetic changes (Kurian et al., 2010a; Kurian et al., 2010b; 
Schwarz et al., 2010) in the brain during postnatal development. However, our study 
differs from all other published work in several fundamental ways. Using a real-time PCR 
panel, we were able to study a network of 48 neuroendocrine genes implicated in the 
hypothalamic control of pubertal development, allowing us to do specific hypothesis 
testing about important genes implicated in brain sexual differentiation (e.g., Esr1, Kiss1, 
Tac2) and at the same time, identify potentially novel pathways not systematically studied 
in the hypothalamus. Second, we utilized developing male and female littermates 
distributed across 6 ages chosen to span perinatal, prepubertal, peripubertal and 
postpubertal periods. This type of systematic approach is important because it eliminates 
confounds of over-reliance on littermates within a single age group. Third, we compared 
rostral (POA) and caudal (MBH) hypothalamic regions to enhance understanding of tissue 




same animals, something rarely done in a single study containing both sexes (Dohler and 
Wuttke, 1974, 1975) and not previously in the context of hypothalamic gene expression. 
Therefore, we believe that we are the first to determine not only how numerous 
neuroendocrine genes change over time but also whether and how their relationships 
change in a sex-specific manner, together with their associations with serum hormones. 
Esr1, Kiss1 and Tac2 mRNAs are sexually dimorphic in the hypothalamus 
 One of the most surprising results of this study was that only three of the 48 genes 
analyzed showed significant sexual dimorphisms: Esr1, Kiss1 and Tac2 – all necessary for 
reproductive function and the pubertal transition (Colledge et al., 2010; Ojeda et al., 
2010a; Ojeda et al., 2010c). Furthermore, these genes are co-expressed in the same 
kisspeptinergic neurons in parts of the hypothalamus. More specifically, in the POA, 
nearly all of Kiss1 neurons co-express Esr1, and in the MBH there are a population of 
Kiss1-expressing neurons that also express Tac2 and Pdyn, often referred to as KNDy 
neurons. The KNDy neurons also express Esr1 and are sensitive to fluctuations in 
estradiol (Reviewed in (Garcia-Galiano et al., 2012)). Our findings of robust 
developmental changes in a sex- and region-specific manner support the importance of 
these genes in the maturation of the hypothalamus. 
 In both hypothalamic regions studied, Kiss1 and Tac2 increased developmentally. 
By contrast, Esr1 decreased in the POA, and in the MBH it increased to P30, then 
decreased from P30 to P60. While the decrease in Esr1 expression was surprising, a recent 
study observed a similar expression pattern (Cao and Patisaul, 2011) in several 




nucleus (ARC), and ventromedial nucleus]. Interestingly, knocking out Esr1 specifically 
in kisspeptin neurons advanced the timing of puberty in females (Mayer et al., 2010) 
suggesting that there may be a functional significance to the developmental decrease seen 
in the current study. The sexual dimorphism of Kiss1 and Esr1 found herein replicated 
previous studies in young animals (Cao and Patisaul, 2011; DonCarlos and Handa, 1994; 
Poling and Kauffman, 2012; Takumi et al., 2011). However, one novel finding of our 
study is that Kiss1 and Esr1 are not sexually dimorphic in the adult (P60) POA. Numerous 
studies have shown that Kiss1 is greater in the female AVPV (Reviewed in (Kauffman, 
2009)) of adult animals. However, in the present study Kiss1 expression is only 
significantly greater in the female POA on P30 and 45 (with a trend on P15; p=0.073). 
Additionally, it should be noted that we do not observe sex differences in expression of 
numerous genes that been reported to be sexually dimorphic in the rostral hypothalamus  
(Reviewed in (Simerly, 2002)) including, but not limited to, Esr1 (Orikasa and Sakuma, 
2003) and androgen receptor (McAbee and DonCarlos, 1998, 1999b). We hypothesize that 
these differences are likely the result of differences in experimental design including the 
time of day the animals were euthanized (our animals are euthanized prior to lights out), 
cycle stage of the females (euthanized here on proestrus) and gonadal status (our rats were 
intact). Furthermore, the POA and MBH dissections utilized here include several smaller 
subnuclei that may be differentially regulated by age, sex, and/or hormones something that 
we are currently addressing in ongoing work using hypothalamic microdissections. Even 
within more discrete hypothalamic regions, it is also necessary to recognize the 




phenotypes, glial cells, blood vessels, etc. – requiring interpretation of all data in light of 
this mix of cells. Therefore, a limitation of gene expression work on homogenized tissue is 
the ability to determine specific cellular changes, something that needs to be accomplished 
by other methodologies such as immunohistochemistry, in situ hybridization, or single cell 
profiling. Despite these potential limitations, our results in POA and MBH highlight the 
complex and differential interplay between sex steroid hormones, neuroendocrine genes, 
and hypothalamic region in response to circadian cycles and gonadal status. Indeed, recent 
studies in females suggest that Kiss1 expression is under circadian control in the AVPV of 
female rodents (males were not investigated) (Robertson et al., 2009; Smarr et al., 2012). 
Future studies should include intact animals euthanized at different circadian intervals to 
gain an understanding of these complex interactions.  
There is little published research on dimorphisms of Tac2, found here in the MBH 
but not the POA of our developing rats. While previous work reported that Tac2 is not 
sexually dimorphic in the KNDy neurons in the ARC (Kauffman et al., 2009; Navarro et 
al., 2011a; Navarro et al., 2009), there are the same caveats as mentioned above for Kiss1. 
Furthermore, Tac2 in the MBH and potentially in the KNDy neurons themselves may also 
be sensitive to circadian/estrous regulation. In support of this hypothesis, Tac2 expression 
in the ARC is greatest on proestrus in females (Rance and Bruce, 1994) (again, males 
were not investigated). While the functional role of the KNDy neurons in the ARC is only 
beginning to be understood, Navarro et al. have hypothesized that Tac2 may function as a 
pacemaking signal for Kiss1 release from these neurons (Navarro et al., 2011a; Navarro et 




Developmental non-sexually dimorphic changes in gene expression 
 The PCR platform identified an additional 28 or 26 genes that changed 
significantly and displayed a greater than 2-fold change throughout postnatal development 
in either the POA or MBH, respectively (Figure 1.2). While there were some differences 
in the extent of fold changes observed between the POA and MBH, many of the genes 
shared similar expression patterns throughout postnatal development. However, there were 
notable differences between the two regions. In the POA but not MBH, two genes 
changed significantly with developmental age: Pdyn increased 4-fold  (Figure 1.2C & D) 
and Gria1 (Figure 1.2I & J) decreased 2-fold from P1 to P60. Additionally, two 
steroidogenic enzymes, Cyp1b and Cyp17a1 had different expression patterns in the MBH 
and POA. Cyp1b1 metabolizes 17β-estradiol and Cyp17a1 catalyzes the conversion of 
cholesterol to progestins (Dumas and Diorio, 2011). Differences in these enzymes might 
indicate a drop in local available steroid neurohormones. There is an intriguing body of 
work suggesting that polymorphisms in Cyp17 alleles may be associated with the 
advancement of puberty in young women (Lai et al., 2001; Mitchell et al., 2008), 
implicating this gene in the tempo of reproductive maturation. 
 Interestingly, the few genes on our array implicated in the inhibition of GnRH 
secretion, namely, Pdyn (MBH only), Gabbr1, Gabbr2, Tgfb1 and Pgrmc1 showed little 
change in expression throughout development (data not shown with exception of Pdyn). 
However, genes associated with excitatory inputs to the GnRH system changed 
substantially in the current study. Previously, it has been hypothesized that the onset of 




the GnRH system (Ojeda et al., 2010c; Terasawa and Fernandez, 2001). The current 
findings provide evidence that the mechanisms regulating these inputs may differ in the 
hypothalamus during development. Importantly, in our study the developmental 
expression patterns seen for stimulatory inputs undergo dynamic change, suggesting that 
there is some “reorganization“ of the excitatory inputs and not just a simple increase in 
stimulation to the GnRH neurons. We hypothesize that during postnatal development, 
stimulatory signals may switch to regulation by neuropeptides that are more responsive to 
peripheral changes in sex steroid hormones, including Kiss1, Gal and Tac2, all of which 
increase dramatically during this period. While this hypothesis needs further evaluation, 
our data provide intriguing preliminary evidence of this possibility. Our data also do not 
negate the potential importance of inhibitory neurotransmitters and their relationship to 
postnatal development, as post-transcriptional changes may occur to these factors that are 
not necessarily paralleled by mRNA changes. 
Cluster analysis reveals sex differences in expression patterns 
 We used cluster analysis to evaluate sex and age differences in correlations of 
genes as a way to predict common regulators of expression (Figure 1.3). In general, genes 
in the POA and MBH clustered according to two expression profiles: those that increased 
from P1 (bottom cluster) or decreased from P1 (top cluster). Interestingly, in the POA 
males and females cluster together by age on P1, P5 and P15 but the two sexes cluster 
separately from P30 to P60 suggesting that sex differences in correlations in the POA 
emerge after P30. This effect was not observed in the MBH where the males and females 




evidence that sexual dimorphisms in expression in the POA are age dependent and that the 
developmental stage of the animals should be taken into account in conducting sex 
differences studies.  
Sex differences in serum hormone concentrations 
 Developmental concentrations of sex hormones have previously been described in 
rodents (Dohler and Wuttke, 1974, 1975; Lieberburg et al., 1979; Piacsek and Goodspeed, 
1978; Poling and Kauffman, 2012; Saksena and Lau, 1979; Vomachka et al., 1981; 
Walker et al., 2009), but to our knowledge only one previous publication has characterized 
sex differences in the 3 major gonadal hormones across development within a single study 
(Dohler and Wuttke, 1975). Concentrations of E2, P4 and T in our rats were quite similar to 
those from the literature, and with only one exception (discussed below), postnatal 
patterns and sex differences were also consistent with the published literature. 
Other reports of postnatal developmental changes in circulating E2 demonstrate that levels 
are at their highest early in life and then experience a decrease, but the exact age at which 
the peak occurs varies among studies. Two groups (Dohler and Wuttke, 1975; Konkle and 
McCarthy, 2011) reported that E2 levels were highest on P1, declined over the next few 
days, then had a smaller peak at about day 9, falling again thereafter. When we measured 
serum E2 levels at P1, 5, 15, 30, 45 and 60 in males, our results matched those of these two 
other groups, with an overall decrease from P1 through P30 (Walker et al., 2009). By 
contrast, in the current study, E2 concentrations were highest in both sexes on P15. The 
developmental changes in serum E2 observed here were also similar to those reported for 




conclusion that we draw from current and past work is that serum estradiol concentrations 
are similar in developing female and male rats, and that they undergo a decrease as the 
animals mature. While we do not know the explanation for differences among studies, 
they may be attributable to intrauterine position, prenatal litter size and sex ratio; postnatal 
litter composition, including pup numbers and sex ratio after culling of litters; time of day 
that animals were euthanized; or differences in hormone binding proteins such as alpha-
fetoprotein, among others. 
Serum testosterone (T) in the current study was greater in males than females for 
most of postnatal development with the exception of P30 when male T concentrations 
dropped to undetectable levels. This finding in males replicated our and others’ previous 
reports (Dohler and Wuttke, 1975; Walker et al., 2009). Additionally, we noted a 
significant peak of T in females on P15, similar to earlier work (Dohler and Wuttke, 
1975).  
Likewise, our results on serum P4 were consistent with the literature (Dohler and 
Wuttke, 1974, 1975). We observed significant sex differences in serum P4 after puberty, 
with much higher P4 concentrations observed in females on P45 and P60. Again similar to 
previous findings, serum P4 peaked in male rats on P30, the same day when serum T is 
undetectable in males (Dohler and Wuttke, 1974, 1975; Walker et al., 2009). Taken 
together, these data provide important developmental time points that may be important 




Network analysis of genes and hormones reveals novel interactions during postnatal 
development 
 As in our previous study (Walker et al., 2009), we noticed that a number of genes 
reported to be regulated by steroid hormones displayed developmental patterns that 
diverged from predicted relationships to specific serum hormone concentrations. For 
example, Pgr (progesterone receptor) is regulated by Esr1 and its ligand E2 in numerous 
areas of the female brain but not the male brain (Guerra-Araiza et al., 2002; Lauber et al., 
1991b, c). However, in our study serum E2 decreased from P15 to P45, a time when Pgr is 
unchanged in both the male and female POA and MBH. Therefore, we used Cytoscape to 
assemble networks of genes and hormones with significant correlations according to 
developmental age in the hopes of generating new hypotheses about how genes and 
hormones interact in an intact rat model throughout development. Furthermore, because 
expression of a gene is not necessarily paralleled by expression of its protein product, 
results on genes that undergo developmental change and/or sex differences should be 
followed up by western blotting or immunohistochemistry. In fact, we hope that our gene 
bionetwork results will serve as a resource to guide future experimentation in this arena. 
Here, to simplify our model, we combined data from the two sexes and highlighted 
thirteen selected endpoints (indicated in larger font and bold text in Figures 1.5 and 1.6) to 
facilitate the identification of regulatory networks. However, we present the entire 
network so that readers can search for relationships among other endpoints of interest. 
This network analysis showed surprising interactions among hormones and sex steroid 
hormone receptors that challenge the traditional dogma of how sex steroid hormone 




development is Pgr positively correlated with E2 (in fact, on P5 in the POA, Pgr is 
negatively correlated with E2). With the exception of the P15 POA, it is rare that any of 
the serum hormones serves as a regulatory hub in either the POA or the MBH. As a whole, 
the network analysis shows the complexity of sex steroid hormone interactions with gene 
expression in the brain of developing rats. 
 Because sex steroid hormone receptors are necessary for sexual differentiation of 
the brain (Reviewed in (Simerly, 2002)) and reproductive function (Reviewed in (Garcia-
Galiano et al., 2012)) we expected that they would be major hubs in our networks 
throughout postnatal development. However, this was rarely the case. One exception was 
Esr2 (estrogen receptor beta), which was a hub at every age in the POA except P15. 
Another consistent relationship that was observed throughout development in both the 
POA and MBH was between Pgr with Ar (androgen receptor), and P4 with T.  On P1, P45 
and P60 in the POA and P1, P5 and P45 in the MBH, Ar and Pgr are positively correlated, 
but at P45 and P60, serum T and P4 are negatively correlated. Together with similar results 
from a previous study (Walker et al., 2009), our data indicate that there is a strong 
relationship between Ar and Pgr that deserves further investigation.  
SUMMARY AND CONCLUSIONS 
Previous work investigating relationships among hormones and gene expression 
has relied almost entirely upon models of gonadectomy, with or without hormone 
treatment, with most work done on adults. Our studies of intact developing male and 
female rats represent a different perspective and revealed several surprising results. First, 




throughout postnatal development. Second, the subset of genes that was sexually 
dimorphic (Esr1, Kiss1, Tac2) represents a defined category of molecules implicated in 
the control of postnatal reproductive development (Colledge et al., 2010). Third, we 
identified novel relationships of sex steroid hormones, their receptors, and neuropeptides 
in the POA and MBH indicating a complex mechanism of regulation that is dependent on 
the developmental time point and sex. The correlation and network analysis approaches 
can be used to generate hypotheses for future testing in studies of postnatal development 






Neuroendocrine disruption of postnatal development caused by prenatal 
PCBs in female and male rats 
ABSTRACT 
Polychlorinated biphenyls (PCBs) are a class of synthetic compounds developed in 
the 1930s for industrial use. Although use of PCBs was banned in the US in the 1970s, 
many congeners remain in the environment and human exposure is ubiquitous through 
contact with contaminated soil, water and food sources. Studies from our laboratory and 
others have found that gestational exposure to Aroclor 1221 (A1221), a commercially 
available mixture of lightly chlorinated PCBs, has long term effects on the neuroendocrine 
reproductive system including altering serum hormone concentrations, estrous cyclicity, 
gene and protein expression, female reproductive behaviors, the timing of puberty and/or 
reproductive senescence and sexual differentiation of the hypothalamus. We tested the 
hypothesis that early life exposure A1221 alters development of the hypothalamus that 
results in altered reproductive function. Pregnant Sprague-Dawley rats were injected on 
embryonic day 16 and 18 with vehicle (DMSO), A1221 (1mg/kg) or estradiol benzoate 
(EB) (50µg/kb) as an estrogenic control. After birth, developmental milestones such as the 
timing of puberty and estrous cyclicity were recorded throughout the life cycle. On 
postnatal days (P) 15, 30, 45, and 90, 1 male and 1 female from each litter was euthanized. 
Punches from two brain regions important for reproductive function were collected: 
anteroventral periventricular nucleus (AVPV) and the arcuate nucleus (ARC) and frozen 
for assessment of mRNA expression of a panel of 48 neuroendocrine genes and analysis 




puberty in males and disrupted estrous cyclicity in females. This was associated with 
disruption of gene expression in the AVPV of females and ARC of males. We also 
identified novel targets of PCBs, including two clock genes Arntl and Per2, which 
displayed a male-typical expression profile in the female AVPV. However, DNA 
methylation of regulatory regions of 2 genes (Per2 and Ar) displaying sex specific 
disruptions of expression in the AVPV was not disrupted. 
INTRODUCTION 
 In order for an individual to attain reproductive competency a myriad of tightly 
coordinated processes must occur beginning in embryonic development and continue 
throughout adulthood. While the entire hypothalamic-pituitary-gonadal (HPG) axis 
undergoes dynamic changes, it is the hypothalamus that integrates internal and external 
stimuli, including metabolic status, serum hormone concentrations, stressors, social 
conditions, circadian indicators and immune function, which lead to and optimize 
reproductive capacity in adulthood (Ebling, 2005). This dynamic process is organized 
during the embryonic/postnatal period and activated during the pubertal process, which 
culminates in the increased synthesis and release of gonadotropin-releasing hormone 
(GnRH), the obligatory decapeptide for reproductive function (Reviewed in (Ojeda et al., 
2010c)). However, GnRH neurons are mature at birth (Wray, 2002). Therefore, it is 
hypothesized that a complex neural and glial network that converges onto these neurons is 
responsible for 1) suppressing GnRH release prepubertally, 2) enabling the increase in 
pulsatile release during the pubertal process and 3) maintaining its release in adulthood 




coordinates the downstream effectors of reproductive function, postnatal developmental 
changes in gene expression (Cao and Patisaul, 2011; McAbee and DonCarlos, 1998; 
Navarro et al., 2004; Navarro et al., 2012; Sladek et al., 2004; Tena-Sempere et al., 2001; 
Walker et al., 2009; Walker et al., 2012), protein expression (Davis et al., 2004; Quadros 
et al., 2002; Sladek et al., 2004; Yokosuka et al., 1997), epigenetic processes (Nugent et 
al., 2011; Schwarz et al., 2010), and morphology (Abeliovich and Beal, 2006; Davis et al., 
1996a; Davis et al., 1996b) have been characterized in the hypothalamus of the developing 
rodent. 
The hypothalamic neuronal network controlling reproduction is also sexually 
dimorphic (Wilson and Davies, 2007). These differences result in sex differences in 
response to peripheral cues and culminate in male- and female-typical reproductive 
function, physiology and developmental processes (Clark et al., 1993; Pignatelli et al., 
2006; Sisk and Zehr, 2005). Sexual differentiation of the brain is highly influenced by sex 
steroid hormones during a critical period of gestation/early postnatal development. 
Although many sexual dimorphisms do not manifest until much later in life following an 
activational period, it is during this organizational sensitive period that the brain is 
permanently masculinized/defeminized or feminized/demasculinized (Davis et al., 1996a; 
Davis et al., 1996b; Jacobson et al., 1980; Rhees et al., 1990a, b). Mounting evidence 
suggests that sexual differentiation of the brain involves epigenetic mechanisms, including 
DNA methylation and chromatin remodeling, which “program” gene expression in a 
male/female typical manner through the actions of sex steroid hormone with their 




exposure to endocrine disrupting chemicals (EDCs) during this critical period of brain 
developmental can result in life-long effects on reproductive physiology and behavior by 
“programming” the expression of sexually dimorphic genes that are necessary for female 
and male typical reproductive function. 
EDCs are defined as “an exogenous chemical, or mixture of chemicals, that 
interferes with any aspect of hormone action” (Zoeller et al., 2012) and include a variety 
of plastics, plasticizers (phthalates and BPA), pharmaceuticals (e.g., DES), pesticides 
(DDT, methoxychlor) and industrial contaminants (PCBs, dioxins), among others. Here, 
we investigated if exposure to an environmentally relevant dose of lightly chlorinated 
PCBs, Aroclor 1221 (A1221), alters the developmental profiles of gene expression in two 
nuclei in the hypothalamus known to regulate reproductive function – the anteroventral 
periventricular (AVPV) and arcuate (ARC) nucleus - and identify relationships between 
gene expression and peripheral changes in endocrine tissues and reproductive physiology. 
The AVPV and ARC are subregions of the gross hypothalamic dissections investigated in 
Chapter 1. Here we used micropunches of hypothalamic regions in order to characterize 
expression changes in more refined regions of the rostral and caudal hypothalamus and 
reduce heterogeneity of our tissues. While numerous studies have investigated how 
gestational exposure to EDCs alters reproductive physiology and gene expression in the 
brain in adulthood (Reviewed in (Dickerson et al, 2007)) we are the first to develop a 
comprehensive developmental profile (Postnatal day (P)15 – P90) of a suite of 48 
neuroendocrine genes in these two brain regions that directly regulate GnRH synthesis and 




mechanisms, namely DNA methylation, that may play roles in the programming of these 
long-term alterations caused by prenatal PCBs. Finally, we identify novel targets of EDCs 
in the hypothalamus, namely 2 clock genes Arntl and Per2, which are programmed in a 
male typical pattern in the female AVPV after exposure to estrogenic compounds. Taken 
together, these data not only highlight mechanisms of estrogenic EDCs but also provides 
us with novel information regarding the functional significance of the AVPV and ARC in 
male and female rats. 
MATERIALS AND METHODS 
Animals 
 All animal protocols were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals and approved by The University of Texas at Austin 
Institutional Animal Care and Use Committee. Animals in this study were part of a larger 
study and were siblings of those discussed in a recent publication. For detailed methods on 
animal husbandry and the generation of individuals in this study see (Chapter 3). Briefly, 
Sprague-Dawley rats (3-4 month virgin females) were purchased from Harlan 
Laboratories, switched to low phytoestrogen Harlan-Teklad 2019 Global Diet ad libitum 
(Houston, TX) and impregnated in house. Rats were given at least 1 week to adjust to the 
new diet and environment before mating and were usually on the new diet for 2-3 weeks 
before conception. On embryonic day (E)16 and E18, (E1 = day after successful mating) 
dams were weighed and randomly assigned to one of 3 treatment groups and injected with 
0.1ml vehicle (DMSO 99.5% Sigma #D4540); 50 µg/kg estradiol benzoate as a positive 




#C221N). Doses, routes and timing of exposure were chosen based on previous work in 
our laboratory (Dickerson et al., 2011a; Dickerson et al., 2011b; Steinberg et al., 2007; 
Steinberg et al., 2008) and others (Chung and Clemens, 1999; Gillette et al., 1987a; 
Gillette et al., 1987b; Murugesan et al., 2005a; Murugesan et al., 2005b). Based on 
previous literature (Takagi et al., 1986), we estimate that each pup is exposed to ~1:500 of 
the dose (i.e., 2 µg/kg A1221 or 100 ng of EB) which is within the range human exposure 
in utero (1 - 9 ppb ) (Karmaus and Zhu, 2004; Lackmann, 2002; Law et al., 2005; 
Longnecker et al., 2005; Schantz, 1996). Animals were housed under constant humidity 
and temperature (21-22°C) with a partially reversed 12:12 light cycle (lights on at 23:00). 
On the day after birth (postnatal day (P) 1), litter composition, birth weights and 
anogenital distance were recorded, and the litters were culled to equal sex ratios with a 
goal of 6 males and 6 females per litter. Body weights were monitored weekly and 
anogenital distance was measured weekly until weaning. Pups were weaned on P21 and 
housed with same sex littermates (2 -3 per cage). Rats were monitored for a secondary sex 
characteristic of the onset of puberty daily (preputial separation in males and vaginal 
opening in females). Following the onset of puberty, estrous cycles were monitored in by 
daily vaginal smears. Investigators were blind to treatment throughout the experiment. 
Because of the large number of animals necessary for both studies, animals were raised in 
5 cohorts with treatments equally distributed across each cohort. 
Tissue Collection and Storage 
On P15, 30, 45 and 90 male and female littermates were euthanized approximately 




endocrine tissues were removed and weighed. Those females who were postpubertal were 
euthanized on proestrus. Because not every litter had 6 males and 6 females each litter 
may not have been represented at each age which resulted in the final sample sizes varied 
for each age. Therefore we present a range of sample sizes for each treatment: DMSO: 14 
- 20; EB: 15 - 21; A1221: 18-25. However, only a subset of 8 animals per group were used 
for gene expression. Brains were removed, sectioned and punches were collected using 
previously reported methods (Chapter 3). Trunk bloods were allowed to clot, and serum 
was separated via centrifugation (1500 X g for 5 min). Tissues and serum were stored at -
80°C until use.  
Extraction of nucleic acids and preparation for PCR and pyrosequencing 
 DNA and RNA were extracted from frozen AVPV and ARC punches of males and 
females using a Qiagen Allprep DNA/RNA mini kit according to manufacturer’s 
protocols. RNA samples were eluted with RNase free water and treated with 1 U of 
TURBO DNase (Applied Biosystems Inc., Foster City, CA) to rid samples of genomic 
DNA before ethanol precipitation. Resuspended samples were diluted to a concentration 
of 50 ng/µl based on concentrations obtained from both nanodrop and Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA) data which was also used to access purity and 
integrity. DNA samples obtained from Qiagen kits was diluted to 20ng/µl and 500ng of 
DNA were shipped to EpigenDX (Worcester, MA) for bisulfite conversion and 
pyrosequencing of Per2 (2 assays: ADS3539 (-597 - -550bp from transcription start site 
(TSS)); ADS872 (-111 - +173bp from TSS) and Ar (1 assays: ADS070F (-70 - +39bp 




Taqman  Microfluidic Real-time PCR Cards 
 RNA samples (200ng) were converted to cDNA using a high capacity cDNA 
reverse transcription kit (Applied Biosystems, Foster City CA) according to 
manufacturer’s protocol and run on custom-designed microfluidic 48-gene PCR cards 
(Applied Biosystems Inc, Foster City, CA). Specific gene assays were chosen based on a 
priori hypotheses and published reports on their importance in neuroendocrine function 
and sensitivity to disruption by EDCs (46 genes of interest and 2 housekeeping genes; 
Tables 2.3 & 2.4).  
 Real-time PCR was carried out on an ABI ViiA7 using Taqman Universal 
Mastermix (Applied Biosystems, Foster City CA) and the following run parameters: 50°C 
for 2 minutes, 95°C for 10 minutes, 45 cycles of 95°C for 15 seconds and 60°C for 1 
minute. Relative expression was determined for each sample using the comparative Ct 
Method (Livak and Schmittgen, 2001; Pfaffl, 2001; Schmittgen and Livak, 2008). 
Samples were normalized to 18s (the other housekeeping gene, Gapdh is sexually 
dimorphic in the AVPV) and calibrated to the median delta-Ct of the group with the 
lowest expression to determine fold-change in expression for each individual. 
Serum hormone assays 
 Serum hormone concentrations were measured in the same radioimmunoassays as 
those presented in Walker et al., 2012 (Chapter 3). A brief description of the methods are 
included here. Serum LH was measured in duplicate 50 µl samples in the laboratory of Dr. 
Michael Woller, University of Wisconsin-Whitewater, by double antibody competitive 




(MP Biomedicals) and estradiol (Beckman Coulter, Webster, TX) and were measured in 1 
(intra-assay CV =1.397%) and 2 (intra-assay CV = 6.48% and 1.64%; inter-assay CV = 
4.55%.) assays respectively. Sensitivity of the testosterone assay was 0.3ng/ml and 
estradiol was 2.2 pg/ml.  
Statistics 
Multiple regression analysis was conducted using PASW software (IBM, 
Armonk NY) to compare each endpoint (genes, hormones, DNA methylation and 
endocrine tissues) using age, sex and treatment as independent variables. For gene 
expression data, statistics were performed using relative expression values for each 
sample. For those endpoints where a significant main effect of age, sex or treatment or an 
interaction was observed data were split by independent variables and follow-up analysis 
was performed to determine specific differences between each group. If data did not meet 
the assumptions for multiple regression analysis, data were transformed (natural log or 
square root) and reanalyzed. In a few cases, transformed data did not meet assumptions for 
statistical analysis by multiple regression. In those cases, data were analyzed using a 
Kruskal-Wallis test followed by Mann-Whitney test between each group. Because 
interactions can not be investigated using non-parametric testing, when a group effect was 
detected, data were split by significant variables and follow-up analysis was performed. If 
non-parametric testing was used for analysis independent variables are listed as 
Sex/Age/Treatment (Trt) rather than using an “X” to indicate interactions. For hormone 
concentrations an effect was considered significant at p < 0.05. For gene expression data a 




1995; Hochberg and Benjamini, 1990) was used to correct our p-values to account for the 
large number of variables measured. Parametric data were tested for outliers using the z-
score of the residuals from the initial regression. A data point was considered an outlier if 
the residual was greater than 2.5 standard deviations from initial line of best fit. Non-
parametric data were tested for outliers using the Grubbs’ outlier test. Confirmed outliers 
were excluded from final analysis. 
Vaginal smear data were analyzed using the same rule-based pattern matching 
techniques utilized previously (Chapter 3) to determine number and length of each cycle 
for each animal. Cycles were identified for each animal by scanning the smear data from 
the day of vaginal opening until euthanasia for the diestrus 2 to proestrus transition. The 
make-up and length of each cycle was recorded throughout the lifecycle. A repeated 
measures ANOVA was conducted using the moving average of the cycle length (using 
three cycle lengths) for each animal to account for any missing data. The output of this 
analysis was also used to investigate subtle differences in the cycles of each animal. This 
was accomplished by categorizing every unique cycle observed in each animals and 
comparing the categories of smears across different animals. This enabled us to look for 
series that were common to all animals and provide us with information regarding the 
composition of regular/irregular smears and determine if specific irregular series were 
more likely to occur in treated vs control females. Differences were analyzed using a Chi 





Hierarchical cluster analysis was performed and heatmaps were generated using 
Multiple Experiment Viewer V4.8.1 (TM4.org) and clusters were validated using R 
statistical packages. 
 To determine if developmental gene expression profiles in females and males from 
each treatment were similar to control animals, gene expression data (sex X treatment) 
was compared using two methods, both implemented as Python scripts. The first method 
used Bayesian analysis to compare 2 developmental profiles (control vs treatment) and 
Bayes factors were computed as an indicator of the probability that gene expression data 
for two groups is generated by the same normal distribution (marginalized over mean and 
variance), versus the probability that the gene expression data is generated by two 
different normal distributions (marginalized over their parameters). A low (0-5), or 
negative, Bayes factor, expressed in decibans (dB), indicates no meaningful difference 
between the groups, whereas a high Bayes (over 20) factor indicates a high probability 
that each group’s expression data was generated by a different distribution. 
The second comparison method used an ad hoc measure of “distance” between the 
gene expression curves. A piecewise-linear curve for each group was generated using the 
average expression at each age, with ages along the x-axis and expression level along the 
y-axis. As a measure of “distance” between curves, the area between the curves was 
calculated using the geometric formulas for the area of a polygon.  
Taken together, the 2 methods allowed us to compare the developmental profiles 
between the 2 sexes. While Bayes factors measure the probability that gene expression 




sensitive to any one age group being different from each other. Therefore, in order to 
reduce the number of false positives, we used the area-between-curves as a way to confirm 
that the 2 sexes were similar or different as it is a measure of the actual difference between 
average gene expression levels. We assumed that a group was similar to the other if the 
area between the curves was reduced by 50% when compared to the control counterparts. 
Results 
 Littermates exposed to A1221 in utero were monitored from birth through 90 days 
of age to determine if exposure to environmental endocrine disrupting chemicals alters 
hypothalamic development and reproductive function. Changes in endocrine tissues, 
female estrous cycles and timing of developmental transitions were monitored. To 
ascertain potential molecular mechanisms underlying the developmental effects of EDCs, 
expression of 48 genes were measured in 2 brain regions that are important for 
reproductive function: AVPV and ARC. We also investigated if developmental changes in 
DNA methylation of the Ar and Per2 promoter regions were altered after exposure to 
EDCs in utero. In the AVPV and ARC, 28 and 12 genes, respectively, were changed by 
treatment (main effect or interaction p < 0.05). Of those affected by treatment, 18 genes in 
AVPV and 2 genes in the ARC survived a Benjamini and Hochberg False-Discovery Rate 
correction (Benjamini and Hochberg, 1995; Benjamini and Hochberg, 2000) and are 
indicated in bold in tables 2.3 and 2.4. However, because genes were specifically chosen 




 Effects of EDCs on somatic and reproductive development 
 In males and females, treatment resulted in sex specific effects on the timing of eye 
opening (female only) and puberty (males only) (Table 2.1). Significant sex differences 
were detected for each endpoint. Therefore, follow-up analysis investigated sex specific 
effects of treatment using a 1-Way ANOVA for treatment. In males, treatment 
significantly delayed the timing of puberty as measured by preputial separation (p = 
0.017) and post-hoc analysis revealed the effect to be specific to males exposed to A1221 
compared to controls. In females, the timing of eye opening was delayed by treatment (p = 
0.027). Post-hoc analysis revealed the effects were specific to females exposed to A1221. 
Treatment effects were also observed on estrous cycles. When compared to DMSO 
controls, females exposed to EB were less likely to be classified as having regular cycles 
(at least 70% of their cycles were regular) (p = 0.008); more likely to have an abnormal 
period of diestrus (6 or more days of L) (p = 0.021); more likely to transition from a 
leukocytic to cornified smear (p = 0.003) and have at least 2 elongated series of cornified 
and/or leukocytic smears (at least 5 days of C and/or L) (p = 0.023). Whereas, females 
exposed to A1221 were more likely to have at least 2 elongated series of cornified and/or 
leukocytic smears (at least 5 days of C and/or L)  (p = 0.096) when compared to DMSO 
controls.  
 Treatment had sex and age specific effects on endocrine tissues and serum 
hormone concentrations. Males exposed to EB (p = 0.122) and A1221 (p = 0.05) had 
lower serum concentrations of LH on P15 and increased adrenal weights on P30 (p = 




somatic index (GSI) (p = 0.079). Females exposed to EB showed a trend for lower serum 
estradiol on P15 (p = 0.07) and significantly higher adrenal weights on P30 (p = 0.025). 
No effects of A1221 were observed in females and no effects of treatment were observed 
in P45 or P90 in either males or females. 
Treatment alters gene expression in genes necessary for reproductive function in the 
female AVPV but not the ARC 
 Kiss1, Tac2, Esr1 and Pdyn are expressed in the same neurons in the ARC 
(Navarro et al., 2009) whereas, in the AVPV only Kiss1 and Esr1 are expressed in the 
same neurons (Mayer et al., 2010). Treatment resulted in age and sex specific effects on 
expression of all four genes in the AVPV (Figure 2.1 left panel) but not the ARC (Figure 
2.1 right panel). To make the figure more legible, expression in the ARC was collapsed 
across treatments. For expression in individual treatments in the AVPV and ARC as well 
as p-values for all main effects and interactions see Tables 2.3 (AVPV) and 2.4 (ARC). In 
the AVPV, a significant effect of treatment (main effect or interaction) was observed for 
all 4 genes (Kiss1: Sex/Age/Trt < 0.001; Tac2: Sex/Age/Trt < 0.001; Esr1: Age X Trt: p = 
0.053; Pdyn: Sex X Trt: p = 0.012). Further analysis revealed that most treatment effects 
were specific to females (Kiss1: age p < 0.001 and treatment p = 0.046; Tac2: age X 
treatment: p = 0.021; Esr1 age X treatment: p = 0.041; Pdyn females age X treatment: p = 
0.017; males: main treatment p = 0.045, expression in males exposed to EB is lower than 
DMSO and A1221 throughout development). T-tests were run between the sexes at each 
age to determine if expression was sexually dimorphic throughout development. Kiss1 and 




0.058). Exposure to EB but not A1221 resulted in sexually dimorphic expression in Kiss1 
(P30, P45, P90 p < 0.05), Tac2 (P90 P < 0.05) and Pdyn (P15 and P90 P < 0.1; P30 and 
P45 p < 0.05) with females having higher expression than males. In the ARC, no treatment 
effects were observed. However, main effects of sex and age were observed for Kiss1 and 
Tac2 (p < 0.001) and an interaction of sex and age was observed for Tac2 (p = 0.006). A 
main effect of age was observed for Esr1 (p < 0.001) along with a trend for an interaction 
of sex and age (p = 0.071). No main effects of age or age by sex interaction were observed 
for Pdyn but a trend for a main effect of sex was observed (p = 0.085).   
Gene expression profiles in the in the female AVPV are similar to males after 
gestational exposure to EDCs 
 In the AVPV, 28 genes were altered by gestational exposure to EDCs (main effect 
or interaction of treatment p < 0.05) and are indicated in red on Figure 2.3 (A and B). 
Further analysis revealed that 21 of those genes were specifically affected in the female 
AVPV but not the male (Pdyn was affected in both males and females). These genes are 
highlighted in bold on Figure 2.3A. In order to determine if the genes affected by 
treatment exhibited a male-typical pattern of expression throughout development, 
expression pattern must have met the following criteria: 1) genes must display an age X 
treatment effect in the females; 2) gene expression in the treated females were determined 
to be from a distribution that was similar to DMSO males using Bayesian analysis; and 3) 
the area between the DMSO male and treated female curves was reduced by 50% when 
compared to the difference between the control males and females. Using these criteria, 




male-typical expression pattern throughout development (Figure 2.2). These genes fell 
into 4 functional groups: steroid hormone receptors (A. Ar, B. Thra, & C. Gper), 
neuropeptides and their receptors (D. Gal, E. Gnrh1, & F. Kiss1r), epigenetic processes 
(G. Dnmt1) and circadian clock genes (H. Arntl & I. Per2).  
In order to determine which genes shared similar expression patterns across 
development in each sex, hierarchical cluster analysis was conducted using the average 
linking method and correlation coefficients to express similarity. In the female AVPV, 2 
large clusters were validated (indicated by a red box in Figure 2.3B). The top cluster 
includes genes that decrease from P15 and the bottom cluster is composed of genes that 
increase from P15 – P90. In males, there were very few validated clusters, but in general, 
the genes in the top clusters decrease from P15 – P90 or undergo very little change and the 
genes in the bottom cluster increase from P15 – P90. The genes significantly altered by 
treatment are indicated in red and those with specific effects in each sex are highlighted in 
bold. When comparing validated clusters in the male AVPV to the female we noted that 
the bottom cluster in the males consisted of 17 genes closely resembled a cluster in the 
female AVPV (indicated by a gray rectangle). These clusters shared 11 of 14 genes, 11 of 
which have a significant treatment effect (main effect or interaction) 5 of which had 
effects specific to females. 
In the female and male ARC, 5 and 6 clusters were validated respectively, and 
many of these clusters had only a few genes (2 – 5). In general genes were groups by those 
that decreased from P15 – P90 (top) or increased from P15 – P90 (bottom). The genes 




each sex are highlighted in bold. When comparing validated clusters in the male ARC to 
the female we noted that the bottom cluster in the males consisted of 14 genes and closely 
resembled the lower cluster in the female ARC (indicated by a gray rectangle). These 
clusters shared 11 of 14 genes, 5 of which have a significant treatment effect (main effect 
or interaction). 
DNA methylation is not altered in Ar or Per2 promoter throughout development 
 In order to determine if epigenetic mechanisms were altered by exposure to EDCs 
we measured DNA methylation on 2 promoter regions of genes that were affected by 
treatment (Ar and Per2). These genes were chosen because each displayed a significant 
sex by age by treatment and had large CpG islands surrounding the transcription start sites 
(TSS). With the exception of two of CpGs the Per2 promoter was almost completely 
demethylated by P15 and remained so throughout development (data not shown). The Ar 
promoter region (Figure 2.4) displayed sexually dimorphic methylation at each CpG 
investigated (-70bp - +39bp from the transcription start site) with females (Figure 2.4A) 
having higher methylation when compared to males (Figure 2.4B). This result was 
anticipated based on the location of Ar on the X chromosome. Further analysis revealed 
that one CpG at -63bp displayed a significant interaction of age and treatment in males (p 
= 0.006). While there were few changes in methylation we also investigated if methylation 
correlated with expression of Ar in individuals across all ages. Significant (p < 0.05) and 
trends (0.05 < p < 0.1) are discussed herein. In females exposed to EB and A1221 but not 
DMSO, expression was positively correlated with methylation at CpGs at -65bp (EB 




and average methylation across the region (EB p = 0.064; A1221 p = 0.085). In males 
exposed to EB, expression was negatively correlated with methylation at CpG -63bp (p = 
0.037). In males exposed to DMSO expression was positively correlated with methylation 
at -57bp (p = 0.07). 
Gene expression in the ARC is altered by treatment in males but not females 
In the ARC, 12 genes were altered by gestational exposure to EDCs (main effect or 
interaction of treatment p < 0.05) and are indicated in red on Figure 2.3 (C and D). Further 
analysis revealed that 6 of those genes were specifically affected in the male ARC but not 
the female (Figure 2.5). These genes fell into 2 general groups: sex steroid hormone 
receptors (A. Ar), neuropeptides and their receptors (B. Lepr, C. Mc3r, and D. Avp; E. 
Oxt), and neurotransmitter receptors (F. Grin2d). Additionally, there were 3 general 
expression patterns observed as a result of treatment. For Ar and Lepr, A1221 and EB 
increased expression at P45 and decreased at P90 (A1221 only). Avp and Grin2d 
expression was affected at P15 with Avp suppressed (although not significantly when 
compared to DMSO males) in the EB group, and Grin2d expression increased at P15 in 
the EB treated males. Avp was also suppressed at P30 in both A1221 and EB groups.  
Finally, Oxt and Mc3r had a significant effect of treatment (p = 0.047 and 0.036 
respectively) with no age effects. For both genes, expression was increased throughout 
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Figure 2.1: Expression profiles of genes required for reproduction in the AVPV & ARC.  
Expression was characterized in females (dotted lines) and males (solid lines) from P15 – 
P90 in the AVPV (left) and ARC (right). Each of these genes had a significant effect of 
treatment or interaction of treatment in the AVPV but not ARC. Further analysis revealed 
that effects were specific to females in all genes except Pdyn where there effects in both 
males and females. Significant sex differences (p <0 .05) are indicated by an * and trends 
(p < 0.1) are indicated by a. In DMSO treated animals (first column), few sex differences 
are observed in the AVPV. In the EB but not A1221 treated animals, Kiss1, Tac2 and 
Pdyn all had significant sex differences on P90 with other sex differences observed on P30 
and P45 for Kiss1 and Pdyn. In the ARC, no significant effects of treatment were observed 
so data were collapsed across groups. For Kiss1, Tac2 and Esr1 significant sex and age 




















































































Sex / Age / Trt p < 0.001
Sex / Age / Trt p = 0.006






















Sex X Age p < 0.001
Ses X Age p < 0.001
Sex X Age p = 0.216
F: Age p < 0.001; 
    Trt p = 0.046
M: Age p < 0.001; 
    Trt p = 0.893
F: Age X Trt p = 0.021





















































Age: p = 0.151 Age: p < 0.001 Age: p < 0.001
P15 Trt: p = 0.047
M: Trt p = 0.008
F: Age X Trt p = 0.017
F: Trt p = 0.406
Sex X Age p = 0.071
Age: p < 0.001
Sex: p < 0.001
Age: p < 0.001
Sex: p < 0.001
Age: p < 0.001
Sex: p = 0.942
Age: p = 0.182







Figure 2.2: Expression profiles of genes affected by treatment in the female AVPV.  
Data is only shown for DMSO males (DM; blue) and females (DF; red dotted) and EB 
females (EF; gray) and A1221 females (AF; yellow) because each gene was altered in the 
female but not males and had an age X treatment interaction (p < 0.05). In order to 
determine if the female profiles were similar to males or females, Bayes analysis was used 
to determine the probably of the two profiles coming from different distributions 
(indicated as dB). Additionally, area between the curves was calculated to determine if 
area was decreased in treated females were compared to the male curves. A gene was 
considered male typical if dB were decreased and the area between the curves was reduced 
by 50% when compared to when compared to the DMSO males and females (DM vs DF). 
Area in bold indicates a 50% reduction when compared to the DMSO curves. Of the 21 
genes altered by treatment, only 9 met the criteria above. These genes fell 4 functional 
groups: steroid hormone receptors (Ar (A), Thra (B) & Gper (C)); neuropeptides and their 
receptors (Gal (D), Gnrh1 (E) & Kiss1r (F)); epigenetic enzymes (Dnmt1 (G)); circadian 
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F: Age X Trt: p < 0.001
DM vs DF = 8.1dB; Area: 8.3
DM vs EF = 0.6dB; Area: 15.2
DM vs AF = 0.6dB; Area: 4.6
F: Age X Trt p = 0.004
DM vs DF = 54.8dB; Area: 71.7
DM vs EF = 32.0dB; Area: 22.8
DM vs AF = 21.5dB; Area: -23.1
F: Age X Trt: p = 0.004
DM vs DF = 54.0dB; Area: 67.1
DM vs EF = 48.9dB; Area: 71.4
DM vs AF = 30.9dB; Area: 4.0
F: A X Trt: p = 0.004
DM vs DF = 8.6dB; Area: 21.4
DM vs EF = 13.0dB Area: 12.9
DM vs AF = -2.4dB; Area:1.1
F: Age X Trt: p = 0.002
DM vs DF = 23.3dB; Area: 43.2
DM vs EF = 20.7dB; Area: 20.9
DM vs AF = 11.9dB; Area: 13.9
F: Age / Trt: p < 0.001
DM vs DF = 74.4dB; Area:120.8
DM vs EF = 64.8dB; Area:101.8
DM vs AF = -46.5dB; Area: 27.2
F: Age X Trt: p = 0.008
DM vs DF = 15.1dB; Area: 11.3
DM vs EF = 4.9dB; Area: 3.2
DM vs AF = -13.5dB; Area: 2.9
F: Age X Trt: p = 0.014
DM vs DF = 28.8dB; Area: 41.6
DM vs EF = 21.0dB; Area: 36.5







F: Age X Trt: p = 0.006
DM vs DF = 18.2dB; Area: 25.7
DM vs EF = 5.7dB; Area: 7.8
DM vs AF = 7.2dB; Area: 19.4
Age (days)
Sex X Age X Trt p = 0.035 Sex X Age X Trt: p = 0.027Sex X Age X Trt: p = 0.007
Sex / Age / Trt p < 0.001 Sex X Age X Trt: p = 0.006Sex / Age / Trt: p < 0.001





Clustergrams of gene 
expression.  
Genes with a 
significant treatment 
(main effect of 
interaction) in males 
(A & C) and females 
(B & D) and the 
AVPV (A & B), ARC 
(C & D) are 
highlighted in red. 
Those with specific 
sex effects in each sex 
are indicated in bold 
text. Validated gene 
clusters are indicated 
by a red box. In males, 
only a few clusters 
were validated in the 
AVPV or ARC. 
Clusters highlighted in 
gray are similar 
between males and 
females. 
  
A. Male AVPV B. Female AVPV






Figure 2.4: Methylation of individual CpG sites in the promoter region of Ar. 
Percent methylation in females (top) and males (bottom) for each treatment group (DMSO  
= Black ; EB  = light gray; A1221 = dark gray) at each age is shown. One site in the 
located at -63bp from the transcription start site (TSS) in the male promoter had a 
significant age X treatment interaction. There were significant sex differences at each 
CpG, with females having more methylation compared to males. Because Ar is on the X 
chromosome we were expected that methylation would be at 50% in the females as a 
reflection of X-inactivation (dotted line). Methylation was positively correlated with 
expression of Ar at the following CpGs in females: -65bp (EB), -57bp (EB & A1221), -
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Figure 2.5: Expression of genes displaying an age X treatment interaction in the male 
ARC.  
P-values obtained initial multiple regression analysis are listed at the top of each graph 
with male specific p-valued listed below. Two genes displayed a significant age X 
treatment interaction and 1 displayed a tread (p<0.1). These genes fell 3 functional groups: 
steroid hormone receptors (Ar (A); neuropeptides and their (Lepr (B), Mc3r (C), Avp (D) 
and Oxt (E)); and neurotransmitters and their receptors (Grin2d (F)). Three genes (Mc3r, 
Oxt and Grin2d) displayed a significant treatment effect (p < 0.05) with greater expression 
in the EB treated males. Three genes displayed a significant age X treatment interaction 
(Ar, Lepr & Avp) (p < 0.05). In DMSO males, Ar and Lepr expression was significantly 
increased on P90 when compared to P15 and P45. In EB males, Lepr is increased on P45 
when compared to P15. In A1221 males, Ar expression is significantly lower on P15 when 
compared to P30 and P45 and Lepr expression is significantly lower on P15 when 
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Table 2.2: Summary of EDC effects on serum hormone concentrations and endocrine 
tissues throughout development. 
Endpoint P-value F/M
P1 Weight 0.401 / 0.293 6.08 (+/- 0.08) 6.12 (+/- 0.08) 6.17 (+/- 0.06) 6.33 (+/- 0.09) 6.45 (+/- 0.08) 6.45 (+/- 0.06)
P1 AGD Ratio 0.124 / 0.524 0.86 (+/- 0.01) 0.90 (+/- 0.01) 0.90 (+/- 0.02) 1.89 (+/- 0.01) 1.90 (+/- 0.02) 1.91 (+/- 0.01)
P7 AGD Ratio 0.976 / 0.275 1.20 (+/- 0.02) 1.20 (+/- 0.01) 1.20 (+/- 0.02) 2.28 (+/- 0.02) 2.33 (+/- 0.03) 2.33 (+/- 0.02)
P14 AGD Ratio 0.287 / 0.070 1.58 (+/- 0.01) 1.55 (+/- 0.01) 1.57 (+/- 0.01) 2.73 (+/- 0.03) 2.67 (+/- 0.02) 2.77 (+/- 0.03)
Eye Opening 0.027 / 0.321 15.19 (+/- 0.08) 15.32 (+/- 0.08) 15.48 (+/- 0.07) 15.36 (+/- 0.09) 15.48 (+/- 0.08) 15.54 (+/- 0.08)
Age Puberty 0.470 / 0.017 34.08 (+/- 0.24) 34.11 (+/- 0.25) 34.45 (+/- 0.23) 42.12 (+/- 0.2) 42.51 (+/- 0.21) 42.94 (+/- 0.2)
Estrous Cycle Stats
% Regular (P90 Females only) 85.0% 63.2% p"="0.008 85.0% p"="1.0
% Animals with PD (All cycling Females) 5.1% 13.5% p"="0.021 6.7% p"="0.64
Skip Proestrus (All cycling Females) 20.5% 40.5% p"="0.003 28.9% p"="0.164
First 3 Cycles Regular (All cycling Females) 89.7% 83.8% p"="0.232 84.4% p"="0.241
at least 2 strings of > 5 days of C/L 10.3% 21.6% p"="0.023 17.8% p"="0.096
A1221 MalesDMSO Females EB Females A1221 Females DMSO Males EB Males
Females
T Concentration 0.02 (+/- 0.003) 0.11 (+/- 0.09) 0.03 (+/- 0.01) N/A 0.11 (+/- 0.02) N/A
LH Concentration 1.93 (+/- 0.6) 1.67 (+/- 0.6) 2.85 (+/- 0.71) 1.33 (+/- 0.16) 1.35 (+/- 0.16) 1.41 (+/- 0.14)
E2 Concentration 93.43 (+/- 13.97) 54.43 (+/- 8.53) 98.29 (+/- 16.1) 7.09 (+/- 0.8) 7.72 (+/- 1.63) 7.06 (+/- 0.98)
Body Wt 30.99 (+/- 1.11) 33.44 (+/- 1.06) 30.88 (+/- 0.76) 82.64 (+/- 1.35) 86.69 (+/- 1.86) 80.74 (+/- 2.18)
GSI 0.25 (+/- 0.01) 0.24 (+/- 0.01) 0.26 (+/- 0.01) 0.39 (+/- 0.01) 0.42 (+/- 0.03) 0.42 (+/- 0.03)
Uterus Wt (mg) 17.20 (+/- 0.8) 18.01 (+/- 0.72) 16.75 (+/- 0.73) 62.13 (+/- 5.07) 80.20 (+/- 17.72) 62.14 (+/- 5.46)
Adrenal Wt (mg) 0.78 (+/- 0.05) 0.78 (+/- 0.04) 0.70 (+/- 0.05) 1.93 (+/- 0.1) 2.34 (+/- 0.11) 2.19 (+/- 0.1)
Pit Wt (mg) 2.19 (+/- 0.22) 2.18 (+/- 0.1) 2.02 (+/- 0.11) 4.12 (+/- 0.19) 4.45 (+/- 0.15) 4.11 (+/- 0.22)
Males
T Concentration 0.23 (+/- 0.1) 0.02 (+/- 0.) 0.12 (+/- 0.05) 0.03 (+/- 0.01) 0.02 (+/- 0.01) 0.05 (+/- 0.02)
LH Concentration 2.27 (+/- 0.46) 1.10 (+/- 0.16) 1.08 (+/- 0.09) 1.35 (+/- 0.16) 1.36 (+/- 0.13) 1.79 (+/- 0.26)
E2 Concentration 95.83 (+/- 15.32) 102.01 (+/- 19.02) 102.06 (+/- 20.62) 8.50 (+/- 1.68) 8.25 (+/- 1.08) 9.96 (+/- 2.68)
Body Wt 31.52 (+/- 1.07) 34.21 (+/- 1.07) 31.78 (+/- 1.01) 91.97 (+/- 1.82) 96.13 (+/- 3.04) 93.08 (+/- 1.7)
GSI 3.14 (+/- 0.09) 3.10 (+/- 0.08) 3.25 (+/- 0.08) 9.54 (+/- 0.15) 9.23 (+/- 0.14) 9.09 (+/- 0.13)
Adrenal Wt (mg) 0.72 (+/- 0.08) 0.80 (+/- 0.05) 0.75 (+/- 0.04) 1.97 (+/- 0.15) 2.35 (+/- 0.07) 2.34 (+/- 0.21)
Pit Wt (mg) 1.86 (+/- 0.23) 2.26 (+/- 0.23) 1.78 (+/- 0.1) 4.43 (+/- 0.24) 4.54 (+/- 0.25) 4.35 (+/- 0.23)
Females
T Concentration 0.02 (+/- 0.) 0.03 (+/- 0.01) 0.03 (+/- 0.01) 0.02 (+/- 0.01) 0.02 (+/- 0.) 0.02 (+/- 0.01)
LH Concentration 4.90 (+/- 2.61) 1.55 (+/- 0.3) 8.69 (+/- 5.29) 4.17 (+/- 2.11) 2.85 (+/- 1.65) 4.61 (+/- 2.11)
E2 Concentration 21.94 (+/- 2.41) 20.36 (+/- 3.41) 28.78 (+/- 4.09) 20.15 (+/- 2.8) 23.04 (+/- 4.55) 20.16 (+/- 2.12)
Body Wt 157.79 (+/- 2.23) 156.91 (+/- 2.12) 161.52 (+/- 3.01) 262.95 (+/- 7.23) 257.30 (+/- 5.19) 249.41 (+/- 4.26)
GSI 0.53 (+/- 0.01) 0.54 (+/- 0.02) 0.50 (+/- 0.02) 0.46 (+/- 0.02) 0.47 (+/- 0.01) 0.46 (+/- 0.01)
Uterus Wt (mg) 510.51 (+/- 33.97) 469.03 (+/- 21.85) 526.55 (+/- 31.09) 666.70 (+/- 31.06) 734.32 (+/- 52.13) 727.10 (+/- 45.37)
Adrenal Wt (mg) 3.64 (+/- 0.15) 3.89 (+/- 0.23) 3.96 (+/- 0.13) 5.72 (+/- 0.14) 5.20 (+/- 0.43) 5.85 (+/- 0.18)
Pit Wt (mg) 9.29 (+/- 0.32) 8.53 (+/- 0.21) 8.91 (+/- 0.36) 13.84 (+/- 0.7) 13.56 (+/- 0.44) 13.42 (+/- 0.61)
Males
T Concentration 0.20 (+/- 0.05) 0.20 (+/- 0.04) 0.34 (+/- 0.07) 0.63 (+/- 0.12) 0.57 (+/- 0.1) 0.68 (+/- 0.16)
LH Concentration 1.29 (+/- 0.14) 1.14 (+/- 0.1) 1.36 (+/- 0.11) 0.72 (+/- 0.05) 0.72 (+/- 0.07) 0.87 (+/- 0.08)
E2 Concentration 7.20 (+/- 0.6) 7.84 (+/- 1.54) 8.77 (+/- 0.75) 7.86 (+/- 1.46) 6.44 (+/- 0.78) 8.11 (+/- 0.89)
Body Wt 195.59 (+/- 3.98) 197.52 (+/- 2.37) 200.19 (+/- 3.39) 384.60 (+/- 7.3) 390.13 (+/- 8.35) 383.46 (+/- 6.7)
GSI 11.55 (+/- 0.62) 12.03 (+/- 0.13) 12.16 (+/- 0.14) 9.62 (+/- 0.5) 10.04 (+/- 0.19) 10.18 (+/- 0.2)
Adrenal Wt (mg) 3.14 (+/- 0.2) 3.28 (+/- 0.08) 3.18 (+/- 0.11) 4.57 (+/- 0.17) 4.83 (+/- 0.1) 4.89 (+/- 0.12)
Pit Wt (mg) 8.30 (+/- 0.23) 8.69 (+/- 0.32) 9.24 (+/- 0.38) 12.56 (+/- 0.64) 12.79 (+/- 0.27) 12.40 (+/- 0.47)
A1221 DMSO EB A1221
A1221
DMSO EB A1221 DMSO EB A1221

























18S Eukaryotic 18S RNA, 18S ribosomal 1 0.131 0.041 0.891 0.732 0.242 0.425 0.862 1.35 (+/-0.07) 1.40 (+/-0.16) 1.34 (+/-0.09) 1.35 (+/-0.09) 1.58 (+/-0.15) 1.36 (+/-0.14) 1.33 (+/-0.14) 1.25 (+/-0.13) 1.44 (+/-0.09) 1.20 (+/-0.08) 1.35 (+/-0.11) 1.15 (+/-0.1)
Ar androgen receptor 0.727 0.000 0.502 0.235 0.839 0.030 0.035 2.33 (+/-0.54) 2.86 (+/-0.5) 3.26 (+/-0.39) 4.10 (+/-0.39) 1.04 (+/-0.18) 3.34 (+/-0.38) 4.99 (+/-0.73) 5.81 (+/-0.86) 1.32 (+/-0.15) 3.69 (+/-0.53) 3.89 (+/-0.38) 6.83 (+/-0.91)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.285 0.000 0.846 0.050 0.345 0.260 0.011 1.70 (+/-0.21) 1.58 (+/-0.25) 1.41 (+/-0.12) 1.45 (+/-0.14) 0.99 (+/-0.13) 1.44 (+/-0.13) 1.91 (+/-0.23) 1.95 (+/-0.23) 1.19 (+/-0.12) 1.48 (+/-0.15) 1.50 (+/-0.12) 1.80 (+/-0.15)
Avpr1a arginine vasopressin receptor 1A 0.002 0.000 0.468 0.672 0.478 0.128 0.024 2.05 (+/-0.29) 1.65 (+/-0.22) 1.60 (+/-0.24) 1.92 (+/-0.22) 1.03 (+/-0.15) 1.67 (+/-0.2) 2.43 (+/-0.34) 2.42 (+/-0.31) 1.42 (+/-0.13) 1.74 (+/-0.17) 2.00 (+/-0.2) 2.45 (+/-0.32)
Bdnf brain-derived neurotrophic factor 0.106 0.007 0.795 0.604 0.015 0.192 0.150 1.67 (+/-0.28) 1.15 (+/-0.23) 1.29 (+/-0.25) 1.27 (+/-0.14) 1.24 (+/-0.29) 1.32 (+/-0.16) 2.20 (+/-0.32) 1.94 (+/-0.22) 1.10 (+/-0.14) 1.45 (+/-0.21) 1.64 (+/-0.1) 2.02 (+/-0.27)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.743 0.000 0.408 0.627 0.120 0.219 0.652 2.37 (+/-0.57) 1.85 (+/-0.34) 2.13 (+/-0.64) 2.46 (+/-0.19) 1.20 (+/-0.34) 2.43 (+/-0.48) 3.70 (+/-0.79) 4.40 (+/-0.67) 1.49 (+/-0.21) 2.18 (+/-0.37) 3.37 (+/-0.52) 5.00 (+/-1.11)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.979 0.003 0.785 0.198 0.696 0.084 0.002 2.25 (+/-0.19) 1.60 (+/-0.18) 1.52 (+/-0.14) 1.28 (+/-0.17) 1.25 (+/-0.16) 1.55 (+/-0.18) 1.88 (+/-0.17) 2.03 (+/-0.32) 1.49 (+/-0.1) 1.62 (+/-0.2) 1.39 (+/-0.09) 2.11 (+/-0.2)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.110 0.000 0.814 0.117 0.699 0.608 0.278 9.43 (+/-2.09) 1.90 (+/-0.31) 1.39 (+/-0.16) 1.03 (+/-0.14) 5.59 (+/-0.9) 1.85 (+/-0.22) 1.90 (+/-0.21) 1.37 (+/-0.23) 6.19 (+/-0.57) 1.92 (+/-0.21) 1.20 (+/-0.09) 1.29 (+/-0.13)
Esr1 estrogen receptor 1 0.726 0.000 0.284 0.600 0.191 0.053 0.530 3.66 (+/-0.92) 3.50 (+/-0.93) 2.73 (+/-0.64) 3.96 (+/-0.53) 1.02 (+/-0.25) 5.08 (+/-1.06) 4.66 (+/-0.91) 7.07 (+/-1.3) 1.94 (+/-0.42) 4.48 (+/-0.81) 4.89 (+/-0.61) 7.22 (+/-1.3)
Esr2 estrogen receptor 2 0.067 0.000 0.922 0.461 0.084 0.178 0.094 1.91 (+/-0.36) 1.81 (+/-0.14) 2.58 (+/-0.35) 3.41 (+/-0.45) 1.06 (+/-0.18) 2.72 (+/-0.39) 4.42 (+/-0.83) 4.66 (+/-0.63) 1.23 (+/-0.1) 2.39 (+/-0.27) 3.71 (+/-0.3) 4.26 (+/-0.58)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.438 0.000 0.985 0.457 0.694 0.501 0.029 1.80 (+/-0.28) 1.84 (+/-0.38) 1.69 (+/-0.19) 1.56 (+/-0.32) 1.10 (+/-0.17) 1.72 (+/-0.18) 2.24 (+/-0.24) 2.21 (+/-0.32) 1.30 (+/-0.25) 1.89 (+/-0.25) 1.48 (+/-0.13) 2.07 (+/-0.18)
Gper G protein-coupled estrogen receptor 1 0.828 0.120 0.927 0.199 0.540 0.003 0.027 2.22 (+/-0.24) 1.18 (+/-0.17) 1.07 (+/-0.1) 1.01 (+/-0.12) 1.13 (+/-0.13) 1.67 (+/-0.07) 1.55 (+/-0.23) 1.37 (+/-0.23) 1.32 (+/-0.13) 1.38 (+/-0.18) 1.40 (+/-0.1) 1.16 (+/-0.11)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.417 0.000 0.909 0.084 0.216 0.580 0.212 1.44 (+/-0.16) 1.63 (+/-0.31) 1.27 (+/-0.06) 1.38 (+/-0.18) 1.13 (+/-0.17) 1.56 (+/-0.05) 1.86 (+/-0.23) 1.90 (+/-0.25) 1.13 (+/-0.08) 1.45 (+/-0.14) 1.38 (+/-0.1) 1.70 (+/-0.12)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.569 0.023 0.471 0.199 0.431 0.437 0.011 1.54 (+/-0.17) 1.30 (+/-0.19) 1.27 (+/-0.1) 1.15 (+/-0.15) 1.16 (+/-0.13) 1.40 (+/-0.12) 1.67 (+/-0.15) 1.62 (+/-0.2) 1.50 (+/-0.19) 1.44 (+/-0.13) 1.28 (+/-0.05) 1.61 (+/-0.11)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.622 0.000 0.546 0.290 0.684 0.817 0.075 2.30 (+/-0.35) 1.25 (+/-0.14) 1.39 (+/-0.16) 1.36 (+/-0.17) 1.80 (+/-0.3) 1.44 (+/-0.17) 1.85 (+/-0.17) 1.70 (+/-0.22) 1.82 (+/-0.14) 1.40 (+/-0.15) 1.32 (+/-0.1) 1.77 (+/-0.19)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.410 0.000 0.460 0.068 0.727 0.721 0.085 1.32 (+/-0.19) 1.69 (+/-0.22) 2.00 (+/-0.18) 1.58 (+/-0.23) 1.01 (+/-0.16) 1.70 (+/-0.17) 2.17 (+/-0.13) 1.97 (+/-0.2) 1.04 (+/-0.18) 1.67 (+/-0.15) 1.65 (+/-0.14) 1.91 (+/-0.18)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.260 0.000 0.749 0.189 0.798 0.611 0.017 2.32 (+/-0.29) 1.51 (+/-0.26) 1.49 (+/-0.21) 1.34 (+/-0.23) 1.70 (+/-0.21) 1.72 (+/-0.17) 1.93 (+/-0.16) 1.82 (+/-0.28) 2.26 (+/-0.26) 1.83 (+/-0.17) 1.39 (+/-0.08) 1.77 (+/-0.18)
Igf1r insulin-like growth factor 1 receptor 0.345 0.000 0.857 0.353 0.382 0.113 0.031 1.38 (+/-0.17) 1.51 (+/-0.18) 1.55 (+/-0.12) 1.24 (+/-0.17) 0.99 (+/-0.12) 1.43 (+/-0.13) 1.87 (+/-0.12) 1.88 (+/-0.16) 1.11 (+/-0.14) 1.49 (+/-0.12) 1.40 (+/-0.08) 1.90 (+/-0.15)
Kiss1r KISS1 receptor 0.148 0.000 0.755 0.626 0.587 0.133 0.006 2.02 (+/-0.29) 1.51 (+/-0.32) 1.66 (+/-0.27) 2.22 (+/-0.3) 0.90 (+/-0.14) 1.86 (+/-0.22) 2.92 (+/-0.28) 3.34 (+/-0.58) 1.19 (+/-0.2) 2.11 (+/-0.29) 2.14 (+/-0.16) 2.47 (+/-0.24)
Mc3r melanocortin 3 receptor 0.282 0.000 0.839 0.952 0.010 0.268 0.100 2.77 (+/-0.59) 2.84 (+/-0.72) 3.35 (+/-0.76) 3.46 (+/-0.51) 1.27 (+/-0.32) 3.57 (+/-0.25) 5.84 (+/-0.93) 6.20 (+/-1.08) 1.85 (+/-0.39) 2.97 (+/-0.44) 4.02 (+/-0.45) 5.08 (+/-0.88)
Mc4r melanocortin 4 receptor 0.096 0.000 0.457 0.141 0.657 0.731 0.168 1.58 (+/-0.22) 2.19 (+/-0.52) 2.13 (+/-0.39) 3.00 (+/-0.32) 1.12 (+/-0.12) 1.92 (+/-0.29) 3.56 (+/-0.82) 3.99 (+/-0.7) 1.14 (+/-0.13) 2.21 (+/-0.33) 2.92 (+/-0.28) 3.22 (+/-0.46)
Oxtr oxytocin receptor 0.922 0.000 0.961 0.298 0.801 0.224 0.241 2.68 (+/-0.43) 1.22 (+/-0.14) 1.55 (+/-0.11) 1.52 (+/-0.22) 1.53 (+/-0.18) 1.45 (+/-0.2) 2.14 (+/-0.35) 2.08 (+/-0.38) 1.95 (+/-0.2) 1.39 (+/-0.2) 1.49 (+/-0.18) 2.01 (+/-0.25)
Pdyn prodynorphin 0.197 0.000 0.402 0.495 0.012 0.121 0.056 1.74 (+/-0.29) 1.63 (+/-0.27) 2.43 (+/-0.31) 2.50 (+/-0.3) 0.85 (+/-0.09) 2.31 (+/-0.25) 4.11 (+/-0.69) 3.84 (+/-0.57) 1.32 (+/-0.24) 2.05 (+/-0.3) 2.87 (+/-0.23) 3.05 (+/-0.44)
Per2 period homolog 2 0.248 0.000 0.636 0.913 0.006 0.448 0.006 1.79 (+/-0.26) 1.85 (+/-0.19) 2.02 (+/-0.2) 2.11 (+/-0.29) 1.00 (+/-0.13) 2.41 (+/-0.33) 3.22 (+/-0.39) 3.55 (+/-0.42) 1.30 (+/-0.18) 2.21 (+/-0.24) 2.36 (+/-0.22) 2.94 (+/-0.39)
Pgr progesterone receptor 0.805 0.000 0.357 0.420 0.145 0.531 0.579 1.42 (+/-0.25) 1.57 (+/-0.14) 2.60 (+/-0.34) 3.37 (+/-0.36) 1.06 (+/-0.15) 2.04 (+/-0.26) 4.65 (+/-0.78) 5.04 (+/-0.8) 1.26 (+/-0.15) 1.98 (+/-0.26) 3.69 (+/-0.24) 4.70 (+/-0.79)
Slc17a6 solute carrier family 17, member 6 0.378 0.000 0.253 0.895 0.010 0.101 0.126 1.39 (+/-0.2) 0.93 (+/-0.11) 1.14 (+/-0.26) 1.40 (+/-0.13) 0.91 (+/-0.13) 1.39 (+/-0.14) 1.96 (+/-0.2) 1.82 (+/-0.25) 1.07 (+/-0.15) 1.36 (+/-0.13) 1.77 (+/-0.09) 1.81 (+/-0.22)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.897 0.000 0.233 0.102 0.539 0.473 0.067 1.48 (+/-0.21) 1.84 (+/-0.23) 2.50 (+/-0.49) 1.42 (+/-0.32) 1.06 (+/-0.11) 1.55 (+/-0.2) 2.09 (+/-0.24) 1.73 (+/-0.23) 1.12 (+/-0.19) 1.83 (+/-0.2) 1.15 (+/-0.12) 1.56 (+/-0.19)
Tgfa transforming growth factor, alpha 0.889 0.000 0.969 0.553 0.272 0.649 0.007 1.70 (+/-0.21) 1.22 (+/-0.19) 1.60 (+/-0.14) 1.32 (+/-0.2) 1.09 (+/-0.12) 1.29 (+/-0.16) 1.96 (+/-0.21) 1.93 (+/-0.24) 1.23 (+/-0.15) 1.37 (+/-0.1) 1.27 (+/-0.11) 1.77 (+/-0.18)
Tgfb1 transforming growth factor, beta 1 0.979 0.068 0.410 0.244 0.763 0.708 0.098 2.45 (+/-0.51) 1.36 (+/-0.15) 1.42 (+/-0.12) 1.11 (+/-0.17) 1.71 (+/-0.11) 1.61 (+/-0.17) 1.92 (+/-0.17) 1.53 (+/-0.21) 1.58 (+/-0.24) 1.76 (+/-0.19) 1.39 (+/-0.12) 1.61 (+/-0.13)
Thra thyroid hormone receptor, alpha 0.835 0.087 0.728 0.124 0.162 0.419 0.001 1.85 (+/-0.28) 1.62 (+/-0.27) 1.51 (+/-0.12) 1.18 (+/-0.18) 1.18 (+/-0.14) 1.66 (+/-0.17) 2.00 (+/-0.21) 1.93 (+/-0.27) 1.32 (+/-0.15) 1.65 (+/-0.2) 1.25 (+/-0.07) 1.67 (+/-0.14)
Thrb thyroid hormone receptor, beta 0.353 0.000 0.980 0.242 0.555 0.344 0.103 1.74 (+/-0.28) 1.97 (+/-0.2) 2.08 (+/-0.17) 1.85 (+/-0.27) 1.26 (+/-0.21) 2.00 (+/-0.22) 2.49 (+/-0.18) 2.31 (+/-0.24) 1.14 (+/-0.09) 1.92 (+/-0.19) 1.69 (+/-0.11) 2.40 (+/-0.17)
Gene 
Symbol Gene Name Sex Age Trt Sex/Age Sex Trt Age/Trt
Sex/Age 
/Trt
Ahr aryl hydrocarbon receptor 0.410 0.000 0.432 0.000 0.693 0.000 0.000 4.13 (+/-0.66) 2.35 (+/-0.42) 2.10 (+/-0.39) 1.08 (+/-0.19) 3.16 (+/-0.35) 2.07 (+/-0.24) 1.83 (+/-0.19) 1.32 (+/-0.22) 3.43 (+/-0.6) 1.92 (+/-0.2) 1.31 (+/-0.13) 1.08 (+/-0.11)
Avp arginine vasopressin 0.743 0.000 0.353 0.002 0.420 0.002 0.015 4.97 (+/-2.3) 1.33 (+/-0.25) 3.19 (+/-1.43) 3.70 (+/-1.22) 1.12 (+/-0.16) 2.66 (+/-0.63) 5.10 (+/-1.67) 9.11 (+/-3.14) 1.15 (+/-0.14) 2.20 (+/-0.43) 2.67 (+/-1.11) 4.78 (+/-2.46)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.634 0.346 0.988 0.256 0.923 0.485 0.130 1.57 (+/-0.21) 1.77 (+/-0.21) 1.90 (+/-0.33) 1.47 (+/-0.3) 0.98 (+/-0.06) 1.51 (+/-0.05) 1.77 (+/-0.16) 1.73 (+/-0.28) 1.46 (+/-0.22) 1.64 (+/-0.11) 1.10 (+/-0.09) 1.62 (+/-0.17)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.437 0.037 0.936 0.057 0.913 0.104 0.030 1.57 (+/-0.17) 1.63 (+/-0.25) 1.50 (+/-0.17) 1.45 (+/-0.22) 0.98 (+/-0.03) 1.43 (+/-0.04) 1.79 (+/-0.2) 1.72 (+/-0.2) 1.38 (+/-0.16) 1.41 (+/-0.09) 1.22 (+/-0.1) 1.76 (+/-0.12)
Gal galanin prepropeptide 0.995 0.000 0.799 0.000 0.308 0.000 0.000 2.16 (+/-0.37) 2.13 (+/-0.37) 4.00 (+/-0.86) 3.91 (+/-0.4) 1.02 (+/-0.19) 4.58 (+/-0.34) 7.45 (+/-1.13) 7.59 (+/-1.44) 1.40 (+/-0.28) 3.65 (+/-0.6) 4.99 (+/-0.26) 5.85 (+/-1.)
Gnrh1 gonadotropin-releasing hormone 1 0.790 0.000 0.944 0.000 0.711 0.000 0.000 2.26 (+/-0.36) 2.07 (+/-0.37) 3.30 (+/-0.83) 3.71 (+/-0.38) 1.11 (+/-0.17) 2.87 (+/-0.36) 6.42 (+/-0.87) 5.26 (+/-0.6) 1.53 (+/-0.39) 3.18 (+/-0.38) 3.84 (+/-0.6) 5.08 (+/-0.68)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.938 0.079 0.856 0.112 0.832 0.375 0.057 1.56 (+/-0.2) 1.60 (+/-0.37) 1.07 (+/-0.05) 1.13 (+/-0.12) 1.11 (+/-0.13) 1.30 (+/-0.12) 1.54 (+/-0.16) 1.59 (+/-0.24) 1.18 (+/-0.06) 1.28 (+/-0.09) 1.21 (+/-0.09) 1.38 (+/-0.08)
Grik2 glutamate receptor, ionotropic, kainate 2 0.942 0.003 0.630 0.002 0.808 0.081 0.019 1.78 (+/-0.25) 1.82 (+/-0.28) 1.27 (+/-0.09) 1.21 (+/-0.17) 1.15 (+/-0.04) 1.30 (+/-0.07) 1.37 (+/-0.11) 1.27 (+/-0.14) 1.45 (+/-0.12) 1.32 (+/-0.07) 1.05 (+/-0.11) 1.33 (+/-0.11)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.484 0.323 0.697 0.509 0.559 0.790 0.553 1.56 (+/-0.2) 1.33 (+/-0.13) 1.36 (+/-0.18) 1.22 (+/-0.18) 1.56 (+/-0.39) 1.48 (+/-0.17) 1.43 (+/-0.12) 1.58 (+/-0.23) 1.35 (+/-0.1) 1.36 (+/-0.13) 1.06 (+/-0.18) 1.52 (+/-0.12)
Igf1 insulin-like growth factor 1 0.016 0.000 0.617 0.000 0.227 0.000 0.000 2.61 (+/-0.62) 1.47 (+/-0.13) 1.76 (+/-0.17) 1.34 (+/-0.16) 1.83 (+/-0.11) 1.29 (+/-0.09) 1.82 (+/-0.21) 2.05 (+/-0.36) 2.46 (+/-0.57) 1.28 (+/-0.06) 1.31 (+/-0.09) 1.75 (+/-0.18)
Kiss1 KiSS-1 metastasis-suppressor 0.000 0.000 0.266 0.000 0.001 0.000 0.000 5.08 (+/-1.58) 6.45 (+/-1.58) 15.26 (+/-4.45) 10.17 (+/-1.35) 3.10 (+/-1.12) 11.06 (+/-2.04) 20.41 (+/-4.05) 25.88 (+/-4.75) 2.74 (+/-0.64) 12.37 (+/-3.3) 20.25 (+/-2.34) 21.23 (+/-4.98)
Lepr leptin receptor 0.431 0.000 0.846 0.000 0.943 0.000 0.000 2.20 (+/-0.59) 2.03 (+/-0.4) 2.00 (+/-0.38) 2.99 (+/-0.63) 1.24 (+/-0.23) 2.19 (+/-0.25) 2.39 (+/-0.34) 3.78 (+/-0.53) 1.20 (+/-0.21) 1.84 (+/-0.27) 2.60 (+/-0.28) 3.68 (+/-0.39)
Oxt oxytocin, prepropeptide 0.900 0.000 0.730 0.000 0.644 0.000 0.000 2.70 (+/-0.69) 4.75 (+/-1.) 15.98 (+/-6.6) 9.20 (+/-1.79) 1.15 (+/-0.29) 7.69 (+/-1.55) 26.01 (+/-8.7) 42.06 (+/-15.71) 1.17 (+/-0.26) 11.97 (+/-2.38) 9.82 (+/-1.58) 13.23 (+/-2.18)
Tac2 tachykinin 2 0.100 0.000 0.903 0.000 0.605 0.002 0.006 1.54 (+/-0.18) 1.96 (+/-0.46) 1.93 (+/-0.29) 1.77 (+/-0.24) 1.01 (+/-0.08) 1.65 (+/-0.25) 2.92 (+/-0.59) 3.29 (+/-0.61) 1.56 (+/-0.22) 1.19 (+/-0.16) 1.43 (+/-0.13) 2.65 (+/-0.45)
Females Nonparametric Statistics
Females Parametric Statistics
P45 P90 P15 P30 P45P30 P45 P90 P15 P30
DMSO EB A1221





Table 2.3, cont’d 
 
EDC effects on gene expression in the AVPV from P15 – P90 in males and females. Bold indicates effects that survived false 
discovery rate correction.
Gene 










18S Eukaryotic 18S RNA, 18S ribosomal 1 0.131 0.041 0.891 0.732 0.242 0.425 0.862 1.30 (+/-0.07) 1.36 (+/-0.09) 1.20 (+/-0.1) 1.15 (+/-0.04) 1.41 (+/-0.2) 1.45 (+/-0.09) 1.20 (+/-0.13) 1.09 (+/-0.1) 1.38 (+/-0.09) 1.29 (+/-0.14) 1.37 (+/-0.12) 1.36 (+/-0.06)
Ar androgen receptor 0.727 0.000 0.502 0.235 0.839 0.030 0.035 1.19 (+/-0.26) 3.82 (+/-0.55) 3.86 (+/-0.4) 5.82 (+/-1.) 1.17 (+/-0.18) 2.80 (+/-0.29) 4.46 (+/-0.52) 5.33 (+/-0.52) 1.17 (+/-0.14) 2.44 (+/-0.37) 4.95 (+/-0.64) 6.91 (+/-0.43)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.285 0.000 0.846 0.050 0.345 0.260 0.011 1.11 (+/-0.2) 1.31 (+/-0.14) 1.45 (+/-0.11) 2.12 (+/-0.11) 1.19 (+/-0.12) 1.09 (+/-0.1) 1.43 (+/-0.08) 1.78 (+/-0.22) 1.27 (+/-0.11) 1.18 (+/-0.13) 1.70 (+/-0.18) 1.92 (+/-0.17)
Avpr1a arginine vasopressin receptor 1A 0.002 0.000 0.468 0.672 0.478 0.128 0.024 1.28 (+/-0.26) 1.67 (+/-0.28) 1.47 (+/-0.14) 1.96 (+/-0.22) 1.33 (+/-0.08) 1.25 (+/-0.17) 1.45 (+/-0.15) 1.72 (+/-0.2) 1.54 (+/-0.24) 1.34 (+/-0.21) 2.04 (+/-0.28) 1.86 (+/-0.15)
Bdnf brain-derived neurotrophic factor 0.106 0.007 0.795 0.604 0.015 0.192 0.150 1.44 (+/-0.32) 1.50 (+/-0.24) 1.42 (+/-0.13) 1.66 (+/-0.28) 1.21 (+/-0.18) 1.00 (+/-0.13) 1.34 (+/-0.16) 1.26 (+/-0.18) 1.49 (+/-0.19) 1.07 (+/-0.16) 1.61 (+/-0.17) 1.56 (+/-0.2)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.743 0.000 0.408 0.627 0.120 0.219 0.652 1.56 (+/-0.22) 2.42 (+/-0.42) 2.65 (+/-0.27) 4.42 (+/-0.62) 1.23 (+/-0.21) 1.43 (+/-0.23) 3.02 (+/-0.63) 3.84 (+/-0.67) 1.33 (+/-0.31) 2.00 (+/-0.35) 3.43 (+/-0.75) 5.08 (+/-0.61)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.979 0.003 0.785 0.198 0.696 0.084 0.002 1.48 (+/-0.28) 1.50 (+/-0.21) 1.56 (+/-0.13) 1.87 (+/-0.26) 1.77 (+/-0.19) 1.25 (+/-0.12) 1.63 (+/-0.2) 1.94 (+/-0.23) 2.08 (+/-0.21) 1.14 (+/-0.15) 1.87 (+/-0.23) 1.91 (+/-0.16)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.110 0.000 0.814 0.117 0.699 0.608 0.278 7.69 (+/-1.38) 2.00 (+/-0.3) 1.51 (+/-0.14) 1.47 (+/-0.28) 8.70 (+/-1.15) 1.57 (+/-0.16) 1.49 (+/-0.2) 1.51 (+/-0.25) 11.72 (+/-2.24) 1.44 (+/-0.21) 1.81 (+/-0.25) 1.59 (+/-0.19)
Esr1 estrogen receptor 1 0.726 0.000 0.284 0.600 0.191 0.053 0.530 2.34 (+/-0.83) 4.80 (+/-0.98) 4.41 (+/-0.51) 5.72 (+/-0.91) 1.11 (+/-0.21) 3.28 (+/-0.69) 4.37 (+/-0.99) 4.74 (+/-0.62) 1.27 (+/-0.18) 3.85 (+/-0.9) 4.84 (+/-0.67) 5.57 (+/-0.56)
Esr2 estrogen receptor 2 0.067 0.000 0.922 0.461 0.084 0.178 0.094 1.72 (+/-0.43) 2.40 (+/-0.37) 2.63 (+/-0.18) 3.96 (+/-0.42) 1.44 (+/-0.17) 1.66 (+/-0.16) 2.46 (+/-0.36) 3.22 (+/-0.37) 1.10 (+/-0.1) 1.87 (+/-0.29) 3.08 (+/-0.41) 3.93 (+/-0.5)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.438 0.000 0.985 0.457 0.694 0.501 0.029 1.27 (+/-0.28) 2.04 (+/-0.36) 1.78 (+/-0.19) 2.28 (+/-0.34) 1.51 (+/-0.19) 1.60 (+/-0.21) 1.65 (+/-0.25) 2.34 (+/-0.38) 1.75 (+/-0.21) 1.30 (+/-0.13) 2.22 (+/-0.3) 2.16 (+/-0.32)
Gper G protein-coupled estrogen receptor 1 0.828 0.120 0.927 0.199 0.540 0.003 0.027 1.43 (+/-0.26) 1.29 (+/-0.19) 1.35 (+/-0.15) 1.32 (+/-0.23) 1.30 (+/-0.12) 1.25 (+/-0.13) 1.47 (+/-0.15) 1.31 (+/-0.14) 1.48 (+/-0.1) 1.21 (+/-0.17) 1.52 (+/-0.19) 1.37 (+/-0.13)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.417 0.000 0.909 0.084 0.216 0.580 0.212 1.37 (+/-0.27) 1.50 (+/-0.17) 1.51 (+/-0.14) 2.03 (+/-0.26) 1.34 (+/-0.12) 1.20 (+/-0.08) 1.44 (+/-0.11) 1.79 (+/-0.2) 1.58 (+/-0.23) 1.21 (+/-0.13) 1.73 (+/-0.16) 1.87 (+/-0.17)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.569 0.023 0.471 0.199 0.431 0.437 0.011 1.26 (+/-0.17) 1.44 (+/-0.19) 1.27 (+/-0.11) 1.82 (+/-0.11) 1.50 (+/-0.12) 1.19 (+/-0.11) 1.39 (+/-0.13) 1.56 (+/-0.2) 1.60 (+/-0.15) 1.11 (+/-0.13) 1.55 (+/-0.12) 1.66 (+/-0.11)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.622 0.000 0.546 0.290 0.684 0.817 0.075 1.57 (+/-0.16) 1.24 (+/-0.14) 1.60 (+/-0.21) 2.17 (+/-0.36) 1.98 (+/-0.06) 1.39 (+/-0.11) 1.37 (+/-0.2) 1.66 (+/-0.15) 2.20 (+/-0.38) 1.09 (+/-0.1) 1.71 (+/-0.2) 2.13 (+/-0.18)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.410 0.000 0.460 0.068 0.727 0.721 0.085 1.05 (+/-0.16) 1.84 (+/-0.2) 1.95 (+/-0.14) 2.25 (+/-0.26) 1.29 (+/-0.24) 1.38 (+/-0.12) 1.79 (+/-0.22) 2.30 (+/-0.22) 1.29 (+/-0.22) 1.26 (+/-0.15) 2.02 (+/-0.21) 2.01 (+/-0.08)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.260 0.000 0.749 0.189 0.798 0.611 0.017 1.99 (+/-0.3) 1.70 (+/-0.24) 1.66 (+/-0.15) 2.05 (+/-0.35) 2.46 (+/-0.24) 1.62 (+/-0.16) 1.60 (+/-0.21) 1.81 (+/-0.24) 2.62 (+/-0.24) 1.09 (+/-0.13) 1.81 (+/-0.2) 1.90 (+/-0.19)
Igf1r insulin-like growth factor 1 receptor 0.345 0.000 0.857 0.353 0.382 0.113 0.031 1.08 (+/-0.14) 1.42 (+/-0.18) 1.40 (+/-0.14) 1.84 (+/-0.17) 1.07 (+/-0.11) 1.26 (+/-0.11) 1.50 (+/-0.2) 1.62 (+/-0.2) 1.35 (+/-0.18) 1.14 (+/-0.1) 1.56 (+/-0.14) 1.81 (+/-0.18)
Kiss1r KISS1 receptor 0.148 0.000 0.755 0.626 0.587 0.133 0.006 1.52 (+/-0.23) 1.97 (+/-0.28) 2.33 (+/-0.23) 2.94 (+/-0.52) 1.54 (+/-0.04) 1.63 (+/-0.13) 2.27 (+/-0.32) 2.77 (+/-0.34) 1.51 (+/-0.15) 1.58 (+/-0.32) 2.78 (+/-0.39) 2.77 (+/-0.33)
Mc3r melanocortin 3 receptor 0.282 0.000 0.839 0.952 0.010 0.268 0.100 1.96 (+/-0.47) 3.43 (+/-0.66) 4.17 (+/-0.51) 4.89 (+/-0.69) 1.48 (+/-0.29) 2.50 (+/-0.53) 2.63 (+/-0.34) 3.93 (+/-0.72) 1.44 (+/-0.36) 2.81 (+/-0.66) 4.99 (+/-1.12) 5.47 (+/-0.62)
Mc4r melanocortin 4 receptor 0.096 0.000 0.457 0.141 0.657 0.731 0.168 1.24 (+/-0.17) 1.96 (+/-0.26) 1.92 (+/-0.23) 2.60 (+/-0.41) 1.64 (+/-0.23) 1.75 (+/-0.2) 1.75 (+/-0.35) 2.49 (+/-0.36) 1.61 (+/-0.23) 1.62 (+/-0.35) 2.95 (+/-0.65) 3.37 (+/-0.36)
Oxtr oxytocin receptor 0.922 0.000 0.961 0.298 0.801 0.224 0.241 2.55 (+/-0.52) 1.49 (+/-0.22) 1.43 (+/-0.15) 2.03 (+/-0.45) 2.05 (+/-0.13) 1.27 (+/-0.14) 1.40 (+/-0.13) 1.71 (+/-0.21) 2.52 (+/-0.28) 0.96 (+/-0.1) 1.85 (+/-0.3) 1.89 (+/-0.22)
Pdyn prodynorphin 0.197 0.000 0.402 0.495 0.012 0.121 0.056 1.56 (+/-0.37) 1.96 (+/-0.16) 2.58 (+/-0.41) 3.21 (+/-0.52) 1.11 (+/-0.08) 1.34 (+/-0.13) 1.93 (+/-0.26) 2.51 (+/-0.33) 1.33 (+/-0.23) 1.83 (+/-0.17) 3.35 (+/-0.47) 2.75 (+/-0.23)
Per2 period homolog 2 0.248 0.000 0.636 0.913 0.006 0.448 0.006 1.17 (+/-0.26) 2.18 (+/-0.4) 2.28 (+/-0.26) 3.32 (+/-0.34) 1.28 (+/-0.17) 1.68 (+/-0.2) 2.29 (+/-0.25) 2.37 (+/-0.3) 1.35 (+/-0.14) 1.79 (+/-0.34) 2.69 (+/-0.36) 2.75 (+/-0.31)
Pgr progesterone receptor 0.805 0.000 0.357 0.420 0.145 0.531 0.579 1.52 (+/-0.25) 2.12 (+/-0.35) 3.15 (+/-0.35) 4.29 (+/-0.8) 1.39 (+/-0.15) 1.66 (+/-0.16) 2.95 (+/-0.36) 3.78 (+/-0.43) 1.41 (+/-0.11) 1.71 (+/-0.27) 3.71 (+/-0.45) 4.49 (+/-0.4)
Slc17a6 solute carrier family 17, member 6 0.378 0.000 0.253 0.895 0.010 0.101 0.126 1.27 (+/-0.21) 1.58 (+/-0.21) 1.47 (+/-0.09) 1.90 (+/-0.23) 1.14 (+/-0.17) 1.14 (+/-0.14) 1.41 (+/-0.11) 1.60 (+/-0.19) 1.22 (+/-0.17) 1.28 (+/-0.21) 1.89 (+/-0.14) 1.81 (+/-0.12)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.897 0.000 0.233 0.102 0.539 0.473 0.067 1.20 (+/-0.18) 1.67 (+/-0.25) 1.60 (+/-0.14) 1.83 (+/-0.25) 1.37 (+/-0.12) 1.50 (+/-0.24) 1.86 (+/-0.38) 2.09 (+/-0.36) 1.32 (+/-0.12) 1.17 (+/-0.1) 1.77 (+/-0.23) 1.68 (+/-0.22)
Tgfa transforming growth factor, alpha 0.889 0.000 0.969 0.553 0.272 0.649 0.007 1.28 (+/-0.21) 1.24 (+/-0.15) 1.50 (+/-0.16) 1.86 (+/-0.23) 1.40 (+/-0.2) 1.13 (+/-0.11) 1.34 (+/-0.2) 1.75 (+/-0.21) 1.53 (+/-0.19) 1.02 (+/-0.09) 1.83 (+/-0.27) 1.77 (+/-0.18)
Tgfb1 transforming growth factor, beta 1 0.979 0.068 0.410 0.244 0.763 0.708 0.098 1.70 (+/-0.32) 1.63 (+/-0.28) 1.41 (+/-0.08) 1.69 (+/-0.25) 1.88 (+/-0.23) 1.30 (+/-0.05) 1.45 (+/-0.18) 1.87 (+/-0.29) 1.95 (+/-0.17) 1.26 (+/-0.15) 1.73 (+/-0.21) 1.67 (+/-0.16)
Thra thyroid hormone receptor, alpha 0.835 0.087 0.728 0.124 0.162 0.419 0.001 1.28 (+/-0.22) 1.78 (+/-0.27) 1.51 (+/-0.17) 2.11 (+/-0.16) 1.55 (+/-0.18) 1.20 (+/-0.12) 1.51 (+/-0.19) 1.72 (+/-0.22) 1.57 (+/-0.16) 1.14 (+/-0.14) 1.91 (+/-0.25) 1.76 (+/-0.21)
Thrb thyroid hormone receptor, beta 0.353 0.000 0.980 0.242 0.555 0.344 0.103 1.16 (+/-0.18) 1.97 (+/-0.32) 1.96 (+/-0.18) 2.34 (+/-0.39) 1.41 (+/-0.19) 1.49 (+/-0.11) 1.82 (+/-0.23) 2.42 (+/-0.33) 1.37 (+/-0.15) 1.36 (+/-0.12) 2.23 (+/-0.23) 2.62 (+/-0.23)
Gene 
Symbol Gene Name Sex Age Trt Sex/Age Sex Trt Age/Trt
Sex/Age 
/Trt
Ahr aryl hydrocarbon receptor 0.410 0.000 0.432 0.000 0.693 0.000 0.000 3.35 (+/-0.39) 1.79 (+/-0.27) 1.62 (+/-0.14) 1.70 (+/-0.35) 3.70 (+/-0.36) 1.83 (+/-0.25) 1.96 (+/-0.36) 1.93 (+/-0.41) 4.92 (+/-0.8) 1.58 (+/-0.17) 1.75 (+/-0.23) 1.42 (+/-0.14)
Avp arginine vasopressin 0.743 0.000 0.353 0.002 0.420 0.002 0.015 1.38 (+/-0.16) 4.71 (+/-1.59) 3.36 (+/-0.52) 3.28 (+/-0.45) 0.96 (+/-0.17) 2.80 (+/-0.51) 3.05 (+/-1.01) 7.03 (+/-3.93) 1.20 (+/-0.21) 3.13 (+/-0.78) 2.23 (+/-0.86) 3.81 (+/-1.26)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.634 0.346 0.988 0.256 0.923 0.485 0.130 1.22 (+/-0.15) 1.49 (+/-0.2) 1.38 (+/-0.08) 1.53 (+/-0.18) 1.52 (+/-0.12) 1.50 (+/-0.27) 1.50 (+/-0.24) 1.93 (+/-0.42) 1.68 (+/-0.26) 1.22 (+/-0.08) 1.46 (+/-0.1) 1.64 (+/-0.17)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.437 0.037 0.936 0.057 0.913 0.104 0.030 1.29 (+/-0.17) 1.40 (+/-0.16) 1.23 (+/-0.1) 1.60 (+/-0.22) 1.53 (+/-0.13) 1.30 (+/-0.13) 1.39 (+/-0.16) 1.62 (+/-0.23) 1.69 (+/-0.28) 1.08 (+/-0.08) 1.51 (+/-0.14) 1.64 (+/-0.11)
Gal galanin prepropeptide 0.995 0.000 0.799 0.000 0.308 0.000 0.000 1.78 (+/-0.57) 4.08 (+/-0.58) 4.74 (+/-0.66) 7.08 (+/-1.26) 1.41 (+/-0.28) 2.61 (+/-0.46) 4.17 (+/-0.39) 6.11 (+/-0.99) 1.51 (+/-0.33) 2.92 (+/-0.61) 6.74 (+/-1.38) 6.28 (+/-0.68)
Gnrh1 gonadotropin-releasing hormone 1 0.790 0.000 0.944 0.000 0.711 0.000 0.000 1.55 (+/-0.27) 3.68 (+/-0.64) 4.37 (+/-0.49) 4.28 (+/-0.84) 1.64 (+/-0.3) 2.26 (+/-0.3) 3.71 (+/-0.6) 4.49 (+/-0.55) 1.40 (+/-0.14) 2.36 (+/-0.29) 4.75 (+/-0.39) 4.06 (+/-0.71)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.938 0.079 0.856 0.112 0.832 0.375 0.057 1.39 (+/-0.24) 1.18 (+/-0.12) 1.25 (+/-0.14) 1.59 (+/-0.18) 1.44 (+/-0.13) 1.11 (+/-0.03) 1.17 (+/-0.09) 1.36 (+/-0.17) 1.42 (+/-0.12) 1.04 (+/-0.05) 1.34 (+/-0.09) 1.37 (+/-0.06)
Grik2 glutamate receptor, ionotropic, kainate 2 0.942 0.003 0.630 0.002 0.808 0.081 0.019 1.49 (+/-0.14) 1.31 (+/-0.17) 1.17 (+/-0.08) 1.40 (+/-0.18) 1.82 (+/-0.15) 1.12 (+/-0.04) 1.15 (+/-0.14) 1.25 (+/-0.17) 1.65 (+/-0.14) 1.20 (+/-0.06) 1.33 (+/-0.08) 1.31 (+/-0.09)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.484 0.323 0.697 0.509 0.559 0.790 0.553 1.19 (+/-0.19) 1.44 (+/-0.2) 1.29 (+/-0.15) 1.88 (+/-0.35) 1.42 (+/-0.14) 1.29 (+/-0.12) 1.36 (+/-0.17) 1.49 (+/-0.2) 1.70 (+/-0.19) 1.16 (+/-0.07) 1.62 (+/-0.13) 1.71 (+/-0.13)
Igf1 insulin-like growth factor 1 0.016 0.000 0.617 0.000 0.227 0.000 0.000 2.01 (+/-0.32) 1.29 (+/-0.19) 1.30 (+/-0.19) 1.38 (+/-0.19) 2.73 (+/-0.33) 1.14 (+/-0.15) 1.24 (+/-0.15) 1.41 (+/-0.23) 3.21 (+/-0.57) 1.06 (+/-0.14) 1.20 (+/-0.08) 1.16 (+/-0.04)
Kiss1 KiSS-1 metastasis-suppressor 0.000 0.000 0.266 0.000 0.001 0.000 0.000 2.45 (+/-0.92) 2.30 (+/-0.64) 8.97 (+/-0.77) 13.33 (+/-1.94) 2.25 (+/-0.68) 1.08 (+/-0.11) 8.14 (+/-2.65) 13.62 (+/-1.66) 2.07 (+/-0.47) 1.29 (+/-0.3) 14.42 (+/-2.79) 9.57 (+/-0.89)
Lepr leptin receptor 0.431 0.000 0.846 0.000 0.943 0.000 0.000 1.49 (+/-0.22) 2.03 (+/-0.13) 2.85 (+/-0.52) 3.79 (+/-0.59) 1.44 (+/-0.19) 1.61 (+/-0.12) 2.80 (+/-0.35) 4.40 (+/-0.55) 1.29 (+/-0.17) 2.16 (+/-0.25) 3.44 (+/-0.1) 3.37 (+/-0.41)
Oxt oxytocin, prepropeptide 0.900 0.000 0.730 0.000 0.644 0.000 0.000 2.85 (+/-0.65) 8.88 (+/-3.22) 18.23 (+/-3.91) 13.40 (+/-3.29) 1.51 (+/-0.39) 8.30 (+/-2.34) 11.98 (+/-2.66) 15.56 (+/-4.16) 0.99 (+/-0.33) 9.60 (+/-2.86) 13.46 (+/-3.52) 20.15 (+/-5.17)
Tac2 tachykinin 2 0.100 0.000 0.903 0.000 0.605 0.002 0.006 1.18 (+/-0.2) 1.41 (+/-0.14) 1.61 (+/-0.21) 1.98 (+/-0.18) 1.55 (+/-0.28) 1.20 (+/-0.11) 1.49 (+/-0.16) 1.71 (+/-0.29) 1.74 (+/-0.42) 1.33 (+/-0.25) 2.15 (+/-0.7) 1.87 (+/-0.22)
Dnmt3l DNA (cytosine-5-)-methyltransferase 3l
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Symbol Gene Name Sex Age Trt Sex X Age Sex X Trt Age X Trt
Sex X Age 
X Trt
18S Eukaryotic 18S RNA, 18S ribosomal 1 0.785 0.262 0.616 0.462 0.961 0.776 0.136 1.14 (+/-0.18) 1.31 (+/-0.16) 1.35 (+/-0.16) 1.25 (+/-0.16) 1.39 (+/-0.14) 1.27 (+/-0.07) 1.46 (+/-0.1) 1.20 (+/-0.07) 1.27 (+/-0.15) 1.33 (+/-0.09) 1.27 (+/-0.16) 1.24 (+/-0.1)
Ahr aryl hydrocarbon receptor 0.467 0.000 0.353 0.252 0.056 0.951 0.991 2.45 (+/-0.25) 1.72 (+/-0.35) 1.26 (+/-0.24) 1.30 (+/-0.27) 2.27 (+/-0.37) 1.35 (+/-0.23) 1.26 (+/-0.22) 1.69 (+/-0.45) 3.02 (+/-0.51) 1.83 (+/-0.2) 1.62 (+/-0.23) 2.08 (+/-0.45)
Ar androgen receptor 0.987 0.000 0.996 0.460 0.163 0.817 0.033 1.32 (+/-0.13) 2.19 (+/-0.37) 2.46 (+/-0.43) 1.89 (+/-0.27) 1.28 (+/-0.23) 1.71 (+/-0.25) 2.01 (+/-0.48) 2.37 (+/-0.37) 1.49 (+/-0.18) 2.28 (+/-0.2) 1.93 (+/-0.27) 2.17 (+/-0.19)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.824 0.155 0.654 0.928 0.347 0.728 0.865 1.42 (+/-0.14) 1.54 (+/-0.23) 1.43 (+/-0.23) 1.46 (+/-0.23) 1.39 (+/-0.27) 1.34 (+/-0.24) 1.25 (+/-0.28) 1.84 (+/-0.23) 1.64 (+/-0.23) 1.52 (+/-0.19) 1.44 (+/-0.24) 1.66 (+/-0.2)
Avpr1a arginine vasopressin receptor 1A 0.149 0.000 0.697 0.465 0.174 0.361 0.459 2.74 (+/-0.38) 2.04 (+/-0.24) 1.67 (+/-0.22) 1.25 (+/-0.21) 1.88 (+/-0.25) 1.37 (+/-0.24) 1.45 (+/-0.23) 1.68 (+/-0.23) 2.20 (+/-0.19) 1.91 (+/-0.24) 1.84 (+/-0.29) 1.70 (+/-0.23)
Bdnf brain-derived neurotrophic factor 0.578 0.000 0.981 0.960 0.341 0.513 0.412 3.48 (+/-0.46) 1.60 (+/-0.28) 1.97 (+/-0.46) 1.69 (+/-0.43) 3.63 (+/-0.86) 1.79 (+/-0.3) 1.58 (+/-0.44) 1.42 (+/-0.21) 3.53 (+/-0.38) 2.07 (+/-0.28) 1.71 (+/-0.26) 1.32 (+/-0.21)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.265 0.014 0.856 0.686 0.160 0.853 0.289 2.19 (+/-0.28) 1.86 (+/-0.35) 1.91 (+/-0.33) 1.53 (+/-0.31) 2.01 (+/-0.39) 1.49 (+/-0.3) 1.31 (+/-0.26) 2.16 (+/-0.36) 2.26 (+/-0.28) 1.91 (+/-0.24) 1.71 (+/-0.25) 1.98 (+/-0.34)
Esr1 estrogen receptor 1 0.942 0.000 0.848 0.071 0.300 0.932 0.549 1.60 (+/-0.28) 1.88 (+/-0.34) 2.12 (+/-0.24) 2.35 (+/-0.45) 1.36 (+/-0.18) 1.69 (+/-0.36) 1.76 (+/-0.25) 2.43 (+/-0.35) 1.42 (+/-0.26) 1.95 (+/-0.28) 2.08 (+/-0.34) 2.78 (+/-0.54)
Esr2 estrogen receptor 2 0.707 0.000 0.356 0.500 0.080 0.731 0.611 1.32 (+/-0.24) 1.68 (+/-0.38) 2.12 (+/-0.17) 2.75 (+/-0.54) 1.18 (+/-0.2) 1.17 (+/-0.13) 1.89 (+/-0.18) 3.88 (+/-0.55) 1.34 (+/-0.23) 1.55 (+/-0.18) 2.21 (+/-0.33) 3.00 (+/-0.43)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.317 0.064 0.224 0.486 0.137 0.950 0.083 1.57 (+/-0.19) 1.65 (+/-0.23) 1.83 (+/-0.22) 1.66 (+/-0.21) 1.72 (+/-0.21) 1.74 (+/-0.28) 1.44 (+/-0.17) 2.42 (+/-0.39) 1.92 (+/-0.19) 1.79 (+/-0.23) 1.87 (+/-0.22) 2.25 (+/-0.37)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.731 0.001 0.765 0.767 0.194 0.826 0.157 2.74 (+/-0.46) 2.25 (+/-0.2) 2.12 (+/-0.23) 1.81 (+/-0.25) 2.41 (+/-0.36) 1.96 (+/-0.23) 1.82 (+/-0.3) 2.35 (+/-0.35) 2.77 (+/-0.26) 2.33 (+/-0.28) 2.13 (+/-0.3) 2.26 (+/-0.37)
Gal galanin prepropeptide 0.760 0.000 0.189 0.861 0.258 0.883 0.761 1.38 (+/-0.24) 3.33 (+/-0.9) 4.71 (+/-0.88) 4.79 (+/-0.96) 1.61 (+/-0.42) 3.10 (+/-0.55) 3.68 (+/-0.99) 6.06 (+/-1.47) 2.03 (+/-0.4) 2.37 (+/-0.31) 3.52 (+/-0.55) 4.41 (+/-0.9)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.357 0.160 0.955 0.763 0.731 0.868 0.502 1.36 (+/-0.22) 1.77 (+/-0.44) 1.81 (+/-0.44) 1.50 (+/-0.31) 1.28 (+/-0.29) 1.30 (+/-0.31) 1.81 (+/-0.58) 2.01 (+/-0.37) 1.59 (+/-0.32) 1.59 (+/-0.16) 1.52 (+/-0.35) 1.76 (+/-0.23)
Gnrh1 gonadotropin-releasing hormone 1 0.104 0.115 0.280 0.242 0.735 1.000 0.313 1.61 (+/-0.28) 1.61 (+/-0.37) 2.30 (+/-0.27) 2.26 (+/-0.49) 1.12 (+/-0.23) 1.37 (+/-0.43) 2.24 (+/-0.45) 2.34 (+/-0.54) 1.84 (+/-0.48) 1.64 (+/-0.51) 1.61 (+/-0.26) 2.12 (+/-0.48)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.480 0.867 0.769 0.763 0.210 0.874 0.109 1.50 (+/-0.15) 1.72 (+/-0.27) 1.97 (+/-0.31) 1.48 (+/-0.23) 1.58 (+/-0.21) 1.52 (+/-0.2) 1.41 (+/-0.29) 1.79 (+/-0.22) 1.80 (+/-0.21) 1.82 (+/-0.23) 1.65 (+/-0.26) 1.58 (+/-0.18)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.775 0.000 0.701 0.397 0.705 0.711 0.134 1.81 (+/-0.15) 1.76 (+/-0.26) 1.61 (+/-0.25) 1.25 (+/-0.17) 1.76 (+/-0.21) 1.42 (+/-0.19) 1.16 (+/-0.19) 1.47 (+/-0.17) 1.78 (+/-0.15) 1.70 (+/-0.19) 1.38 (+/-0.18) 1.34 (+/-0.1)
Grik2 glutamate receptor, ionotropic, kainate 2 0.689 0.003 0.690 0.604 0.202 0.896 0.018 1.65 (+/-0.17) 1.32 (+/-0.19) 1.61 (+/-0.2) 1.17 (+/-0.15) 1.42 (+/-0.14) 1.29 (+/-0.14) 1.05 (+/-0.13) 1.41 (+/-0.19) 1.78 (+/-0.2) 1.51 (+/-0.12) 1.33 (+/-0.16) 1.35 (+/-0.11)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.736 0.000 0.928 0.420 0.037 0.895 0.200 1.61 (+/-0.16) 1.41 (+/-0.22) 1.33 (+/-0.15) 1.07 (+/-0.16) 1.53 (+/-0.23) 1.30 (+/-0.17) 1.06 (+/-0.19) 1.33 (+/-0.19) 1.82 (+/-0.21) 1.57 (+/-0.15) 1.31 (+/-0.2) 1.33 (+/-0.15)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.932 0.341 0.808 0.890 0.096 0.774 0.238 1.64 (+/-0.26) 1.43 (+/-0.21) 1.54 (+/-0.29) 1.19 (+/-0.23) 1.47 (+/-0.23) 1.35 (+/-0.21) 1.07 (+/-0.22) 1.36 (+/-0.16) 1.63 (+/-0.15) 1.47 (+/-0.18) 1.47 (+/-0.25) 1.43 (+/-0.14)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.926 0.000 0.604 0.764 0.447 0.778 0.299 2.20 (+/-0.24) 1.73 (+/-0.35) 1.65 (+/-0.2) 1.56 (+/-0.23) 2.34 (+/-0.39) 1.36 (+/-0.22) 1.62 (+/-0.32) 1.77 (+/-0.18) 2.24 (+/-0.31) 1.77 (+/-0.14) 1.60 (+/-0.21) 1.62 (+/-0.15)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.968 0.000 0.739 0.715 0.349 0.816 0.226 1.15 (+/-0.17) 2.77 (+/-0.49) 3.75 (+/-0.73) 3.00 (+/-0.61) 1.41 (+/-0.42) 2.57 (+/-0.45) 3.05 (+/-0.89) 3.04 (+/-0.46) 1.22 (+/-0.07) 2.72 (+/-0.23) 2.71 (+/-0.31) 3.31 (+/-0.63)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.587 0.000 0.075 0.467 0.004 0.349 0.138 3.05 (+/-0.33) 1.74 (+/-0.34) 1.70 (+/-0.3) 1.54 (+/-0.24) 3.05 (+/-0.53) 1.75 (+/-0.27) 1.23 (+/-0.21) 1.84 (+/-0.21) 3.28 (+/-0.33) 1.95 (+/-0.2) 1.85 (+/-0.33) 1.73 (+/-0.24)
Igf1 insulin-like growth factor 1 0.974 0.085 0.417 0.919 0.559 0.960 0.819 1.98 (+/-0.34) 1.45 (+/-0.3) 1.65 (+/-0.33) 1.61 (+/-0.33) 1.86 (+/-0.34) 1.59 (+/-0.22) 1.72 (+/-0.42) 1.77 (+/-0.28) 1.73 (+/-0.22) 1.68 (+/-0.33) 1.50 (+/-0.34) 2.12 (+/-0.43)
Igf1r insulin-like growth factor 1 receptor 0.872 0.003 0.569 0.896 0.116 0.676 0.613 1.43 (+/-0.23) 1.57 (+/-0.27) 1.42 (+/-0.16) 1.48 (+/-0.21) 1.12 (+/-0.21) 1.37 (+/-0.22) 1.46 (+/-0.3) 1.91 (+/-0.27) 1.49 (+/-0.2) 1.70 (+/-0.21) 1.47 (+/-0.21) 2.07 (+/-0.26)
Kiss1 KiSS-1 metastasis-suppressor 0.000 0.000 0.337 0.276 0.592 0.971 0.729 3.58 (+/-0.86) 4.77 (+/-1.66) 13.74 (+/-2.96) 10.34 (+/-2.5) 2.87 (+/-0.59) 3.86 (+/-0.77) 8.12 (+/-1.54) 13.17 (+/-2.77) 3.14 (+/-0.83) 4.04 (+/-0.7) 8.14 (+/-0.98) 8.45 (+/-2.05)
Kiss1r KISS1 receptor 0.086 0.000 0.635 0.577 0.130 0.944 0.689 1.41 (+/-0.28) 1.98 (+/-0.49) 2.33 (+/-0.38) 3.20 (+/-0.89) 1.34 (+/-0.28) 1.67 (+/-0.31) 1.88 (+/-0.25) 3.91 (+/-0.67) 1.42 (+/-0.12) 1.61 (+/-0.18) 2.62 (+/-0.29) 3.45 (+/-0.44)
Lepr leptin receptor 0.821 0.000 0.616 0.495 0.207 0.642 0.030 1.74 (+/-0.23) 2.00 (+/-0.34) 2.28 (+/-0.28) 2.24 (+/-0.27) 1.04 (+/-0.12) 1.85 (+/-0.23) 1.84 (+/-0.25) 2.90 (+/-0.44) 1.61 (+/-0.23) 2.46 (+/-0.31) 2.30 (+/-0.34) 2.76 (+/-0.31)
Mc3r melanocortin 3 receptor 0.824 0.277 0.413 0.408 0.006 0.808 0.410 1.59 (+/-0.26) 1.98 (+/-0.32) 1.76 (+/-0.22) 1.30 (+/-0.25) 1.22 (+/-0.23) 1.24 (+/-0.21) 1.38 (+/-0.32) 1.24 (+/-0.14) 1.41 (+/-0.18) 1.75 (+/-0.23) 1.50 (+/-0.27) 1.27 (+/-0.16)
Oxt oxytocin, prepropeptide 0.459 0.000 0.335 0.025 0.046 0.396 0.200 1.38 (+/-0.19) 5.99 (+/-1.98) 11.88 (+/-4.5) 7.49 (+/-1.86) 1.36 (+/-0.29) 3.60 (+/-0.99) 6.69 (+/-2.79) 17.80 (+/-4.61) 2.79 (+/-1.04) 7.94 (+/-1.63) 10.72 (+/-4.18) 15.89 (+/-4.79)
Per2 period homolog 2 0.949 0.016 0.710 0.389 0.070 0.896 0.569 1.90 (+/-0.4) 1.86 (+/-0.4) 1.97 (+/-0.36) 2.22 (+/-0.29) 1.64 (+/-0.26) 1.71 (+/-0.34) 1.61 (+/-0.36) 2.35 (+/-0.29) 1.83 (+/-0.33) 1.99 (+/-0.31) 2.02 (+/-0.4) 2.84 (+/-0.54)
Pgr progesterone receptor 0.000 0.000 0.193 0.087 0.186 0.939 0.186 1.49 (+/-0.14) 1.66 (+/-0.29) 4.88 (+/-0.7) 3.88 (+/-0.59) 1.37 (+/-0.18) 1.56 (+/-0.21) 3.25 (+/-0.38) 5.07 (+/-0.8) 1.42 (+/-0.18) 1.73 (+/-0.14) 3.86 (+/-0.62) 3.90 (+/-0.72)
Slc17a6 solute carrier family 17, member 6 0.435 0.003 0.508 0.768 0.222 0.504 0.106 2.35 (+/-0.2) 2.01 (+/-0.4) 2.26 (+/-0.41) 1.66 (+/-0.29) 2.29 (+/-0.28) 1.79 (+/-0.16) 1.41 (+/-0.26) 1.61 (+/-0.19) 2.35 (+/-0.21) 2.18 (+/-0.3) 1.83 (+/-0.32) 1.56 (+/-0.16)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.217 0.133 0.473 0.195 0.437 0.748 0.885 1.87 (+/-0.25) 2.00 (+/-0.31) 1.79 (+/-0.27) 1.79 (+/-0.37) 2.02 (+/-0.38) 1.85 (+/-0.38) 1.62 (+/-0.45) 2.22 (+/-0.3) 2.15 (+/-0.24) 2.17 (+/-0.23) 1.82 (+/-0.3) 1.90 (+/-0.24)
Tac2 tachykinin 2 0.000 0.000 0.458 0.006 0.666 0.860 0.322 2.62 (+/-0.66) 3.90 (+/-1.17) 10.28 (+/-1.7) 10.29 (+/-3.07) 2.24 (+/-0.31) 3.43 (+/-0.66) 6.52 (+/-0.76) 13.72 (+/-3.22) 2.59 (+/-0.55) 3.35 (+/-0.61) 8.86 (+/-1.28) 7.92 (+/-2.07)
Tgfa transforming growth factor, alpha 0.224 0.000 0.602 0.449 0.490 0.431 0.578 1.66 (+/-0.19) 1.67 (+/-0.31) 1.45 (+/-0.1) 1.79 (+/-0.34) 1.63 (+/-0.27) 1.33 (+/-0.21) 1.33 (+/-0.28) 2.50 (+/-0.41) 1.93 (+/-0.33) 1.50 (+/-0.19) 1.64 (+/-0.26) 1.99 (+/-0.3)
Tgfb1 transforming growth factor, beta 1 0.594 0.004 0.639 0.828 0.101 0.549 0.927 1.82 (+/-0.24) 1.62 (+/-0.32) 1.48 (+/-0.17) 1.66 (+/-0.31) 1.72 (+/-0.36) 1.30 (+/-0.27) 1.32 (+/-0.27) 2.17 (+/-0.35) 2.18 (+/-0.34) 1.59 (+/-0.18) 1.88 (+/-0.29) 2.13 (+/-0.34)
Thra thyroid hormone receptor, alpha 0.510 0.286 0.922 0.836 0.247 0.882 0.471 1.68 (+/-0.24) 1.68 (+/-0.35) 1.61 (+/-0.29) 1.30 (+/-0.24) 1.59 (+/-0.33) 1.37 (+/-0.26) 1.18 (+/-0.29) 1.68 (+/-0.25) 1.87 (+/-0.26) 1.72 (+/-0.23) 1.53 (+/-0.31) 1.43 (+/-0.24)
Thrb thyroid hormone receptor, beta 0.966 0.000 0.889 0.406 0.090 0.919 0.428 1.43 (+/-0.17) 2.89 (+/-0.55) 3.08 (+/-0.33) 2.71 (+/-0.44) 1.45 (+/-0.24) 2.29 (+/-0.43) 2.27 (+/-0.43) 4.01 (+/-0.62) 1.63 (+/-0.24) 2.69 (+/-0.35) 2.81 (+/-0.45) 4.30 (+/-0.77)
Gene 
Symbol Gene Name Sex Age Trt Sex/Age Sex Trt Age/Trt
Sex/Age 
/Trt
Avp arginine vasopressin 0.050 0.023 0.447 0.000 0.267 0.049 0.000 10.89 (+/-6.75) 7.99 (+/-2.27) 3.48 (+/-0.88) 1.57 (+/-0.28) 2.15 (+/-0.62) 12.87 (+/-5.62) 2.38 (+/-1.03) 3.43 (+/-1.) 3.91 (+/-1.15) 6.40 (+/-1.41) 1.99 (+/-0.51) 2.27 (+/-0.59)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.212 0.001 0.592 0.004 0.359 0.031 0.012 1.14 (+/-0.1) 1.60 (+/-0.21) 1.99 (+/-0.38) 1.57 (+/-0.17) 1.47 (+/-0.35) 1.11 (+/-0.11) 1.79 (+/-0.39) 1.80 (+/-0.18) 1.28 (+/-0.12) 1.89 (+/-0.21) 1.49 (+/-0.19) 1.53 (+/-0.29)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.802 0.000 0.994 0.000 0.995 0.000 0.000 6.49 (+/-0.81) 1.78 (+/-0.42) 1.25 (+/-0.21) 1.18 (+/-0.21) 5.76 (+/-1.34) 1.36 (+/-0.27) 1.54 (+/-0.45) 1.72 (+/-0.29) 5.61 (+/-0.71) 1.50 (+/-0.12) 1.54 (+/-0.3) 1.54 (+/-0.2)
Gnrhr gonadotropin-releasing hormone receptor 0.15 0.035 0.109 0.002 0.214 0.109 0.03 0.64 (+/-0.3) 0.93 (+/-0.09) 1.60 (+/-0.32) 1.54 (+/-0.5) 0.53 (+/-0.12) 0.71 (+/-0.24) 1.13 (+/-0.21) 3.94 (+/-1.14) 0.55 (+/-0.12) 1.09 (+/-0.29) 1.57 (+/-0.77) 0.94 (+/-0.29)
Gper G protein-coupled estrogen receptor 1 0.611 0.001 0.560 0.011 0.517 0.051 0.159 2.38 (+/-0.33) 1.60 (+/-0.36) 1.56 (+/-0.22) 1.11 (+/-0.17) 2.19 (+/-0.4) 1.56 (+/-0.35) 1.63 (+/-0.36) 1.43 (+/-0.19) 2.17 (+/-0.27) 1.87 (+/-0.29) 1.69 (+/-0.34) 1.59 (+/-0.23)
Mc4r melanocortin 4 receptor 0.092 0.034 0.802 0.074 0.622 0.065 0.223 1.57 (+/-0.26) 1.36 (+/-0.22) 1.85 (+/-0.46) 1.55 (+/-0.25) 1.68 (+/-0.3) 1.78 (+/-0.35) 1.36 (+/-0.32) 1.56 (+/-0.29) 2.56 (+/-0.65) 1.67 (+/-0.45) 0.91 (+/-0.07) 1.67 (+/-0.13)
Oxtr oxytocin receptor 0.086 0.000 0.558 0.000 0.282 0.005 0.009 1.67 (+/-0.18) 1.82 (+/-0.32) 3.14 (+/-0.55) 3.45 (+/-0.81) 1.63 (+/-0.29) 1.57 (+/-0.26) 3.38 (+/-0.78) 3.23 (+/-0.45) 1.76 (+/-0.32) 2.15 (+/-0.18) 3.16 (+/-0.69) 3.01 (+/-0.71)
Pdyn prodynorphin 0.085 0.182 0.517 0.216 0.129 0.386 0.107 2.53 (+/-0.3) 3.44 (+/-0.6) 3.26 (+/-0.57) 2.08 (+/-0.37) 2.35 (+/-0.38) 1.96 (+/-0.31) 3.12 (+/-0.84) 2.41 (+/-0.32) 2.52 (+/-0.19) 3.20 (+/-0.49) 2.73 (+/-0.61) 2.02 (+/-0.33)
Female Parametric Statistics
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Table 2.4, cont.  
EDC effects on gene expression in the ARC from P15 – P90 in males and females. Bold indicates effects that survived false 
discovery rate correction.
Gene 
Symbol Gene Name Sex Age Trt Sex X Age Sex X Trt Age X Trt
Sex X Age 
X Trt
18S Eukaryotic 18S RNA, 18S ribosomal 1 0.785 0.262 0.616 0.462 0.961 0.776 0.136 1.37 (+/-0.08) 1.24 (+/-0.11) 1.42 (+/-0.1) 1.05 (+/-0.12) 1.32 (+/-0.13) 1.55 (+/-0.13) 1.05 (+/-0.13) 1.30 (+/-0.07) 1.26 (+/-0.11) 1.35 (+/-0.08) 1.24 (+/-0.06) 1.18 (+/-0.14)
Ahr aryl hydrocarbon receptor 0.467 0.000 0.353 0.252 0.056 0.951 0.991 2.20 (+/-0.31) 1.51 (+/-0.31) 1.62 (+/-0.4) 1.65 (+/-0.18) 2.96 (+/-0.47) 1.57 (+/-0.35) 1.79 (+/-0.26) 2.48 (+/-0.62) 2.43 (+/-0.1) 1.30 (+/-0.3) 1.43 (+/-0.24) 2.02 (+/-0.35)
Ar androgen receptor 0.987 0.000 0.996 0.460 0.163 0.817 0.033 1.34 (+/-0.22) 2.16 (+/-0.42) 1.56 (+/-0.23) 2.85 (+/-0.32) 1.41 (+/-0.19) 2.09 (+/-0.42) 2.53 (+/-0.26) 2.33 (+/-0.27) 1.32 (+/-0.11) 1.40 (+/-0.24) 2.54 (+/-0.27) 1.99 (+/-0.36)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.824 0.155 0.654 0.928 0.347 0.728 0.865 1.41 (+/-0.25) 1.42 (+/-0.23) 1.14 (+/-0.13) 1.64 (+/-0.21) 1.60 (+/-0.24) 1.52 (+/-0.28) 1.49 (+/-0.21) 1.82 (+/-0.2) 1.60 (+/-0.14) 1.13 (+/-0.21) 1.50 (+/-0.15) 1.42 (+/-0.22)
Avpr1a arginine vasopressin receptor 1A 0.149 0.000 0.697 0.465 0.174 0.361 0.459 2.61 (+/-0.39) 1.59 (+/-0.24) 1.60 (+/-0.14) 1.87 (+/-0.29) 2.34 (+/-0.34) 1.92 (+/-0.28) 2.08 (+/-0.33) 1.87 (+/-0.27) 2.54 (+/-0.22) 1.37 (+/-0.26) 2.13 (+/-0.26) 1.72 (+/-0.31)
Bdnf brain-derived neurotrophic factor 0.578 0.000 0.981 0.960 0.341 0.513 0.412 3.77 (+/-0.61) 1.74 (+/-0.33) 1.07 (+/-0.12) 1.73 (+/-0.34) 3.39 (+/-0.45) 2.13 (+/-0.38) 1.91 (+/-0.36) 1.79 (+/-0.54) 3.11 (+/-0.52) 1.21 (+/-0.22) 2.01 (+/-0.23) 1.23 (+/-0.21)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.265 0.014 0.856 0.686 0.160 0.853 0.289 2.43 (+/-0.37) 1.86 (+/-0.38) 1.37 (+/-0.18) 2.15 (+/-0.25) 2.50 (+/-0.46) 1.68 (+/-0.39) 2.53 (+/-0.34) 2.20 (+/-0.3) 2.21 (+/-0.11) 1.36 (+/-0.3) 1.93 (+/-0.28) 1.87 (+/-0.39)
Esr1 estrogen receptor 1 0.942 0.000 0.848 0.071 0.300 0.932 0.549 1.08 (+/-0.18) 2.11 (+/-0.49) 2.09 (+/-0.25) 2.93 (+/-0.34) 1.47 (+/-0.21) 1.53 (+/-0.31) 3.14 (+/-0.46) 2.68 (+/-0.39) 1.11 (+/-0.14) 1.23 (+/-0.24) 2.75 (+/-0.45) 2.56 (+/-0.53)
Esr2 estrogen receptor 2 0.707 0.000 0.356 0.500 0.080 0.731 0.611 1.04 (+/-0.11) 1.46 (+/-0.24) 2.16 (+/-0.23) 3.24 (+/-0.33) 1.35 (+/-0.17) 1.61 (+/-0.29) 2.77 (+/-0.41) 3.88 (+/-0.39) 1.06 (+/-0.14) 0.96 (+/-0.11) 2.35 (+/-0.38) 2.89 (+/-0.34)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.317 0.064 0.224 0.486 0.137 0.950 0.083 1.75 (+/-0.23) 1.79 (+/-0.32) 1.57 (+/-0.19) 2.28 (+/-0.23) 2.02 (+/-0.26) 1.91 (+/-0.36) 2.68 (+/-0.32) 2.04 (+/-0.3) 1.84 (+/-0.16) 1.33 (+/-0.26) 2.02 (+/-0.29) 1.93 (+/-0.25)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.731 0.001 0.765 0.767 0.194 0.826 0.157 2.48 (+/-0.33) 2.06 (+/-0.28) 1.69 (+/-0.17) 2.49 (+/-0.33) 3.05 (+/-0.44) 2.54 (+/-0.54) 2.39 (+/-0.3) 2.05 (+/-0.29) 3.09 (+/-0.33) 1.47 (+/-0.28) 2.30 (+/-0.28) 1.87 (+/-0.29)
Gal galanin prepropeptide 0.760 0.000 0.189 0.861 0.258 0.883 0.761 1.32 (+/-0.27) 3.35 (+/-0.84) 3.25 (+/-0.55) 4.70 (+/-0.67) 1.80 (+/-0.35) 4.95 (+/-1.73) 4.96 (+/-0.72) 5.69 (+/-1.2) 1.15 (+/-0.2) 2.10 (+/-0.43) 3.60 (+/-0.44) 4.69 (+/-1.14)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.357 0.160 0.955 0.763 0.731 0.868 0.502 1.42 (+/-0.3) 1.68 (+/-0.34) 1.34 (+/-0.17) 2.05 (+/-0.25) 1.43 (+/-0.27) 1.80 (+/-0.42) 1.93 (+/-0.28) 2.08 (+/-0.25) 1.51 (+/-0.21) 1.35 (+/-0.33) 1.78 (+/-0.22) 1.78 (+/-0.38)
Gnrh1 gonadotropin-releasing hormone 1 0.104 0.115 0.280 0.242 0.735 1.000 0.313 2.00 (+/-0.44) 1.70 (+/-0.26) 1.78 (+/-0.38) 1.81 (+/-0.45) 1.97 (+/-0.64) 1.26 (+/-0.17) 1.43 (+/-0.31) 1.49 (+/-0.28) 1.22 (+/-0.18) 1.01 (+/-0.21) 1.99 (+/-0.32) 1.30 (+/-0.29)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.480 0.867 0.769 0.763 0.210 0.874 0.109 1.74 (+/-0.21) 1.58 (+/-0.26) 1.31 (+/-0.14) 1.90 (+/-0.27) 1.68 (+/-0.22) 1.52 (+/-0.33) 1.91 (+/-0.22) 1.66 (+/-0.16) 1.43 (+/-0.13) 1.25 (+/-0.2) 1.82 (+/-0.23) 1.24 (+/-0.2)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.775 0.000 0.701 0.397 0.705 0.711 0.134 1.97 (+/-0.18) 1.52 (+/-0.18) 1.12 (+/-0.15) 1.63 (+/-0.16) 1.80 (+/-0.23) 1.42 (+/-0.22) 1.58 (+/-0.14) 1.43 (+/-0.13) 2.03 (+/-0.25) 1.34 (+/-0.25) 1.69 (+/-0.14) 1.17 (+/-0.17)
Grik2 glutamate receptor, ionotropic, kainate 2 0.689 0.003 0.690 0.604 0.202 0.896 0.018 1.65 (+/-0.15) 1.41 (+/-0.2) 1.07 (+/-0.12) 1.68 (+/-0.15) 1.72 (+/-0.18) 1.27 (+/-0.18) 1.45 (+/-0.11) 1.43 (+/-0.15) 1.56 (+/-0.11) 1.13 (+/-0.16) 1.57 (+/-0.14) 1.27 (+/-0.19)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.736 0.000 0.928 0.420 0.037 0.895 0.200 1.84 (+/-0.23) 1.41 (+/-0.26) 1.01 (+/-0.13) 1.50 (+/-0.16) 1.84 (+/-0.26) 1.28 (+/-0.26) 1.70 (+/-0.2) 1.34 (+/-0.13) 1.53 (+/-0.11) 1.00 (+/-0.18) 1.41 (+/-0.14) 1.12 (+/-0.19)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.932 0.341 0.808 0.890 0.096 0.774 0.238 1.62 (+/-0.21) 1.44 (+/-0.3) 1.01 (+/-0.15) 1.76 (+/-0.27) 1.63 (+/-0.26) 1.55 (+/-0.28) 1.57 (+/-0.15) 1.48 (+/-0.21) 1.41 (+/-0.18) 1.02 (+/-0.22) 1.55 (+/-0.24) 1.08 (+/-0.14)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.926 0.000 0.604 0.764 0.447 0.778 0.299 2.19 (+/-0.27) 1.54 (+/-0.26) 1.36 (+/-0.21) 2.14 (+/-0.23) 2.31 (+/-0.35) 1.82 (+/-0.36) 2.03 (+/-0.19) 1.61 (+/-0.21) 1.92 (+/-0.2) 1.26 (+/-0.29) 1.93 (+/-0.19) 1.47 (+/-0.29)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.968 0.000 0.739 0.715 0.349 0.816 0.226 1.32 (+/-0.32) 2.79 (+/-0.53) 2.53 (+/-0.41) 3.52 (+/-0.42) 1.45 (+/-0.27) 2.95 (+/-0.6) 3.85 (+/-0.35) 2.70 (+/-0.26) 1.40 (+/-0.25) 2.08 (+/-0.64) 2.90 (+/-0.4) 2.46 (+/-0.45)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.587 0.000 0.075 0.467 0.004 0.349 0.138 2.72 (+/-0.27) 1.72 (+/-0.35) 1.33 (+/-0.17) 1.85 (+/-0.22) 4.49 (+/-0.25) 2.15 (+/-0.47) 2.12 (+/-0.25) 1.60 (+/-0.2) 3.22 (+/-0.34) 1.20 (+/-0.23) 1.71 (+/-0.14) 1.36 (+/-0.21)
Igf1 insulin-like growth factor 1 0.974 0.085 0.417 0.919 0.559 0.960 0.819 1.75 (+/-0.34) 1.53 (+/-0.32) 1.17 (+/-0.23) 1.81 (+/-0.22) 2.09 (+/-0.3) 1.82 (+/-0.45) 1.76 (+/-0.29) 2.05 (+/-0.45) 1.95 (+/-0.22) 1.11 (+/-0.19) 1.62 (+/-0.09) 1.94 (+/-0.37)
Igf1r insulin-like growth factor 1 receptor 0.872 0.003 0.569 0.896 0.116 0.676 0.613 1.29 (+/-0.19) 1.59 (+/-0.32) 1.22 (+/-0.18) 1.85 (+/-0.17) 1.41 (+/-0.21) 1.66 (+/-0.36) 1.79 (+/-0.18) 2.03 (+/-0.29) 1.37 (+/-0.15) 1.09 (+/-0.22) 1.64 (+/-0.16) 1.73 (+/-0.24)
Kiss1 KiSS-1 metastasis-suppressor 0.000 0.000 0.337 0.276 0.592 0.971 0.729 1.77 (+/-0.34) 2.15 (+/-0.63) 5.75 (+/-0.97) 5.13 (+/-0.64) 2.02 (+/-0.29) 2.18 (+/-0.76) 9.88 (+/-2.16) 6.14 (+/-1.39) 1.63 (+/-0.34) 1.75 (+/-0.49) 6.85 (+/-1.83) 4.89 (+/-1.02)
Kiss1r KISS1 receptor 0.086 0.000 0.635 0.577 0.130 0.944 0.689 1.26 (+/-0.17) 2.02 (+/-0.45) 2.75 (+/-0.39) 4.53 (+/-0.57) 1.46 (+/-0.2) 2.42 (+/-0.61) 3.81 (+/-0.47) 4.92 (+/-0.97) 1.45 (+/-0.17) 1.62 (+/-0.35) 2.49 (+/-0.37) 3.40 (+/-0.42)
Lepr leptin receptor 0.821 0.000 0.616 0.495 0.207 0.642 0.030 1.33 (+/-0.19) 2.22 (+/-0.43) 1.93 (+/-0.24) 3.40 (+/-0.34) 1.50 (+/-0.27) 1.58 (+/-0.19) 2.79 (+/-0.38) 2.60 (+/-0.39) 1.32 (+/-0.15) 1.83 (+/-0.3) 2.52 (+/-0.27) 2.33 (+/-0.4)
Mc3r melanocortin 3 receptor 0.824 0.277 0.413 0.408 0.006 0.808 0.410 1.43 (+/-0.22) 1.33 (+/-0.24) 1.19 (+/-0.3) 1.58 (+/-0.23) 1.59 (+/-0.32) 1.70 (+/-0.35) 1.92 (+/-0.33) 1.63 (+/-0.23) 1.09 (+/-0.11) 1.04 (+/-0.17) 1.82 (+/-0.21) 1.03 (+/-0.26)
Oxt oxytocin, prepropeptide 0.459 0.000 0.335 0.025 0.046 0.396 0.200 3.13 (+/-1.08) 5.31 (+/-1.29) 4.13 (+/-1.4) 10.64 (+/-2.28) 3.93 (+/-1.) 6.74 (+/-2.01) 12.22 (+/-3.76) 21.56 (+/-5.96) 4.14 (+/-0.81) 2.20 (+/-0.53) 4.28 (+/-0.56) 14.66 (+/-4.14)
Per2 period homolog 2 0.949 0.016 0.710 0.389 0.070 0.896 0.569 1.96 (+/-0.43) 1.63 (+/-0.33) 1.54 (+/-0.21) 2.22 (+/-0.28) 1.95 (+/-0.33) 1.85 (+/-0.39) 2.77 (+/-0.43) 2.59 (+/-0.43) 2.27 (+/-0.41) 1.14 (+/-0.23) 1.93 (+/-0.22) 1.97 (+/-0.42)
Pgr progesterone receptor 0.000 0.000 0.193 0.087 0.186 0.939 0.186 1.48 (+/-0.19) 1.43 (+/-0.29) 1.98 (+/-0.25) 2.94 (+/-0.31) 1.66 (+/-0.24) 1.47 (+/-0.29) 3.18 (+/-0.39) 3.21 (+/-0.42) 1.21 (+/-0.09) 0.98 (+/-0.16) 2.60 (+/-0.43) 2.55 (+/-0.44)
Slc17a6 solute carrier family 17, member 6 0.435 0.003 0.508 0.768 0.222 0.504 0.106 2.48 (+/-0.33) 1.82 (+/-0.27) 1.30 (+/-0.26) 2.03 (+/-0.42) 2.28 (+/-0.35) 1.89 (+/-0.23) 1.86 (+/-0.17) 1.80 (+/-0.2) 1.73 (+/-0.24) 1.53 (+/-0.29) 2.24 (+/-0.33) 1.25 (+/-0.24)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.217 0.133 0.473 0.195 0.437 0.748 0.885 2.01 (+/-0.34) 1.73 (+/-0.38) 1.58 (+/-0.27) 2.62 (+/-0.29) 2.31 (+/-0.4) 1.95 (+/-0.38) 2.12 (+/-0.27) 2.90 (+/-0.4) 2.14 (+/-0.22) 1.54 (+/-0.41) 2.23 (+/-0.35) 2.04 (+/-0.31)
Tac2 tachykinin 2 0.000 0.000 0.458 0.006 0.666 0.860 0.322 2.05 (+/-0.42) 1.46 (+/-0.27) 3.03 (+/-0.42) 4.92 (+/-0.93) 2.02 (+/-0.36) 1.52 (+/-0.38) 5.78 (+/-1.3) 5.50 (+/-1.21) 2.23 (+/-0.35) 1.28 (+/-0.3) 2.61 (+/-0.54) 4.70 (+/-1.)
Tgfa transforming growth factor, alpha 0.224 0.000 0.602 0.449 0.490 0.431 0.578 1.85 (+/-0.35) 1.48 (+/-0.31) 1.36 (+/-0.19) 2.47 (+/-0.32) 1.89 (+/-0.27) 1.47 (+/-0.31) 2.24 (+/-0.33) 2.45 (+/-0.37) 1.99 (+/-0.2) 1.05 (+/-0.18) 1.89 (+/-0.24) 2.00 (+/-0.38)
Tgfb1 transforming growth factor, beta 1 0.594 0.004 0.639 0.828 0.101 0.549 0.927 1.80 (+/-0.35) 1.62 (+/-0.34) 1.38 (+/-0.25) 2.16 (+/-0.18) 1.92 (+/-0.33) 1.61 (+/-0.34) 2.04 (+/-0.2) 2.43 (+/-0.36) 1.92 (+/-0.27) 1.09 (+/-0.25) 1.85 (+/-0.26) 1.85 (+/-0.35)
Thra thyroid hormone receptor, alpha 0.510 0.286 0.922 0.836 0.247 0.882 0.471 1.95 (+/-0.32) 1.62 (+/-0.35) 1.14 (+/-0.15) 1.83 (+/-0.24) 1.83 (+/-0.31) 1.61 (+/-0.36) 1.92 (+/-0.31) 1.71 (+/-0.25) 1.75 (+/-0.21) 1.23 (+/-0.26) 1.60 (+/-0.25) 1.34 (+/-0.25)
Thrb thyroid hormone receptor, beta 0.966 0.000 0.889 0.406 0.090 0.919 0.428 1.39 (+/-0.23) 2.86 (+/-0.64) 2.61 (+/-0.3) 3.90 (+/-0.56) 1.56 (+/-0.26) 2.61 (+/-0.55) 3.83 (+/-0.3) 4.14 (+/-0.6) 1.19 (+/-0.12) 1.97 (+/-0.36) 3.26 (+/-0.51) 3.28 (+/-0.58)
Gene 
Symbol Gene Name Sex Age Trt Sex/Age Sex Trt Age/Trt
Sex/Age 
/Trt
Avp arginine vasopressin 0.050 0.023 0.447 0.000 0.267 0.049 0.000 19.81 (+/-8.35) 5.59 (+/-1.33) 2.85 (+/-0.87) 5.64 (+/-1.77) 8.78 (+/-2.9) 2.30 (+/-0.5) 3.97 (+/-0.83) 6.03 (+/-1.81) 32.00 (+/-10.) 1.23 (+/-0.32) 2.81 (+/-0.53) 4.17 (+/-1.06)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.212 0.001 0.592 0.004 0.359 0.031 0.012 1.43 (+/-0.15) 1.67 (+/-0.49) 1.58 (+/-0.2) 2.57 (+/-0.44) 1.49 (+/-0.2) 1.93 (+/-0.29) 1.68 (+/-0.15) 2.13 (+/-0.26) 1.05 (+/-0.15) 1.12 (+/-0.14) 2.28 (+/-0.37) 1.78 (+/-0.22)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.802 0.000 0.994 0.000 0.995 0.000 0.000 5.98 (+/-1.13) 1.63 (+/-0.37) 1.26 (+/-0.23) 1.56 (+/-0.21) 6.45 (+/-1.19) 1.73 (+/-0.42) 1.38 (+/-0.27) 1.73 (+/-0.22) 6.67 (+/-0.81) 1.18 (+/-0.33) 1.63 (+/-0.25) 1.49 (+/-0.33)
Gnrhr gonadotropin-releasing hormone receptor 0.15 0.035 0.109 0.002 0.214 0.109 0.03 2.03 (+/-0.77) 1.20 (+/-0.63) 1.60 (+/-0.45) 1.13 (+/-0.32) 2.02 (+/-0.34) 1.03 (+/-0.31) 1.66 (+/-0.44) 1.61 (+/-0.48) 1.43 (+/-0.49) 0.64 (+/-0.16) 0.97 (+/-0.38) 1.86 (+/-0.81)
Gper G protein-coupled estrogen receptor 1 0.611 0.001 0.560 0.011 0.517 0.051 0.159 1.99 (+/-0.35) 1.85 (+/-0.39) 1.30 (+/-0.18) 1.59 (+/-0.16) 2.32 (+/-0.32) 2.01 (+/-0.43) 2.15 (+/-0.25) 1.54 (+/-0.22) 2.01 (+/-0.26) 1.36 (+/-0.3) 2.04 (+/-0.32) 1.30 (+/-0.26)
Mc4r melanocortin 4 receptor 0.092 0.034 0.802 0.074 0.622 0.065 0.223 1.58 (+/-0.31) 1.42 (+/-0.19) 1.62 (+/-0.27) 2.17 (+/-0.4) 2.85 (+/-0.63) 2.54 (+/-0.77) 1.66 (+/-0.48) 1.97 (+/-0.48) 2.60 (+/-0.31) 1.35 (+/-0.51) 1.75 (+/-0.28) 2.39 (+/-0.57)
Oxtr oxytocin receptor 0.086 0.000 0.558 0.000 0.282 0.005 0.009 1.89 (+/-0.32) 1.86 (+/-0.4) 1.48 (+/-0.25) 3.17 (+/-0.68) 2.06 (+/-0.33) 1.55 (+/-0.34) 2.94 (+/-0.61) 2.93 (+/-0.59) 1.82 (+/-0.23) 1.10 (+/-0.19) 2.40 (+/-0.32) 1.75 (+/-0.55)
Pdyn prodynorphin 0.085 0.182 0.517 0.216 0.129 0.386 0.107 3.42 (+/-0.55) 2.17 (+/-0.45) 1.64 (+/-0.3) 2.25 (+/-0.42) 2.85 (+/-0.64) 2.83 (+/-0.63) 2.83 (+/-0.53) 2.39 (+/-0.49) 1.90 (+/-0.27) 1.78 (+/-0.27) 2.62 (+/-0.31) 1.45 (+/-0.41)
Dnmt3l DNA (cytosine-5-)-methyltransferase 3l
Mc5r melanocortin5 receptor
P45 P90 P15 P30 P45 P90P30
P45 P90P15 P30 P45 P90 P15 P30 P45 P90 P15 P30
DMSO EB A1221Male Parametric Statistics
Male Nonparametric Statistics
Assays Not Expressed or Did Not Amplify





Because of their long-term effects on reproductive function and physiology, 
endocrine disrupting chemicals have become a major focus of investigation seeking to 
identify molecular and epigenetic mechanisms underlying the increase in reproductive 
disorders observed in wildlife and human populations. EDCs are associated with reduced 
fertility and fecundity and increase risk of reproductive cancers. However, with the 
exception of a few studies (Cao et al., 2012; Ho et al., 2006; Prins et al., 2001) there is a 
dearth of studies examining the effects EDCs in a developmental context, especially in 
the hypothalamus. Here we sought to determine if exposure to an environmentally 
relevant dose of estrogenic EDCs alters the developmental profiles of neuroendocrine 
gene expression in the hypothalamus. Our lab and others have determined specific effects 
of A1221 on numerous reproductive parameters including disruption of estrous cycles 
(Chapter 3, (Dickerson et al., 2011b), altered reproductive behavior (Chung and Clemens, 
1999; Steinberg et al., 2007), altered timing of puberty (Dickerson et al., 2011b) and 
reproductive senescence (Gellert, 1978b). Numerous studies have identified long-term 
effects of other EDCs on reproductive physiology and gene expression throughout the 
HPG axis (Reviewed in (Dickerson and Gore, 2007)). However, our study differs from 
the current literature in several fundamental ways. First we are the first to develop a 
comprehensive developmental profile of 48 neuroendocrine gene expression in 2 key 
hypothalamic nuclei necessary for reproductive function beginning in the juvenile period 
(P15) through puberty (P30 and P45) and continuing into adulthood (P90). We have also 




two of the key subnuclei, the AVPV and ARC, in the current analysis. Furthermore, we 
investigated effects in developing littermates to determine if gestational exposure to 
EDCs altered timing and progression of developmental processes dependent on 
hypothalamic function, allowing us to relate changes is reproductive physiology and 
function back to gene expression changes in the hypothalamus. Finally, we investigated if 
epigenetic mechanisms are disrupted by characterizing changes in DNA methylation of 2 
of the genes that were significantly disrupted in a sex- and age-specific manner. Finally, 
investigating a large number of genes allowed us to identify novel gene targets and 
molecular mechanisms of endocrine disruption. 
Genes necessary for reproductive function are disrupted by exposure to EDCs in the 
AVPV but not the ARC  
One of the most surprising findings of this study is that Kiss1 expression was not 
sexually dimorphic in the adult (P90) AVPV in our DMSO control animals. However, 
after exposure to EDCs in utero, there was a marked difference between the sexes. In 
addition, its expression was sexually dimorphic in the ARC of adult animals exposed to 
DMSO. It has been widely reported that Kiss1 is sexually dimorphic in the adult AVPV 
but not the ARC (Reviewed in (Oakley et al., 2009)) therefore, it may be tempting to 
conclude that our vehicle control is masculinizing the hypothalamus. However, there is 
substantial evidence that this is not the case. First, the developmental profile of Kiss1 
observed in the AVPV and ARC of our animals exposed to DMSO replicates previous 
work in untreated animals from our lab (POA and MBH) (Walker et al., 2012) and 




(females on diestrus; AVPV and ARC specific) (Cao and Patisaul, 2011; Takumi et al., 
2011). Second, the expression patterns of Tac2 in our DMSO controls replicate those 
published by Navarro et al. (Gill et al., 2012) (ARC of females) and our lab (MBH 
dissections; (Walker et al., 2012) in untreated animals as do the sex differences in 
expression of Tac2 in the ARC (Ruiz-Pino et al., 2012; Walker et al., 2012). Finally, Esr1 
(Cao and Patisaul, 2011; DonCarlos and Handa, 1994; Lauber et al., 1991a; Zhou et al., 
1995) and Pdyn (Simerly et al., 1996) have been reported to be sexually dimorphic in the 
AVPV and organized by sex steroid hormones (Esr1: (Cao et al., 2012; Dickerson et al., 
2011b; Simerly and Young, 1991); Pdyn: (Simerly, 1991)). However, expression is 
highly dependent on cycle stage of the females, as differences are most pronounced when 
the females are in diestrus (Esr1 (Zhou et al., 1995) and Pdyn (Simerly et al., 1996)) or 
estrus (Pdyn only) but not on proestrus when our comparisons were made.  
The 4 genes highlighted in Figure 2.1 have been identified as key players in 
regulating the synthesis and release of GnRH and initiating the timing of puberty. 
Additionally, in the ARC, they are all expressed in the same neurons, commonly referred 
to as the KNDy neurons (Navarro et al., 2009). While it is generally recognized that the 
kisspeptin neurons in the AVPV are integral for generating the preovulatory GnRH/LH 
surge (Smith et al., 2006) the functional role of the KNDy neurons in the ARC has not 
been fully characterized. In rodents, it has been proposed that these neurons regulate 
negative feedback of GnRH through the actions of circulating sex steroid hormones 
(Kauffman et al., 2009) and that these neurons, especially Tac2, serve as the pacemaking 




they also play a role in the preovulatory surge (Merkley et al., 2012; Smith et al., 2009). 
Data from our current study support the pacemaking hypothesis and suggest that the 
KNDy neurons may play a role in the preovulatory surge, potentially by regulating the 
increase in pulse amplitude and frequency of LH during the surge.  
Previous reports from our lab indicate that the LH surge may be disrupted in 
females exposed to A1221 (Steinberg et al., 2008). Therefore, our goal was to euthanize 
our females during their LH surge (1 -3 hours before lights out on proestrus) (Scarbrough 
and Wise, 1990; Urbanski and Ojeda, 1986). Not only does this provide us with 
information regarding how the surge may be affected by EDCs but also provides insight 
into mechanisms of the surge. For example, in the ARC of our animals, the levels of the 
neuropeptides known to stimulate GnRH (kisspeptin and neurokinin B) are significantly 
greater in the adult female than the male. These data suggest that these neurons may play 
a role in the LH surge by sending more excitatory signals to GnRH neurons in females 
during this time. The alterations in estrus cyclicity observed in our treated females 
support this hypothesis. Females exposed to EB had significantly fewer animals with 
regular cycles. For A1221, effects on the cycle were more subtle; however, both EDC 
treatment groups tended to have at least 2 elongated series (5 or more days) of cornified 
and/or leukocytic smears (p < 0.1) and were more likely to transition from diestrus to 
estrus (thus skipping the proestrus phase) (EB p = 0.003; A1221 p = 0.16) when 
compared to the DMSO controls. Additionally, both EDC-treated groups of females had 
increased expression of Kiss1, Tac2, Esr1 and Pdyn on P90 in the AVPV when compared 




Therefore, we hypothesize that the differences in cycles are the result of dysregulation of 
the excitatory and inhibitory signals converging on the GnRH system from the ARC and 
AVPV.  
Disruption of gene expression in the AVPV may be the result of altered circadian 
function 
 While there were a few effects of treatment on gene expression in the male AVPV 
(Figure 2.3A), most (21) of the 28 genes affected by treatment were specifically affected 
in the female AVPV. Interestingly, we noticed that many of the expression profiles 
appeared to resemble those observed in the males, which is difficult to test using 
traditional statistics. Therefore, we utilized a combination of analytical methods to 
determine if genes expression profiles in the EDC females’ AVPVs were more similar to 
that of control females than males (i.e., were the EDC females more similar to DMSO 
females, or were they more similar to DMSO males, the latter suggesting 
masculinization). Using the criteria described above, we determined that 9 genes in the 
female AVPV exposed to EB or A1221 closely resemble the DMSO male (Figure 2.2) 
but not the DMSO female suggesting that these 9 genes may be “masculinized” by 
treatment. Many of these genes were decreased on P15 and increased on P90 when 
compared to the DMSO females. However, during the pubertal transition (P30 – P45) 
few effects were observed in the A1221 treated females, while in the EB treated females, 
expression was increased on P45 when compared to all other groups (Gnrh1, Kiss1r, Gal 
and Per2). There is evidence that the structural changes in the female AVPV aren’t 




P90 even though it is organized by neonatal hormone exposure (Davis et al., 1996b). We 
hypothesize that the age and sex specific differences in gene expression observed 
between the control females and the DMSO males /treated females reflect this process, 
with the P15 changes in gene expression reflecting the initiation and the P90 changes 
reflecting the completion of sexual differentiation of the AVPV. 
 One novel finding of our study was that the 2 clock genes (Arntl and Per2) 
included on our array were different between the sexes in the AVPV of our DMSO 
animals on P15 (trend; Arntl p =0.06; Per2 p = 0.119) and P90 (Arntl p = 0.003; Per2 p = 
0.018) and furthermore, that gestational exposure to EDCs resulted in a male typical 
expression profile throughout development in the female AVPV. Other studies have 
investigated the sex differences in clock genes in the SCN (Iwahana et al., 2008; 
Karatsoreos et al., 2011) and other tissues (Hirao et al., 2011; Textoris et al., 2010) as 
well as how EDCs (notably dioxin) affect clock gene expression and function throughout 
the body (Mukai et al., 2008; Mukai and Tischkau, 2007; Tischkau et al., 2011). To our 
knowledge we are the first to show that clock genes in the AVPV are sexually dimorphic, 
a target of EDCs, and that expression can be programmed by gestational exposure to 
estrogenic compounds. A recent study focusing on clock genes in the suprachiasmatic 
nucleus (SCN), the central regulator of circadian rhythms, reported that rhythmic 
expression of Arntl and Per2, among other clock genes, was activated between E19 and 
P3 with the rhythms becoming more pronounced by P10 in juvenile rats (Sladek et al., 




rhythmic expression clock genes is developing during the critical period of sexual 
differentiation of the brain.  
Recent evidence suggests that the AVPV plays an important role in circadian 
regulation of GnRH synthesis and release. Our current study supports and expands on this 
hypothesis. While it has not been investigated in males, Kiss1 displays rhythmic 
expression in the female AVPV (Robertson et al., 2009; Smarr et al., 2012; Xu et al., 
2011) and is directly regulated by the circadian transcription factor DBP. We hypothesize 
that the lack of sexually dimorphic expression of Kiss1 in our untreated (Walker et al., 
2012) and DMSO animals is a reflection of circadian expression of Kiss1 in the male 
AVPV and is a plausible explanation as to why Kiss1 expression is sexually dimorphic in 
the AVPV of treated animals but not the DMSO animals. There is a paucity of data 
investigating the function of the male AVPV. To our knowledge this is the first study to 
provide evidence that the AVPV maybe important for regulating circadian GnRH release 
in both males and females. While further research is necessary, there is evidence that 
there are sex differences in diurnal expression of Gnrh mRNA in the POA (Gore, 1998; 
Gore and Roberts, 1995; Gore et al., 1996) as well as sex differences in diurnal LH 
release (Gore, 1998; Urbanski and Ojeda, 1985). Finally, Per2 protein and mRNA 
expression in the SCN is modulated sex steroid hormone fluctuations in females during 
the estrous cycle (Perrin et al., 2006) and in males after gonadectomy (Karatsoreos et al., 
2011). We propose that Kiss1 neurons in the male AVPV regulate the circadian release of 
LH, whereas, in the female it is necessary to integrate hormonal and circadian cues in 




sexes are organized during the perinatal period, develop through the juvenile period, and 
culminate in adulthood as sexually dimorphic release of GnRH. 
Subtle differences in DNA methylation may be programmed by gestational exposure 
to EDC 
We measured DNA methylation of promoter regions of 2 genes (Per2 and Ar) 
displaying sex differences in the AVPV and displaying male typical expression patterns 
in the treated females. The Per2 promoter region was almost completely demethylated by 
P15, an effect that has been reported in the SCN (Ji et al., 2010). There were a few 
significant effects of treatment (data not shown), however, because the level of 
methylation was so low (< 5% at most sites) the tissue used to obtain the DNA sample 
was heterogeneous these results may not be biologically relevant or reproducible. As 
expected, methylation of the promoter region of Ar was sexually dimorphic. Because Ar 
is on the X-chromosome, methylation should be ~50% in the female due to X-
inactivation. A significant treatment effect was observed for one CpG in the male AVPV, 
but this should be interpreted with caution as this site was almost completely 
demethylated and the change was less than 5%. By investigating a gene on the X-
chromosome we are able to conclude that EDCs are probably not altering global 
methylation. If this were the case, we would expect that these CpG would be escaping X-
inactivation, an effect that was not observed. Finally, we noted small but significant 
differences in correlations of specific CpGs with Ar expression. More specifically, in the 
treated females Ar expression was positively correlated with methylation of several CpGs 




Interestingly, two of these sites (-57 and -51) are a putative binding site for REV-ERBα, 
a transcriptional repressor of circadian gene expression (Guillaumond et al., 2005; 
Preitner et al., 2002) providing support for our hypothesis that the AVPV is an important 
regulator of circadian signaling. Again, this needs further testing in future experiments. 
Gene expression changes in the ARC are specific to males and may provide 
information regarding the timing of puberty 
 As mentioned, the ARC regulates negative feedback onto the GnRH system and is 
not considered to be a sexually dimorphic nucleus in the hypothalamus in terms of 
morphology (Reviewed in (Navarro, 2012)). Therefore, we were not expecting 
gestational exposure to EDCs to results in sex specific effects in the ARC. Contrary to 
this prediction, 12 of the 48 genes measured were altered by gestational exposure to 
EDCs (main effect or interaction of treatment p < 0.05). Of those, 6 were affected 
specifically in the male ARC. In addition, males exposed to A1221 went through puberty 
later than their DMSO counterparts. Therefore, we hypothesize that genes altered in the 
male ARC by A1221 may be important in regulating the timing of puberty. Consistent 
with this idea, there is some limited evidence that the ARC is important for regulating the 
timing of reproductive transitions (Navarro et al., 2011b). With specific reference to 
A1221, two genes, Ar and Lepr, were significantly altered. These genes are critical for 
the hypothalamus to sense and respond to peripheral changes in metabolism (Lepr) and 
gonadal status (Ar) – two of the permissive cues that are known to drive the onset of 




expression profiles but were “out of phase” with the DMSO males – when expression 
was up in the DMSO animals it was suppressed in the A1221 animals and vice versa. 
SUMMARY AND CONCLUSIONS 
  Numerous studies have focused on gene expression in the adult hypothalamus 
after gestational exposure to EDCs. However, many have focused on one developmental 
time point or sex. (Reviewed in (Dickerson and Gore, 2007)). Here we present a 
comprehensive developmental profile of gene expression in two nuclei of the 
hypothalamus and relate them back to altered reproductive physiology and development. 
This approach has enabled us to identify novel targets of EDCs, notably the clock genes 
Per2 and Arntl, as well as develop new hypotheses regarding the functional outcomes of 
sexual differentiation of the brain. Finally, characterizing gene expression changes in a 
developmental context provide valuable insight into how we define a masculinized 
phenotype. Many of our genes did not show differences during the pubertal transition but 
were similar to the male throughout development. It is important to consider 







Disruption of Reproductive Aging in Rats by Gestational Exposure to Estrogenic 
Endocrine Disruptors 
ABSTRACT 
 Polychlorinated Biphenyls (PCBs) are industrial contaminants and known 
endocrine-disrupting chemicals (EDC). Previous work has shown that gestational 
exposure to PCBs cause changes in reproductive neuroendocrine processes. Here, we 
extended work farther down the life spectrum, and tested the hypothesis that early life 
exposure to Aroclor 1221 (A1221), a mixture of estrogenic PCBs, results in sexually 
dimorphic aging-associated alterations to reproductive parameters in rats, and gene 
expression changes in hypothalamic nuclei that regulate reproductive function. Pregnant 
Sprague-Dawley rats were injected on gestational days 16 and 18 with vehicle (DMSO), 
A1221 (1mg/kg) or estrogenic control [estradiol benzoate (EB, 50 µg/kg)]. 
Developmental parameters, estrous cyclicity (females), and timing of reproductive 
senescence were monitored in the offspring through 9 months of age. Expression of 48 
genes was measured in three hypothalamic nuclei, the anteroventral periventricular 
nucleus (AVPV), arcuate nucleus (ARC), and median eminence (ME; female only) by 
real-time RT-PCR. Serum LH, testosterone, and estradiol (E2) were assayed in the same 
animals. In males, A1221 had no effects; however, prenatal EB increased serum E2, gene 
expression in the AVPV (1 gene) and the ARC (2 genes) compared to controls.  In 
females, estrous cycles were longer in the A1221 exposed females throughout the 




caused by A1221 in the ARC and ME as a function of cycling status. Bionetwork 
analysis demonstrated fundamental differences in physiology and gene expression 
between cycling and acyclic females independent of treatment. Thus, gestational 
exposure to biologically-relevant levels of estrogenic EDCs has sexually dimorphic 
effects, with an altered transition to reproductive aging in female rats, but relatively little 
effect in males.  
INTRODUCTION 
 In mammals, reproductive aging is associated with the loss of reproductive 
capacity and involves dysregulation of the hypothalamic-pituitary-gonadal (HPG)-axis. 
In the hypothalamus, there are transcriptional (Gore et al., 1996), translational 
(Chakraborty et al., 2003a; Chakraborty et al., 2003b; Lederman et al., 2010; Sahu and 
Kalra, 1998; Zuo et al., 1996) and ultrastructural morphological changes (Yin et al., 
2009a) culminating in altered expression and release of gonadotropin-releasing hormone 
(GnRH), the obligatory decapeptide for reproductive function. Additionally, feedback of 
gonadal sex steroid hormones on the hypothalamus and the pituitary gland becomes 
eroded during the process of reproductive aging. While all levels of the HPG axis 
undergo age-related changes, there is mounting evidence suggesting that changes in the 
neuronal/glial network regulating GnRH release from the hypothalamus plays a key role 
in the process of reproductive senescence, particularly in the rodent model (Kermath and 
Gore, 2012). 
 Recently, it has become clear that the process of reproductive aging is regulated 




associated with the menopausal transition, especially in humans (Reviewed in (Kok et al., 
2005)). Other studies have focused on the role of the environment and especially 
endocrine disrupting chemicals (EDCs) in the reduction of fertility and fecundity in both 
sexes (Reviewed in (Dickerson and Gore, 2007)). EDCs are “an exogenous chemical, or 
mixture of chemicals, that interfere with any aspect of hormone action” (Zoeller et al., 
2012) and include plastics and plasticizers (phthalates, BPA), pharmaceuticals (DES), 
pesticides (DDT) and industrial contaminants (PCBs, dioxins), among others. Because 
hormone systems regulate physiological processes such as metabolism, reproduction, and 
stress, these compounds undoubtedly have adverse effects on endocrine health in wildlife 
and humans. Exposure to EDCs during critical periods of development (e.g. the perinatal 
period), when cellular and molecular changes are most profound, can result in lifelong 
alterations and an increased disease burden in adulthood – a concept referred to as the 
fetal basis of adult disease (Reviewed in (Barker, 2003)). With regard to reproductive 
senescence, emerging evidence suggests that exposure to EDCs during a critical period of 
development hastens the transition to acyclicity and causes other reproductive changes in 
female rodents (Adewale et al., 2009; Armenti et al., 2008; Dickerson and Gore, 2007; 
Gellert, 1978a, b; Gore et al., 2011; Shi et al., 2007). However, to our knowledge, no 
study has investigated the effects of gestational exposure to EDCs on the aging male 
hypothalamus.  
 Here, we investigated sexually dimorphic effects of perinatal exposure to a lightly 
chlorinated mixture of PCBs, Aroclor 1221 (A1221) on the aging hypothalamus of rats. 




compounds have been banned for decades, exposure continues through contamination of 
soil, water and food sources as well as bioaccumulation. In this study, we examined 
whether gestational exposure to A1221 resulted in 1) altered timing and progression of 
reproductive senescence (acyclicity) in female rats; 2) alterations in gene expression in 
key brain regions associated with the progression of reproductive aging in females; and 
3) changes in male reproductive physiology and gene expression throughout the lifecycle. 
Our overarching goal was to determine the molecular underpinnings of hypothalamic 
reproductive aging and how those processes might be disrupted by perinatal exposure to 
EDCs. 
MATERIALS AND METHODS 
Animals 
 All animal protocols were conducted in accordance with the Guide for the Care 
and Use of Laboratory Animals and approved by The University of Texas at Austin 
Institutional Animal Care and Use Committee. Sprague-Dawley rats (3-4 month virgin 
females) were purchased from Harlan Laboratories (Houston, TX) and impregnated in 
house in a manner similar to work previously conducted in our laboratory (Dickerson et 
al., 2011a; Dickerson et al., 2011b). Because standard soy-based rat chow contains 
phytoestrogens, animals were switched to low phytoestrogen Harlan-Teklad 2019 Global 
Diet ad libitum. Animals were housed individually under constant humidity and 
temperature (21-22°C) with a partially reversed 12:12 light cycle (lights on at 23:00). 
Rats were given at least 1 week to adjust to the new diet and environment before mating 




mating (sperm positive vaginal smear) was termed embryonic day (E) 1. On E16 and 
E18, during the period of sexual differentiation of the rat brain (Davis et al., 1996b; 
Jacobson et al., 1980; Rhees et al., 1990a, b), dams were weighed and randomly assigned 
to one of 3 treatment groups and injected with 0.1ml vehicle (DMSO 99.5% Sigma 
#D4540); 50 µg/kg estradiol benzoate as a positive estrogenic control (EB, Sigma 
#E8515); or 1 mg/kg Aroclor 1221 (A1221; AccuStandard, #C221N). Doses and routes 
of exposure were chosen based on previous work in our laboratory (Dickerson et al., 
2011a; Dickerson et al., 2011b; Steinberg et al., 2007; Steinberg et al., 2008) and others 
(Chung and Clemens, 1999; Gillette et al., 1987a; Gillette et al., 1987b; Murugesan et al., 
2005a; Murugesan et al., 2005b). Although we did not save carcasses to measure body 
burden, we estimate that each pup is exposed to ~1:500 of the dose (i.e., 2 µg/kg A1221 
or 100 ng of EB) based on previous literature (Takagi et al., 1986). Studies investigating 
human exposure have found that concentrations in maternal serum (Karmaus and Zhu, 
2004; Law et al., 2005; Longnecker et al., 2005; Schantz, 1996), cord blood (Lackmann, 
2002) and milk fat (Schantz, 1996) are between 1 and 9 ppb. Therefore, our dose is 
estimated to be within the range of human exposure. Because of differences in 
metabolism of the estrogenic control (EB) (Eaton et al., 1975; Landau, 1976) and A1221 
(Anderson et al., 1977; Heinrich-Hirsch et al., 1997; Lutz et al., 1984; Mathews and 
Anderson, 1975; Matthews and Dedrick, 1984; Tampal et al., 2002), and to maintain 
consistency with other experiments in our laboratory (Dickerson et al., 2011a; Dickerson 
et al., 2011b; Steinberg et al., 2007; Steinberg et al., 2008), injections were given via one 




were given as subcutaneous injections, and A1221 and half of the DMSO treatments were 
given as intraperitoneal injections. Any effects of route were considered as a covariate for 
analysis. On the day after birth [postnatal day (P) 1], litter composition, birth weights and 
anogenital distance were recorded, and the litters were culled to equal sex ratios. Body 
weights were monitored weekly throughout the lifecycle and anogenital distance was 
measured weekly until weaning. Pups were weaned on P21 and housed with same sex 
littermates (2-3 per cage) until P90. For a companion study, littermates were euthanized 
on P15, 30, 45 and 90. Rats were monitored for a secondary sex characteristic of the 
onset of puberty daily (preputial separation in males and vaginal opening in females). 
Beginning on P90, animals were randomly assigned a new cage mate based on the age of 
each litter. Investigators were blind to treatment throughout the experiment. Therefore, 
cage mate treatment was not taken into account when rehousing rats. Because of the large 
number of animals necessary for both studies, animals were raised in 5 cohorts with 
treatments equally distributed across each cohort. 
Tissue Collection and Storage 
 Females were classified as reproductively cyclic (regular or irregular cycles) or as 
acyclic (persistent estrus; see below for more details). Those females in persistent estrus 
were euthanized after at least 14 consecutive days of cornified smears and as close to 9 
months of age as possible. Unless females were in persistent estrus, they were euthanized 
on the day of proestrus. Final sample sizes for females were Cyclic DMSO: 13; Acyclic 
DMSO: 8; Cyclic EB: 11; Acyclic EB: 6; Cyclic A1221: 9; Acyclic A1221: 13. For 




of the somatic and hormonal data, however only a subset of hypothalamic punches were 
used to measure gene expression (DMSO: 11, EB: 8, A1221: 11). Rats were euthanized 
by rapid decapitation approximately 1 to 3 hours before lights out. Brains were removed 
and sectioned in 1 mm coronal sections using an ice-cold stainless steal brain matrix. 
Sections were placed on an ice-cold microscope slide and snap frozen on dry ice. Frozen 
sections were placed on a freezing stage, allowed to equilibrate to -15 to -20°C, and 
micropunches (0.98 mm diameter) were taken from each region of interest and placed in 
a frozen eppendorf tube. Photographs were captured of sections before and after punches 
were taken to ensure consistency across the cohorts. Trunk bloods were collected, 
allowed to clot, and serum was separated via centrifugation (1500 X g for 5 min). Tissues 
and serum were stored at -80°C until use.  
RNA Extraction 
 RNA was extracted from frozen anteroventral periventricular (AVPV) and arcuate 
(ARC) nuclei of males and females using a Qiagen Allprep DNA/RNA mini kit and from 
frozen median eminence (ME – female only) dissections using a Qiagen Allprep 
DNA/RNA micro kit due to the smaller tissue volume, all according to manufacturer’s 
protocols. RNA samples were eluted with RNase free water and treated with 1 U of 
TURBO DNase (Applied Biosystems Inc., Foster City, CA) to rid samples of genomic 
DNA before ethanol precipitation. Resuspended samples were diluted to a concentration 
of 50 ng/µl (AVPV, ARC) or 1 ng/µl (ME) based on nanodrop and bioanalyzer analysis. 
All samples were run on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) to 




Taqman  Microfluidic Real-time PCR Cards 
 Samples were run on custom-designed microfluidic 48-gene PCR cards (Applied 
Biosystems Inc, Foster City, CA), with specific gene assays chosen based on a priori 
hypotheses and published reports on their importance in neuroendocrine function and 
sensitivity to disruption by EDCs (46 genes of interest and 2 housekeeping genes; Tables 
3.1, 3.2, 3.4, 3.5). For technical reasons ME samples were run on a separate TLDA array 
(Table 3.3), which was composed of a slightly modified panel of neuroendocrine genes. 
We did not have enough arrays from this lot to run the male MEs, which could not be 
assayed in this study. Messenger RNA (200 ng AVPV, ARC; 10 ng ME) was converted 
to cDNA using a high capacity cDNA reverse transcription kit (Applied Biosystems, 
Foster City CA) according to manufacturer’s protocol. Product was stored at -20°C until 
use. 
 Real-time PCR was carried out on an ABI ViiA7 using Taqman Universal 
Mastermix (Applied Biosystems, Foster City CA) and the following run parameters: 
50°C for 2 minutes, 95°C for 10 minutes, 45 cycles of 95°C for 15 seconds and 60°C for 
1 minute. Relative expression was determined for each sample using the comparative Ct 
Method (Livak and Schmittgen, 2001; Pfaffl, 2001; Schmittgen and Livak, 2008). 
Samples were normalized to either 18s or Gapdh and calibrated to the median delta-Ct of 
the DMSO controls to determine relative change in expression for each gene. 
Serum hormone assays 
Serum LH was measured in duplicate 50 µl samples in the laboratory of Dr. 




binding radioimmunoassay (RIA). The assay was performed using the rat LH RP-3 
standard from the National Hormone and Pituitary Program of the NIDDK (kindly 
provided by Dr. A.F. Parlow). All samples were measured in a single assay, and the intra-
assay variability was 3.85%. 
 Serum concentrations of sex steroid hormones were measured using RIA for 
estradiol (Beckman Coulter, Webster, TX) and testosterone (MP Biomedicals) according 
to the manufacturer’s recommended protocols. Samples were run in duplicate if possible. 
Samples having a CV of 10% or greater were rerun when possible or dropped from 
analysis. 
Two estradiol assays, were run with assay sensitivity of 2.2 pg/ml and intra-assay 
variability of 6.48% and 1.64% respectively. Inter-assay CV was 4.55%. One testosterone 
assay was run with assay sensitivity of 0.03 ng/ml and intra-assay variability of 1.40%.  
Statistics 
Data in females were analyzed for interactions of reproductive cycle status and 
treatment for all somatic markers recorded as well as gene expression data. Females were 
classified as either cyclic or acyclic using the smear data from the last 30 days of life. We 
categorized a female as cyclic if she had greater than 4 nucleated (indicative of proestrus) 
days in the last 30 days (regular cyclers should have at least 5), or as acyclic if there were 
fewer than 4 nucleated days during the last 30 days of life and/or the female was in 
persistent estrus for at least 14 days. For gene expression data, statistics were performed 
using relative expression values for each sample. For females, multiple regression 




endpoint (genes, hormones, and endocrine tissues) using cycle status and treatment as 
independent variables. For those endpoints where a significant main effect of cycle status 
or treatment or an interaction was observed data were split by independent variables and 
follow-up analysis was performed to determine specific differences between each group. 
For the males, a one-way ANOVA was conducted to compare each endpoint using 
treatment as an independent variable. In both sexes, if data did not meet the assumptions 
for multiple regression analysis, data were transformed (natural log or square root) and 
reanalyzed. In a few cases, transformed data did not meet assumptions for statistical 
analysis by multiple regression. In those cases, data were analyzed using a Kruskal-
Wallis test followed by a Mann-Whitney test between each group. For hormone 
concentrations, an effect was considered significant at p<0.05. For gene expression data a 
Benjamini and Hochberg False-Discovery Rate correction (Benjamini and Hochberg, 
1995; Hochberg and Benjamini, 1990) was used to correct our p-values to account for the 
large number of variables measured. Parametric data were tested for outliers using the z-
score of the residuals from the initial regression. A data point was considered an outlier if 
the residual was greater than 2.5 standard deviations from initial line of best fit. Non-
parametric data were tested for outliers using the Grubbs’ outlier test. Confirmed outliers 
were excluded from final analysis. 
 Vaginal smear data were analyzed with a python script using rule-based pattern 
matching techniques to determine the number and length of each cycle for each animal. 
Briefly, cycles were identified for each animal by scanning the smear data from the day 




and length of each cycle was recorded throughout the lifecycle. A repeated-measures 
ANOVA was conducted using the moving average of the cycle length (using three cycle 
lengths) for each animal to account for any missing data.  
A bootstrap technique (Efron and Tibshirani, 1993) that has been previously 
employed by our laboratory (Walker et al., 2012) was used to examine possible 
relationships between gene expression, endocrine tissues and serum hormones throughout 
development using Matlab (The Mathworks, Natick MA) software. Briefly, original 
paired data were resampled with replacement for 1000 repetitions, and a Pearson's 
correlation coefficient was computed on each of these new bootstrapped data sets to build 
a distribution of coefficients. Significance of Pearson's correlation coefficient for each 
interaction was determined from the bootstrapped distributions. Only those correlation 
coefficients that survived a Benjamini and Hochberg False Discovery Rate (Benjamini 
and Hochberg, 1995; Hochberg and Benjamini, 1990) at a p-value < 0.05 were 
considered significant. 
Hierarchical cluster analysis and heatmaps were performed using Multiple Experiment 
Viewer V4.8.1 (TM4.org) and clusters were validated using R statistical packages. 
RESULTS 
 Animals exposed to A1221 during gestation were monitored daily from birth to 9 
months of age to determine if perinatal exposure to environmental endocrine disruptors 
altered reproductive aging in males and females. We measured changes in reproductive 
tissues, tracked female estrous cycles, and measured 48 genes using a Taqman low-




AVPV and ARC (male and female) and ME (female only). While no genes survived a 
Benjamini and Hochberg False Discovery Rate correction (Benjamini and Hochberg, 
1995; Hochberg and Benjamini, 1990), all genes had been specifically chosen based on 
our a priori hypotheses about their known neuroendocrine functions, therefore we have 
reported gene expression data as significant (p<0.05) or as a trend (p<0.1).  
Effects of prenatal EDCs on females – somatic measurements, hormones, and 
estrous cycles 
 In females, few effects of treatment were observed on pituitary weight, gonadal 
somatic index, or uterine weight (Figure 3.1). However, there were main effects of cycle 
status between cyclic and acyclic females. In the acyclic animals, pituitary weights were 
increased, and gonadal somatic index (GSI) and uterine weights were decreased 
compared to cyclic counterparts. Serum LH concentrations in cyclic control (DMSO) rats 
were substantially higher than in cyclic EB or A1221 rats. The lack of significance in this 
dataset is likely attributable to the pulsatile nature of LH release. For serum estradiol, 
there were no significant effects of cycle status or treatment.  
Repeated-measures ANOVA analysis of the moving average of the cycle length indicated 
there was a significant effect of treatment (p=0.03) on cycle length throughout the 
lifecycle (Figure 3.2). Post-hoc analysis revealed that females exposed to A1221, but not 
EB, had significantly longer cycles throughout their lifecycle when compared to the 





Effects of prenatal EDCs on females – gene expression in AVPV, ARC, and ME 
Analysis of gene expression in hypothalamic regions of females revealed that 
cycle status (cyclic or acyclic) played a substantial role in results. Therefore, data are 
presented for effects of prenatal treatment, cycle status, and interactions of treatment by 
cycle status. Significant effects (p < 0.05) and a trends (0.05 < p < 0.075) are graphed. 
Data for all the genes detected in each hypothalamic subregion are provided in 
Supplemental Tables. In the female AVPV (Table 3.1), only one gene was significantly 
altered by treatment: Grin2c (p=0.046) was increased in EB treated females compared to 
DMSO controls. 
In the ARC (Figure 3.3, Table 3.2), 2 genes were significantly affected by 
treatment: Lepr and Gnrhr. One gene, Oxt, was significantly altered by cycle status. A 
total of 14 genes displayed a significant status by treatment interaction (p<0.05; Table 
3.2) and are also indicated in red on Figure 3.5B. Further analysis revealed that 8 of these 
latter mRNAs (Dnmt3a, Ar, Pdyn, Lepr, Mc3r, Oxt, Grin2b, Grin2d; Figure 3.3) had 
lower expression in the acyclic A1221 females when compared to acyclic DMSO 
counterparts. One gene, Esr1, was higher in the cyclic A1221 females when compared to 
cyclic DMSO and cyclic EB counterparts (Figure 3.3). As a whole, affected genes fell 
into four functional categories: epigenetic processes (Dnmt3a); steroid hormone receptors 
(Esr1 and Ar); neuropeptide signaling (Pdyn, Lepr, Mc3r and Oxt); and glutamate 
signaling (Grin2b and Grin2d).  
In the ME (Table 3.3), there were no significant main effects of treatment or 




interactions (Figure 3.4; also see red text on Figure 3.5C) in two functional categories: 1) 
steroid hormone receptors (Esr1, Nr3c1) and 2) neurotransmitter systems (Grin2b, 
Gad2). As shown in Figure 3.4, these four genes were expressed at higher levels in 
DMSO cycling than DMSO acyclic rats (significant for Nr3c1 and Grin2b; trend for 
Esr1). By contrast, this cycling status effect was not seen in EB or A1221 rats. In 
addition, DMSO cyclic females had higher Esr1 mRNA levels compared to EB and 
A1221 cyclic rats, and a trend for higher Gad2 mRNA compared to EB cyclic rats. 
Effects of prenatal EDCs on males – estradiol and gene expression in AVPV and 
ARC 
 In males, treatment had no effect on body weight, pituitary weight, gonad weight, 
serum LH, or serum testosterone (Table 3.6). A main effect of treatment was observed on 
serum estradiol in males (p=0.022), although post-hoc analysis revealed only trends for 
higher estradiol levels in the EB (p=0.066) and A1221 (p=0.053) males when compared 
to their DMSO counterparts. One gene was altered in the male AVPV: Avpr1a (p = 0.05; 
Table 3.1). Two genes were significantly altered in ARC of males: Bdnf (p=0.008) and 
Ahr (p=0.006), with trends for Slc17a6 and Oxt. The complete male datasets are shown in 
Tables 3.4 (AVPV) and 3.5 (ARC).  
Hierarchical cluster analysis of relationships by cycle status and treatment in 
females  
In order to determine if specific gene expression patterns within each brain region 
are related by treatment and cycle status in females, hierarchical cluster analysis was 
conducted and clustergrams were generated for each brain region (Walker et al., 2012). 




validate the clusters. Multiple experiment viewer (MeV 4.8.1) software was used 
generate the heat maps and to perform the analysis using the average linkage method and 
the correlation coefficients to express similarity. Clusters were validated using R 
statistical packages.  
Clusters by cycle status and treatment revealed only treatment differences in the 
AVPV (Figure 3.5A, top) with EB females clustering separately from DMSO and A1221 
(p=0.08). However, no validated gene clusters (Figure 3.5A, side) were observed in the 
AVPV so it is difficult to determine which genes might be driving the differences 
observed in the clustering of the EB animals. 
In the ARC, DMSO cyclic females tended to cluster with the acyclic A1221 
females (p=0.07) and vice versa (A1221 cyclic with DMSO acyclic) (p=0.08) (Figure 
3.5B). This effect was also observed in the ME although with a weak trend (p=0.1 and 
0.14 respectively). In the ARC 2 validated gene clusters were identified: 1) the upper 
cluster composed of Gnrhr and Bdnf displayed increased expression in the EB females, 
and 2) the lower cluster consisting of decreased expression in the A1221 acyclic vs 
DMSO acyclic but similar expression to cyclic DMSO females.  
In the ME, the 2 validated gene clusters were distinguished by increased 
expression in the A1221 cyclic females (upper cluster) and differences between the 
DMSO cyclic females and EDC-treated acyclic females (EB acyclic and A1221 acyclic) 





Integration of genes, hormones and somatic data networks in females 
  To examine the relationships among gonadal hormones, somatic changes and 
hypothalamic gene expression relative to reproductive cycling status in females, we used 
the network analysis platform Cytoscape (Kohl, 2011; Kohl et al., 2011; O'Connell and 
Hofmann, 2012) to generate networks based on significant Pearson correlation 
coefficients between hormones, endocrine tissues, and relative gene expression in each 
brain region. Data were first collapsed across the treatment groups in each region to 
identify common relationships that change during the transition from cyclicity to 
acyclicity. Genes with a significant interaction of treatment and cycling status in the ARC 
and ME are indicated with larger font (p < 0.1) and bolded (p < 0.05) to determine how/if 
their relationships with other genes, hormones, and somatic markers might be changing in 
the process to acyclicity (Figure 3.6). 
 Relationships in the AVPV showed the greatest difference between cyclic and 
acyclic females with the cyclic females displaying a number of positive and negative 
correlations (Figure 3.6). In the acyclic females there were few correlations, mostly 
negative with serum LH level. While there were not as many differences in the number of 
significant correlations in the ARC with reproductive aging there were differences in 
endpoints that serve as “hubs” of regulation. In the cyclic ARC, Gnrh had numerous 
positive correlations, 13 of the 27 were genes that were significantly altered in the ARC 
whereas the gonadosomatic index (GSI) and serum estradiol had mostly negative 
correlations. In the acyclic ARC, there were numerous positive correlations with Gnrhr 




uterine weight. Finally in the ME, a similar number of correlations were observed in both 
networks, with most between genes rather than with hormone or somatic endpoints. 
Notably, the number of positive correlations with Nr3c1 almost doubles from 8 to 14 





FIGURES AND TABLES 
 
 
Figure 3.1: Effects of prenatal EDCs on hormones and somatic markers in aging female 
rats.  
Females were classified as cyclic or acyclic. Significant p-values or trends for main 
effects of Treatment or Status, and Status x Treatment interactions, are indicated at the 
top of graphs. Differences between cyclic and acyclic animals within groups are indicated 
by p-values overlaid on relevant bar pairs. Cycle status had significant effects on pituitary 
weight, gonadal somatic index and uterine weights. Although not significant, serum 
luteinizing hormone (A) was decreased in acyclic females exposed to DMSO and EB an 
effect not observed in the A1221 animals. Pituitary weights (B) significantly increase in 
acyclic animals whereas GSI (D) and uterine weights (E) decrease in acyclic females 











































































Status X Treatment p = 0.113
Status p = 0.001





























Figure 3.2: Length of estrous cycles in females treated throughout the lifecycle.  
The length of each cycle was determined beginning from vaginal opening through the 
end of life. Data were transformed to the moving average for each animal to account for 
any missing data and analyzed by repeated measures ANOVA. The length of all cycles 
increased over time independent of treatment. Additionally, treatment significantly 
altered the length of estrous cycles (p=0.03). Post-hoc analysis revealed that females 
treated with A1221 (dashed line) had longer cycles when compared to the DMSO 
controls (solid black line) throughout the lifecycle (p=0.03). EB exposure (gray line) had 




































Figure 3.3: Expression of 10 genes in the ARC affected by treatment. 
These genes were selected based on significant effects of Treatment, Cycle Status, or 
interactions of Status x Treatment. The most frequent finding was an interaction effect, 
with lower gene expression in the acyclic A1221 females when compared to acyclic 
DMSO counterparts. In addition, many genes show increased expression in DMSO 




























































































Status X Treatment p = 0.006 Status X Treatment p = 0.011 Status X Treatment p = 0.025
Status X Treatment p = 0.042 Status X Treatment p = 0.033 Status X Treatment p = 0.004





















Status X Treatment p = 0.052
Figure 3.3:
 Treatment p = 0.044




























Figure 3.4: Expression of 4 genes in the ME affected by treatment. 
Genes were selected based on significant effects interactions of Status x Treatment. In 
general, there was lower expression in the cyclic A1221 and the cyclic EB females when 
compared to cyclic DMSO counterparts. In DMSO females, all four genes had lower 



























































































Status X Treatment p = 0.031 Status X Treatment p = 0.014






Figure 3.5: Clustergrams of gene expression in females. 
Data for AVPV (A), ARC (B) and ME (C) is shown. Clusters were validated using R 
statistical packages and validated gene clusters are indicated by a red box. To maintain 
legibility of the figure, red boxes indicate the most external validated gene clusters (side) 
whereas, p-values are indicated for clusters by treatment and cycle status (top). Genes 
with a Status x Treatment interaction are indicated in red text (p < 0.1) and bolded (p < 
0.05) to identify gene clusters associated with specific status/treatment related expression 
patterns. This effect was observed in the ARC where all significantly altered genes are in 
one cluster. The p-value from the validation is listed for the clusters of the groups. 
Abbreviations: DC, DMSO cyclic; DA, DMSO acyclic; EC, EB cyclic; EA, EB acyclic; 
AC, A1221 cyclic; AA, A1221 acyclic. 
  
Figure 3.5.





Figure 3.6: Cyctoscape networks of genes, hormones and somatic changes 
Data are presented for 3 brain regions involved in reproductive function (AVPV, ARC 
and ME) in cyclic vs acyclic females. Genes with a significant interaction of treatment X 
status are indicated by larger font (p < 0.1) and bolded (p < 0.05). Overall results show 




































































































































































































































A. Cyclic AVPV B. Acyclic AVPV
C. Cyclic ARC
D. Acyclic ARC






Table 3.1: Gene Expression in the Female Anteroventral Periventricular Nucleus (AVPV) 
Relative gene expression for each treatment group is shown. P-values are listed for each variable. Significant main effects of 
treatment and status, or interaction of treatment x status are bolded (p < 0.05). Italics indicated that there was a trend (p < 0.1). 









18S Eukaryotic 18S RNA, 18S ribosomal 1 0.848 0.932 0.535 0.98 (+/-0.11) 0.91 (+/-0.09) 0.86 (+/-0.09) 1.01 (+/-0.13) 0.98 (+/-0.06) 0.96 (+/-0.08)
Ahr aryl hydrocarbon receptor 0.88 0.392 0.712 1.06 (+/-0.19) 1.70 (+/-0.57) 1.45 (+/-0.23) 1.20 (+/-0.22) 1.36 (+/-0.16) 1.43 (+/-0.37)
Ar androgen receptor 0.571 0.753 0.286 0.85 (+/-0.1) 1.00 (+/-0.17) 0.91 (+/-0.08) 1.10 (+/-0.11) 0.99 (+/-0.12) 0.82 (+/-0.14)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.792 0.818 0.299 0.96 (+/-0.1) 1.19 (+/-0.2) 1.10 (+/-0.09) 1.13 (+/-0.06) 1.12 (+/-0.13) 0.95 (+/-0.14)
Avp arginine vasopressin 0.963 0.413 0.932 3.36 (+/-1.33) 3.24 (+/-1.56) 3.24 (+/-1.5) 3.74 (+/-1.98) 2.17 (+/-0.56) 1.64 (+/-0.67)
Avpr1a arginine vasopressin receptor 1A 0.426 0.108 0.127 0.85 (+/-0.1) 1.01 (+/-0.18) 1.07 (+/-0.14) 1.43 (+/-0.25) 1.13 (+/-0.13) 0.89 (+/-0.14)
Bdnf brain-derived neurotrophic factor 0.849 0.606 0.494 0.89 (+/-0.12) 1.04 (+/-0.24) 1.11 (+/-0.13) 1.09 (+/-0.14) 1.06 (+/-0.12) 0.86 (+/-0.16)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.801 0.223 0.505 0.92 (+/-0.15) 1.23 (+/-0.29) 1.42 (+/-0.22) 1.42 (+/-0.29) 1.16 (+/-0.18) 0.99 (+/-0.19)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.647 0.224 0.436 1.00 (+/-0.1) 0.89 (+/-0.18) 1.10 (+/-0.07) 1.24 (+/-0.12) 1.09 (+/-0.12) 0.92 (+/-0.15)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.507 0.159 0.709 0.86 (+/-0.11) 1.10 (+/-0.2) 1.27 (+/-0.12) 1.28 (+/-0.22) 1.01 (+/-0.12) 1.02 (+/-0.19)
Esr1 estrogen receptor 1 0.587 0.562 0.586 0.90 (+/-0.16) 1.04 (+/-0.25) 1.27 (+/-0.2) 1.11 (+/-0.25) 1.13 (+/-0.15) 0.89 (+/-0.18)
Esr2 estrogen receptor 2 0.905 0.519 0.354 0.80 (+/-0.1) 1.04 (+/-0.17) 1.10 (+/-0.14) 1.07 (+/-0.2) 1.02 (+/-0.13) 0.86 (+/-0.14)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.682 0.765 0.272 1.22 (+/-0.23) 1.82 (+/-0.42) 1.26 (+/-0.11) 1.27 (+/-0.15) 1.24 (+/-0.1) 1.17 (+/-0.2)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.28 0.474 0.136 0.91 (+/-0.07) 1.12 (+/-0.16) 0.89 (+/-0.05) 1.11 (+/-0.09) 0.97 (+/-0.1) 0.83 (+/-0.12)
Gal galanin prepropeptide 0.391 0.074 0.226 0.83 (+/-0.12) 1.01 (+/-0.22) 1.15 (+/-0.16) 1.58 (+/-0.31) 1.14 (+/-0.17) 0.92 (+/-0.17)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.412 0.866 0.59 0.92 (+/-0.12) 1.14 (+/-0.24) 1.02 (+/-0.09) 1.17 (+/-0.11) 1.05 (+/-0.13) 0.98 (+/-0.18)
Gnrh1 gonadotropin-releasing hormone 1 0.933 0.088 0.692 0.81 (+/-0.11) 0.76 (+/-0.23) 1.16 (+/-0.24) 1.38 (+/-0.31) 1.18 (+/-0.17) 1.05 (+/-0.25)
Gper G protein-coupled estrogen receptor 1 0.78 0.487 0.373 0.84 (+/-0.09) 1.03 (+/-0.18) 1.01 (+/-0.12) 1.06 (+/-0.18) 0.95 (+/-0.1) 0.80 (+/-0.12)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.586 0.499 0.278 0.82 (+/-0.09) 0.97 (+/-0.16) 0.95 (+/-0.07) 1.10 (+/-0.1) 0.98 (+/-0.11) 0.83 (+/-0.14)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.93 0.406 0.294 0.90 (+/-0.09) 1.12 (+/-0.16) 1.20 (+/-0.1) 1.16 (+/-0.13) 1.20 (+/-0.11) 1.04 (+/-0.16)
Grik2 glutamate receptor, ionotropic, kainate 2 0.545 0.866 0.361 1.01 (+/-0.13) 1.30 (+/-0.23) 1.20 (+/-0.08) 1.19 (+/-0.12) 1.16 (+/-0.09) 1.08 (+/-0.16)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.353 0.75 0.669 0.96 (+/-0.08) 1.12 (+/-0.17) 1.04 (+/-0.07) 1.15 (+/-0.09) 1.02 (+/-0.11) 1.00 (+/-0.11)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.899 0.206 0.511 0.86 (+/-0.1) 0.95 (+/-0.18) 1.12 (+/-0.12) 1.26 (+/-0.19) 1.16 (+/-0.13) 0.98 (+/-0.18)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.235 0.267 0.199 0.80 (+/-0.1) 1.12 (+/-0.18) 0.97 (+/-0.08) 1.10 (+/-0.12) 0.89 (+/-0.1) 0.79 (+/-0.14)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.23 0.046 0.316 0.85 (+/-0.1) 1.10 (+/-0.19) 1.17 (+/-0.14) 1.43 (+/-0.14) 1.02 (+/-0.12) 0.92 (+/-0.16)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.407 0.529 0.387 0.80 (+/-0.11) 1.10 (+/-0.22) 1.00 (+/-0.08) 1.00 (+/-0.15) 0.87 (+/-0.1) 0.84 (+/-0.13)
Igf1 insulin-like growth factor 1 0.651 0.807 0.335 0.84 (+/-0.11) 1.01 (+/-0.22) 0.97 (+/-0.13) 0.83 (+/-0.13) 0.93 (+/-0.1) 0.75 (+/-0.11)
Igf1r insulin-like growth factor 1 receptor 0.905 0.603 0.242 0.93 (+/-0.12) 1.12 (+/-0.21) 1.11 (+/-0.08) 1.19 (+/-0.12) 1.15 (+/-0.1) 0.92 (+/-0.14)
Kiss1 KiSS-1 metastasis-suppressor 0.961 0.301 0.434 1.00 (+/-0.2) 1.69 (+/-0.42) 2.00 (+/-0.42) 1.94 (+/-0.73) 1.70 (+/-0.25) 1.31 (+/-0.36)
Kiss1r KISS1 receptor 0.916 0.518 0.764 0.97 (+/-0.08) 0.95 (+/-0.19) 1.08 (+/-0.11) 1.17 (+/-0.1) 1.08 (+/-0.14) 0.97 (+/-0.18)
Lepr leptin receptor 0.299 0.099 0.875 0.98 (+/-0.07) 0.88 (+/-0.12) 1.16 (+/-0.12) 1.09 (+/-0.19) 1.33 (+/-0.15) 1.13 (+/-0.19)
Mc3r melanocortin 3 receptor 0.721 0.317 0.102 0.82 (+/-0.13) 0.84 (+/-0.22) 0.83 (+/-0.12) 1.24 (+/-0.18) 0.96 (+/-0.15) 0.67 (+/-0.12)
Mc4r melanocortin 4 receptor 0.267 0.753 0.619 0.98 (+/-0.15) 1.01 (+/-0.2) 1.15 (+/-0.17) 0.90 (+/-0.14) 1.24 (+/-0.15) 0.99 (+/-0.17)
Oxt oxytocin, prepropeptide 0.206 0.209 0.114 0.75 (+/-0.14) 1.55 (+/-0.27) 1.62 (+/-0.45) 2.49 (+/-0.76) 2.09 (+/-0.65) 1.29 (+/-0.36)
Oxtr oxytocin receptor 0.538 0.492 0.259 0.89 (+/-0.1) 1.18 (+/-0.16) 1.08 (+/-0.12) 1.12 (+/-0.1) 1.00 (+/-0.11) 0.88 (+/-0.15)
Pdyn prodynorphin 0.393 0.93 0.132 0.80 (+/-0.14) 1.23 (+/-0.21) 1.00 (+/-0.13) 1.17 (+/-0.23) 1.17 (+/-0.17) 0.93 (+/-0.14)
Per2 period homolog 2 0.548 0.521 0.531 0.87 (+/-0.1) 1.06 (+/-0.21) 1.01 (+/-0.14) 1.15 (+/-0.18) 0.96 (+/-0.13) 0.85 (+/-0.15)
Pgr progesterone receptor 0.511 0.798 0.368 0.83 (+/-0.12) 0.97 (+/-0.19) 1.06 (+/-0.14) 0.95 (+/-0.12) 1.11 (+/-0.13) 0.84 (+/-0.15)
Slc17a6 solute carrier family 17, member 6 0.605 0.807 0.288 0.86 (+/-0.12) 1.03 (+/-0.19) 1.07 (+/-0.15) 1.01 (+/-0.09) 1.16 (+/-0.13) 0.87 (+/-0.15)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.703 0.972 0.511 1.08 (+/-0.19) 1.37 (+/-0.28) 1.18 (+/-0.11) 1.19 (+/-0.18) 1.25 (+/-0.14) 1.12 (+/-0.2)
Tac2 tachykinin 2 0.605 0.221 0.216 0.90 (+/-0.12) 0.96 (+/-0.16) 1.03 (+/-0.16) 1.42 (+/-0.29) 1.09 (+/-0.18) 0.86 (+/-0.13)
Tgfa transforming growth factor, alpha 0.99 0.993 0.374 0.86 (+/-0.12) 1.07 (+/-0.19) 1.01 (+/-0.09) 0.95 (+/-0.13) 1.04 (+/-0.11) 0.89 (+/-0.16)
Tgfb1 transforming growth factor, beta 1 0.976 0.708 0.559 0.97 (+/-0.13) 1.14 (+/-0.24) 1.19 (+/-0.12) 1.16 (+/-0.11) 1.14 (+/-0.1) 1.00 (+/-0.17)
Thra thyroid hormone receptor, alpha 0.297 0.351 0.346 0.87 (+/-0.11) 1.20 (+/-0.19) 1.09 (+/-0.11) 1.17 (+/-0.1) 0.96 (+/-0.11) 0.90 (+/-0.16)
Thrb thyroid hormone receptor, beta 0.729 0.522 0.663 1.03 (+/-0.09) 1.11 (+/-0.2) 1.07 (+/-0.1) 1.20 (+/-0.12) 1.03 (+/-0.11) 0.94 (+/-0.16)





Table 3.2: Gene Expression in the Female Arcuate Nucleus (ARC) 
Relative gene expression for each treatment group is shown. P-values are listed for each variable. Significant main effects of 
treatment and status, or interaction of treatment x status are bolded (p < 0.05). Italics indicated that there was a trend (p < 0.1). 










18S Eukaryotic 18S RNA, 18S ribosomal 1 0.788 0.99 0.375 1.05 (+/-0.06) 0.94 (+/-0.14) 0.96 (+/-0.1) 1.01 (+/-0.1) 0.92 (+/-0.05) 1.04 (+/-0.08)
Ahr aryl hydrocarbon receptor 0.991 0.358 0.608 0.96 (+/-0.08) 1.16 (+/-0.16) 1.11 (+/-0.17) 1.07 (+/-0.17) 1.05 (+/-0.21) 0.90 (+/-0.2)
Ar androgen receptor 0.595 0.281 0.011 0.89 (+/-0.07) 1.12 (+/-0.09) 0.84 (+/-0.08) 1.02 (+/-0.15) 1.00 (+/-0.1) 0.72 (+/-0.05)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.814 0.088 0.113 1.04 (+/-0.07) 1.06 (+/-0.05) 0.98 (+/-0.08) 1.19 (+/-0.18) 0.99 (+/-0.08) 0.81 (+/-0.09)
Avp arginine vasopressin 0.13 0.36 0.097 0.85 (+/-0.14) 1.78 (+/-0.34) 0.88 (+/-0.34) 1.54 (+/-0.49) 1.51 (+/-0.32) 0.90 (+/-0.17)
Avpr1a arginine vasopressin receptor 1A 0.675 0.929 0.034 0.90 (+/-0.1) 1.03 (+/-0.08) 0.75 (+/-0.1) 1.07 (+/-0.27) 1.10 (+/-0.11) 0.78 (+/-0.09)
Bdnf brain-derived neurotrophic factor 0.918 0.085 0.605 1.25 (+/-0.19) 0.99 (+/-0.17) 1.50 (+/-0.39) 1.81 (+/-0.47) 1.05 (+/-0.14) 1.06 (+/-0.28)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.248 0.105 0.097 0.89 (+/-0.09) 1.36 (+/-0.35) 0.74 (+/-0.09) 0.85 (+/-0.12) 1.00 (+/-0.11) 0.86 (+/-0.09)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.399 0.397 0.188 0.95 (+/-0.1) 1.19 (+/-0.11) 1.00 (+/-0.14) 1.21 (+/-0.26) 1.03 (+/-0.09) 0.85 (+/-0.12)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.795 0.545 0.006 0.82 (+/-0.09) 1.25 (+/-0.15) 0.90 (+/-0.12) 0.95 (+/-0.2) 1.11 (+/-0.15) 0.70 (+/-0.1)
Esr1 estrogen receptor 1 0.294 0.642 0.052 0.87 (+/-0.08) 1.26 (+/-0.13) 0.80 (+/-0.09) 1.34 (+/-0.37) 1.16 (+/-0.11) 0.84 (+/-0.07)
Esr2 estrogen receptor 2 0.511 0.318 0.291 1.01 (+/-0.09) 1.05 (+/-0.15) 0.94 (+/-0.15) 0.97 (+/-0.12) 1.00 (+/-0.07) 0.74 (+/-0.06)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.62 0.311 0.115 0.92 (+/-0.1) 1.03 (+/-0.08) 0.86 (+/-0.1) 1.11 (+/-0.22) 0.94 (+/-0.09) 0.73 (+/-0.08)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.35 0.524 0.022 0.87 (+/-0.07) 1.10 (+/-0.09) 0.74 (+/-0.09) 0.99 (+/-0.19) 1.03 (+/-0.1) 0.78 (+/-0.09)
Gal galanin prepropeptide 0.674 0.448 0.122 0.89 (+/-0.11) 1.19 (+/-0.12) 0.76 (+/-0.13) 0.90 (+/-0.22) 1.10 (+/-0.18) 0.82 (+/-0.12)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.521 0.317 0.122 0.87 (+/-0.1) 1.12 (+/-0.09) 0.78 (+/-0.11) 0.91 (+/-0.2) 0.94 (+/-0.1) 0.74 (+/-0.11)
Gnrh1 gonadotropin-releasing hormone 1 0.565 0.836 0.6 0.81 (+/-0.09) 0.93 (+/-0.24) 1.11 (+/-0.23) 0.77 (+/-0.28) 1.03 (+/-0.22) 0.95 (+/-0.23)
Gnrhr gonadotropin-releasing hormone receptor 0.44 0.03 0.335 0.98 (+/-0.44) 1.50 (+/-0.65) 3.48 (+/-1.22) 1.99 (+/-0.91) 1.09 (+/-0.18) 0.81 (+/-0.34)
Gper G protein-coupled estrogen receptor 1 0.293 0.568 0.015 0.99 (+/-0.09) 1.36 (+/-0.18) 0.94 (+/-0.12) 1.31 (+/-0.2) 1.21 (+/-0.12) 0.85 (+/-0.17)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.221 0.505 0.094 0.88 (+/-0.07) 1.08 (+/-0.1) 0.79 (+/-0.08) 1.03 (+/-0.18) 0.94 (+/-0.08) 0.80 (+/-0.09)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.394 0.171 0.055 0.91 (+/-0.08) 1.19 (+/-0.14) 0.84 (+/-0.08) 0.95 (+/-0.14) 0.98 (+/-0.08) 0.81 (+/-0.07)
Grik2 glutamate receptor, ionotropic, kainate 2 0.816 0.25 0.128 1.06 (+/-0.1) 1.23 (+/-0.13) 1.01 (+/-0.09) 1.14 (+/-0.15) 1.08 (+/-0.1) 0.86 (+/-0.06)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.179 0.641 0.161 0.96 (+/-0.09) 1.18 (+/-0.12) 0.92 (+/-0.12) 1.22 (+/-0.21) 1.04 (+/-0.09) 0.91 (+/-0.11)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.957 0.683 0.29 1.12 (+/-0.13) 1.16 (+/-0.14) 1.14 (+/-0.2) 1.40 (+/-0.27) 1.27 (+/-0.13) 0.99 (+/-0.16)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.245 0.306 0.024 0.88 (+/-0.08) 1.14 (+/-0.1) 0.79 (+/-0.12) 1.16 (+/-0.21) 0.96 (+/-0.11) 0.68 (+/-0.05)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.732 0.995 0.13 0.86 (+/-0.08) 1.06 (+/-0.12) 0.85 (+/-0.14) 1.06 (+/-0.2) 1.11 (+/-0.18) 0.82 (+/-0.08)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.289 0.226 0.048 0.92 (+/-0.08) 1.11 (+/-0.11) 0.82 (+/-0.11) 1.09 (+/-0.14) 0.95 (+/-0.09) 0.75 (+/-0.08)
Igf1 insulin-like growth factor 1 0.452 0.631 0.252 1.00 (+/-0.1) 1.15 (+/-0.15) 1.12 (+/-0.16) 1.03 (+/-0.16) 1.12 (+/-0.18) 0.78 (+/-0.13)
Igf1r insulin-like growth factor 1 receptor 0.514 0.254 0.165 0.99 (+/-0.08) 1.10 (+/-0.11) 1.03 (+/-0.09) 1.02 (+/-0.15) 1.02 (+/-0.1) 0.77 (+/-0.09)
Kiss1 KiSS-1 metastasis-suppressor 0.806 0.596 0.225 0.91 (+/-0.06) 1.26 (+/-0.19) 0.93 (+/-0.18) 1.09 (+/-0.32) 1.18 (+/-0.16) 0.84 (+/-0.11)
Kiss1r KISS1 receptor 0.085 0.093 0.057 0.92 (+/-0.1) 1.21 (+/-0.12) 0.93 (+/-0.19) 1.50 (+/-0.32) 0.96 (+/-0.12) 0.77 (+/-0.11)
Lepr leptin receptor 0.304 0.044 0.042 0.92 (+/-0.11) 1.35 (+/-0.27) 0.81 (+/-0.07) 1.00 (+/-0.23) 0.93 (+/-0.09) 0.67 (+/-0.06)
Mc3r melanocortin 3 receptor 0.372 0.184 0.033 0.81 (+/-0.09) 1.10 (+/-0.08) 0.64 (+/-0.09) 0.83 (+/-0.16) 0.98 (+/-0.12) 0.74 (+/-0.07)
Mc4r melanocortin 4 receptor 0.519 0.23 0.313 1.14 (+/-0.16) 1.24 (+/-0.18) 0.85 (+/-0.15) 0.88 (+/-0.12) 1.33 (+/-0.18) 0.91 (+/-0.15)
Oxt oxytocin, prepropeptide 0.031 0.206 0.004 0.93 (+/-0.17) 2.08 (+/-0.35) 0.75 (+/-0.19) 1.49 (+/-0.42) 1.37 (+/-0.26) 0.87 (+/-0.14)
Oxtr oxytocin receptor 1 0.102 0.478 0.98 (+/-0.1) 1.11 (+/-0.15) 0.74 (+/-0.12) 0.78 (+/-0.09) 1.00 (+/-0.14) 0.84 (+/-0.1)
Pdyn prodynorphin 0.088 0.214 0.025 0.83 (+/-0.1) 1.19 (+/-0.13) 0.65 (+/-0.09) 0.98 (+/-0.13) 0.95 (+/-0.12) 0.75 (+/-0.09)
Per2 period homolog 2 0.914 0.311 0.303 1.03 (+/-0.11) 1.01 (+/-0.11) 0.92 (+/-0.12) 1.13 (+/-0.2) 0.96 (+/-0.13) 0.74 (+/-0.12)
Pgr progesterone receptor 0.64 0.168 0.109 0.96 (+/-0.06) 1.08 (+/-0.09) 0.80 (+/-0.11) 0.84 (+/-0.11) 1.09 (+/-0.12) 0.81 (+/-0.08)
Slc17a6 solute carrier family 17, member 6 0.792 0.309 0.387 0.98 (+/-0.11) 1.07 (+/-0.13) 0.83 (+/-0.14) 0.99 (+/-0.14) 0.92 (+/-0.13) 0.75 (+/-0.09)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.654 0.95 0.121 0.93 (+/-0.08) 1.18 (+/-0.13) 0.99 (+/-0.14) 1.13 (+/-0.17) 1.21 (+/-0.14) 0.96 (+/-0.1)
Tac2 tachykinin 2 0.851 0.867 0.132 0.98 (+/-0.1) 1.28 (+/-0.22) 1.01 (+/-0.2) 1.19 (+/-0.35) 1.23 (+/-0.16) 0.85 (+/-0.14)
Tgfa transforming growth factor, alpha 0.8 0.439 0.042 0.91 (+/-0.08) 1.15 (+/-0.18) 0.88 (+/-0.11) 1.01 (+/-0.18) 1.04 (+/-0.1) 0.73 (+/-0.09)
Tgfb1 transforming growth factor, beta 1 0.514 0.79 0.044 0.91 (+/-0.07) 1.12 (+/-0.12) 0.85 (+/-0.09) 1.12 (+/-0.21) 1.08 (+/-0.13) 0.79 (+/-0.12)
Thra thyroid hormone receptor, alpha 0.671 0.836 0.183 0.87 (+/-0.09) 1.06 (+/-0.09) 0.88 (+/-0.12) 1.01 (+/-0.16) 1.00 (+/-0.1) 0.80 (+/-0.13)
Thrb thyroid hormone receptor, beta 0.752 0.503 0.033 0.87 (+/-0.07) 1.06 (+/-0.1) 0.86 (+/-0.11) 1.07 (+/-0.19) 1.01 (+/-0.11) 0.70 (+/-0.1)





Table 3.3: Gene Expression in the Female Median Eminence (ME) 
Relative gene expression for each treatment group is shown. P-values are listed for each variable. Significant main effects of 
treatment and status, or interaction of treatment x status are bolded (p < 0.05). Italics indicated that there was a trend (p < 0.1). 









18S Eukaryotic 18S rRNA 0.567 0.893 0.778 1.52 (+/-0.54) 1.10 (+/-0.2) 1.17 (+/-0.16) 1.22 (+/-0.33) 1.21 (+/-0.21) 1.10 (+/-0.2)
Ar androgen receptor 0.086 0.855 0.288 1.14 (+/-0.11) 0.66 (+/-0.13) 0.98 (+/-0.13) 0.97 (+/-0.23) 0.98 (+/-0.09) 0.83 (+/-0.15)
Avp arginine vasopressin 0.204 0.654 0.686 1.34 (+/-0.52) 2.32 (+/-1.01) 1.10 (+/-0.34) 1.19 (+/-0.59) 1.00 (+/-0.38) 2.41 (+/-0.92)
Avpr1a arginine vasopressin receptor 1A 0.371 0.325 0.126 1.56 (+/-0.37) 0.87 (+/-0.14) 1.17 (+/-0.24) 1.68 (+/-0.22) 0.73 (+/-0.11) 1.32 (+/-0.23)
Bdnf brain-derived neurotrophic factor 0.808 0.271 0.027 2.21 (+/-1.1) 0.65 (+/-0.29) 1.11 (+/-0.25) 1.31 (+/-0.3) 0.92 (+/-0.39) 3.84 (+/-1.41)
Comt catechol-O-methyltransferase 0.575 0.742 0.435 1.25 (+/-0.23) 0.99 (+/-0.15) 1.15 (+/-0.24) 1.42 (+/-0.41) 0.94 (+/-0.08) 1.29 (+/-0.19)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.508 0.368 0.143 1.09 (+/-0.06) 0.80 (+/-0.1) 0.97 (+/-0.09) 1.12 (+/-0.05) 1.12 (+/-0.14) 1.08 (+/-0.15)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3 alpha 0.769 0.086 0.498 0.94 (+/-0.1) 0.98 (+/-0.11) 1.22 (+/-0.11) 1.32 (+/-0.28) 1.40 (+/-0.15) 1.15 (+/-0.16)
Drd2 dopamine receptor D2 0.334 0.992 0.21 1.42 (+/-0.24) 0.65 (+/-0.17) 0.86 (+/-0.17) 1.12 (+/-0.23) 1.19 (+/-0.39) 1.19 (+/-0.41)
Esr1 estrogen receptor 1 0.989 0.584 0.031 1.27 (+/-0.15) 0.67 (+/-0.17) 0.67 (+/-0.14) 1.07 (+/-0.26) 0.66 (+/-0.17) 0.87 (+/-0.22)
Gad1 glutamate decarboxylase 1 0.938 0.586 0.048 1.40 (+/-0.21) 0.93 (+/-0.26) 1.18 (+/-0.09) 1.40 (+/-0.14) 1.00 (+/-0.22) 1.73 (+/-0.4)
Gad2 glutamate decarboxylase 2 0.595 0.613 0.051 1.18 (+/-0.16) 0.68 (+/-0.18) 0.74 (+/-0.11) 0.93 (+/-0.07) 0.73 (+/-0.13) 0.85 (+/-0.14)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.609 0.978 0.324 1.18 (+/-0.45) 1.47 (+/-0.26) 1.34 (+/-0.17) 1.24 (+/-0.28) 1.54 (+/-0.18) 1.00 (+/-0.15)
Gper G protein-coupled estrogen receptor 1 0.518 0.402 0.207 1.34 (+/-0.23) 1.00 (+/-0.17) 1.04 (+/-0.18) 1.72 (+/-0.64) 0.94 (+/-0.27) 1.04 (+/-0.24)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.545 0.708 0.154 1.25 (+/-0.13) 0.83 (+/-0.19) 1.15 (+/-0.1) 1.18 (+/-0.13) 1.05 (+/-0.21) 1.22 (+/-0.16)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.333 0.934 0.223 1.10 (+/-0.14) 0.89 (+/-0.09) 1.00 (+/-0.12) 1.12 (+/-0.08) 0.81 (+/-0.14) 1.52 (+/-0.37)
Grik2 glutamate receptor, ionotropic, kainate 2 0.587 0.552 0.823 0.99 (+/-0.19) 1.01 (+/-0.16) 1.16 (+/-0.09) 1.27 (+/-0.18) 1.02 (+/-0.16) 2.11 (+/-0.65)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.856 0.498 0.196 1.15 (+/-0.12) 0.82 (+/-0.06) 1.08 (+/-0.04) 1.19 (+/-0.19) 1.04 (+/-0.15) 1.33 (+/-0.25)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.467 0.614 0.755 1.50 (+/-0.33) 1.53 (+/-0.64) 1.28 (+/-0.24) 1.40 (+/-0.21) 1.45 (+/-0.2) 2.11 (+/-0.69)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.163 0.552 0.006 1.37 (+/-0.12) 0.65 (+/-0.08) 1.13 (+/-0.12) 1.18 (+/-0.17) 0.95 (+/-0.11) 1.14 (+/-0.17)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.507 0.714 0.167 1.08 (+/-0.13) 0.85 (+/-0.2) 0.77 (+/-0.08) 0.97 (+/-0.08) 0.83 (+/-0.08) 1.08 (+/-0.18)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.644 0.597 0.074 1.30 (+/-0.18) 0.76 (+/-0.07) 1.22 (+/-0.17) 1.22 (+/-0.21) 0.97 (+/-0.2) 1.30 (+/-0.17)
Igf1 insulin-like growth factor 1 0.8 0.677 0.193 1.17 (+/-0.2) 0.94 (+/-0.2) 0.98 (+/-0.2) 1.57 (+/-0.26) 1.29 (+/-0.46) 1.09 (+/-0.24)
Igf1r insulin-like growth factor 1 receptor 0.842 0.389 0.466 1.02 (+/-0.1) 0.76 (+/-0.14) 1.01 (+/-0.23) 1.24 (+/-0.41) 0.78 (+/-0.11) 0.92 (+/-0.11)
Kiss1 KiSS-1 metastasis-suppressor 0.471 0.226 0.844 0.98 (+/-0.15) 0.99 (+/-0.06) 0.73 (+/-0.15) 0.82 (+/-0.29) 0.65 (+/-0.2) 0.85 (+/-0.3)
Kiss1r KISS1 receptor 0.634 0.705 0.752 1.22 (+/-0.19) 1.10 (+/-0.19) 0.99 (+/-0.22) 1.11 (+/-0.23) 1.12 (+/-0.36) 1.46 (+/-0.36)
Lepr leptin receptor 0.997 0.306 0.413 1.25 (+/-0.2) 0.90 (+/-0.28) 1.14 (+/-0.28) 1.46 (+/-0.28) 0.89 (+/-0.11) 0.92 (+/-0.2)
Mc3r melanocortin 3 receptor 0.622 0.643 0.448 0.94 (+/-0.16) 0.75 (+/-0.17) 0.70 (+/-0.18) 1.26 (+/-0.43) 0.61 (+/-0.14) 0.70 (+/-0.17)
Nr3c1 nuclear receptor subfamily 3, group C, member 1 0.484 0.764 0.014 1.20 (+/-0.11) 0.70 (+/-0.09) 0.92 (+/-0.08) 1.11 (+/-0.13) 0.88 (+/-0.07) 0.99 (+/-0.15)
Nrf1 nuclear respiratory factor 1 0.993 0.794 0.541 1.21 (+/-0.15) 0.90 (+/-0.06) 1.10 (+/-0.12) 1.41 (+/-0.36) 1.19 (+/-0.27) 1.49 (+/-0.38)
Oxt oxytocin, prepropeptide 0.865 0.635 0.656 1.11 (+/-0.29) 1.19 (+/-0.47) 0.56 (+/-0.12) 0.65 (+/-0.14) 7.49 (+/-6.82) 0.67 (+/-0.13)
Oxtr oxytocin receptor 0.842 0.302 0.337 1.43 (+/-0.31) 0.67 (+/-0.18) 1.01 (+/-0.43) 1.53 (+/-0.8) 0.59 (+/-0.16) 0.62 (+/-0.14)
Per2 period homolog 2 0.489 0.218 0.253 1.07 (+/-0.14) 0.76 (+/-0.13) 0.97 (+/-0.14) 1.16 (+/-0.21) 0.86 (+/-0.09) 0.71 (+/-0.12)
Pgr progesterone receptor 0.572 0.622 0.342 1.24 (+/-0.16) 0.79 (+/-0.2) 0.77 (+/-0.16) 0.88 (+/-0.26) 0.84 (+/-0.13) 0.90 (+/-0.24)
Pomc proopiomelanocortin 0.218 0.688 0.247 1.20 (+/-0.29) 0.93 (+/-0.32) 0.56 (+/-0.15) 0.60 (+/-0.14) 3.19 (+/-1.46) 0.57 (+/-0.15)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 1 0.091 0.664 0.3 0.80 (+/-0.08) 1.43 (+/-0.13) 0.92 (+/-0.14) 1.01 (+/-0.09) 1.20 (+/-0.31) 1.29 (+/-0.27)
Tac2 tachykinin 2 0.666 0.517 0.259 1.19 (+/-0.16) 0.76 (+/-0.22) 0.73 (+/-0.16) 0.78 (+/-0.19) 0.77 (+/-0.19) 0.95 (+/-0.2)
Tgfa transforming growth factor alpha 0.081 0.593 0.274 1.20 (+/-0.1) 0.98 (+/-0.08) 0.98 (+/-0.08) 1.01 (+/-0.2) 1.30 (+/-0.15) 0.94 (+/-0.13)
Tgfb1 transforming growth factor, beta 1 0.375 0.529 0.743 1.04 (+/-0.13) 1.08 (+/-0.12) 1.53 (+/-0.33) 1.19 (+/-0.21) 1.29 (+/-0.32) 0.99 (+/-0.18)
Th tyrosine hydroxylase 0.318 0.238 0.449 1.10 (+/-0.19) 0.97 (+/-0.33) 0.57 (+/-0.14) 0.83 (+/-0.22) 0.51 (+/-0.18) 0.92 (+/-0.23)





Table 3.4: Gene Expression in the Male Anteroventral Periventricular Nucleus (AVPV) 
Relative gene expression for each treatment group is shown. P-values are listed for each 
variable. Significant main effects are bolded (p < 0.05). Italics indicated that there was a 







18S Eukaryotic 18S RNA, 18S ribosomal 1 0.581 1.03 (+/-0.09) 0.97 (+/-0.08) 0.92 (+/-0.06)
Ahr aryl hydrocarbon receptor 0.825 1.57 (+/-0.26) 1.57 (+/-0.24) 1.37 (+/-0.26)
Ar androgen receptor 0.532 1.11 (+/-0.14) 1.35 (+/-0.13) 1.16 (+/-0.16)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.13 1.09 (+/-0.09) 1.45 (+/-0.14) 1.16 (+/-0.14)
Avp arginine vasopressin 0.265 2.43 (+/-0.98) 16.53 (+/-8.27) 3.38 (+/-1.85)
Avpr1a arginine vasopressin receptor 1A 0.05 0.75 (+/-0.1) 1.24 (+/-0.19) 0.93 (+/-0.11)
Bdnf brain-derived neurotrophic factor 0.713 0.83 (+/-0.13) 0.90 (+/-0.11) 0.76 (+/-0.12)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.408 1.32 (+/-0.27) 1.86 (+/-0.36) 1.46 (+/-0.23)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.428 1.13 (+/-0.1) 1.30 (+/-0.13) 1.09 (+/-0.1)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.474 1.35 (+/-0.15) 1.60 (+/-0.21) 1.31 (+/-0.15)
Esr1 estrogen receptor 1 0.739 0.92 (+/-0.17) 1.11 (+/-0.18) 0.98 (+/-0.16)
Esr2 estrogen receptor 2 0.331 0.81 (+/-0.11) 0.98 (+/-0.12) 0.78 (+/-0.07)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.401 1.55 (+/-0.22) 1.49 (+/-0.14) 1.23 (+/-0.14)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.259 1.02 (+/-0.1) 1.25 (+/-0.09) 1.01 (+/-0.11)
Gal galanin prepropeptide 0.115 0.88 (+/-0.19) 1.52 (+/-0.26) 1.08 (+/-0.18)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.541 1.34 (+/-0.14) 1.25 (+/-0.13) 1.13 (+/-0.14)
Gnrh1 gonadotropin-releasing hormone 1 0.961 1.04 (+/-0.16) 1.08 (+/-0.22) 0.99 (+/-0.26)
Gper G protein-coupled estrogen receptor 1 0.112 1.03 (+/-0.08) 1.28 (+/-0.12) 1.03 (+/-0.08)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.473 1.06 (+/-0.11) 1.28 (+/-0.14) 1.13 (+/-0.11)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.547 1.13 (+/-0.1) 1.34 (+/-0.17) 1.19 (+/-0.13)
Grik2 glutamate receptor, ionotropic, kainate 2 0.928 1.41 (+/-0.12) 1.44 (+/-0.18) 1.36 (+/-0.16)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.67 1.21 (+/-0.11) 1.30 (+/-0.1) 1.16 (+/-0.1)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.868 1.35 (+/-0.12) 1.35 (+/-0.13) 1.26 (+/-0.18)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.584 1.13 (+/-0.09) 1.23 (+/-0.15) 1.04 (+/-0.13)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.237 1.06 (+/-0.1) 1.41 (+/-0.14) 1.25 (+/-0.15)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.823 1.15 (+/-0.11) 1.12 (+/-0.05) 1.06 (+/-0.13)
Igf1 insulin-like growth factor 1 0.825 0.71 (+/-0.09) 0.75 (+/-0.07) 0.66 (+/-0.11)
Igf1r insulin-like growth factor 1 receptor 0.267 1.18 (+/-0.1) 1.31 (+/-0.17) 1.03 (+/-0.1)
Kiss1 KiSS-1 metastasis-suppressor 0.487 0.96 (+/-0.14) 0.96 (+/-0.2) 0.75 (+/-0.12)
Kiss1r KISS1 receptor 0.791 1.28 (+/-0.12) 1.40 (+/-0.15) 1.24 (+/-0.21)
Lepr leptin receptor 0.938 1.47 (+/-0.17) 1.45 (+/-0.22) 1.39 (+/-0.19)
Mc3r melanocortin 3 receptor 0.382 0.84 (+/-0.17) 1.18 (+/-0.18) 0.89 (+/-0.15)
Mc4r melanocortin 4 receptor 0.571 1.09 (+/-0.16) 1.13 (+/-0.19) 0.90 (+/-0.14)
Oxt oxytocin, prepropeptide 0.171 1.32 (+/-0.58) 3.74 (+/-1.81) 1.32 (+/-0.32)
Oxtr oxytocin receptor 0.264 0.89 (+/-0.11) 1.18 (+/-0.13) 0.95 (+/-0.13)
Pdyn prodynorphin 0.477 0.75 (+/-0.11) 0.96 (+/-0.17) 0.77 (+/-0.1)
Per2 period homolog 2 0.115 0.89 (+/-0.1) 1.38 (+/-0.23) 1.00 (+/-0.15)
Pgr progesterone receptor 0.792 0.93 (+/-0.16) 1.08 (+/-0.17) 0.95 (+/-0.15)
Slc17a6 solute carrier family 17, member 6 0.714 1.05 (+/-0.15) 1.18 (+/-0.2) 0.99 (+/-0.13)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.943 1.59 (+/-0.21) 1.56 (+/-0.23) 1.49 (+/-0.21)
Tac2 tachykinin 2 0.197 0.99 (+/-0.17) 1.50 (+/-0.23) 1.16 (+/-0.17)
Tgfa transforming growth factor, alpha 0.584 1.08 (+/-0.1) 1.26 (+/-0.13) 1.09 (+/-0.15)
Tgfb1 transforming growth factor, beta 1 0.919 1.26 (+/-0.1) 1.20 (+/-0.13) 1.28 (+/-0.14)
Thra thyroid hormone receptor, alpha 0.599 1.20 (+/-0.1) 1.31 (+/-0.13) 1.13 (+/-0.12)






Table 3.5: Gene Expression in the Male Arcuate Nucleus (ARC) 
Relative gene expression for each treatment group is shown. P-values are listed for each 
variable. Significant main effects are bolded (p < 0.05). Italics indicated that there was a 












18S Eukaryotic 18S RNA, 18S ribosomal 1 0.43 0.99 (+/-0.05) 1.00 (+/-0.09) 0.87 (+/-0.09)
Ahr aryl hydrocarbon receptor 0.006 1.18 (+/-0.14) 1.49 (+/-0.18) 0.84 (+/-0.06)
Ar androgen receptor 0.462 0.95 (+/-0.08) 1.10 (+/-0.06) 0.97 (+/-0.1)
Arntl aryl hydrocarbon receptor nuclear translocator-like 0.409 1.01 (+/-0.12) 1.06 (+/-0.1) 0.85 (+/-0.11)
Avp arginine vasopressin 0.265 1.58 (+/-0.27) 1.85 (+/-0.37) 0.80 (+/-0.12)
Avpr1a arginine vasopressin receptor 1A 0.963 1.03 (+/-0.13) 0.99 (+/-0.11) 0.99 (+/-0.12)
Bdnf brain-derived neurotrophic factor 0.008 0.90 (+/-0.13) 2.14 (+/-0.35) 1.42 (+/-0.26)
Cyp19a1 cytochrome P450, family 19, subfamily A, polypeptide 1 0.232 1.00 (+/-0.18) 2.75 (+/-1.07) 1.07 (+/-0.14)
Dnmt1 DNA (cytosine-5-)-methyltransferase 1 0.464 1.14 (+/-0.15) 1.08 (+/-0.11) 0.90 (+/-0.15)
Dnmt3a DNA (cytosine-5-)-methyltransferase 3a 0.667 1.19 (+/-0.17) 1.19 (+/-0.19) 1.02 (+/-0.1)
Esr1 estrogen receptor 1 0.642 0.92 (+/-0.08) 0.84 (+/-0.09) 0.96 (+/-0.09)
Esr2 estrogen receptor 2 0.587 1.10 (+/-0.12) 0.96 (+/-0.07) 0.96 (+/-0.11)
Gad1 glutamate decarboxylase 1 (brain, 67kDa) 0.758 1.18 (+/-0.16) 0.97 (+/-0.04) 1.02 (+/-0.08)
Gad2 glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) 0.669 0.96 (+/-0.11) 0.86 (+/-0.08) 0.86 (+/-0.07)
Gal galanin prepropeptide 0.6 0.69 (+/-0.11) 0.77 (+/-0.12) 0.61 (+/-0.08)
Gapdh glyceraldehyde-3-phosphate dehydrogenase 0.469 0.96 (+/-0.14) 1.02 (+/-0.09) 0.83 (+/-0.09)
Gnrh1 gonadotropin-releasing hormone 1 0.515 0.73 (+/-0.15) 0.60 (+/-0.14) 0.85 (+/-0.14)
Gnrhr gonadotropin-releasing hormone receptor 0.83 0.80 (+/-0.17) 0.67 (+/-0.14) 1.41 (+/-0.78)
Gper G protein-coupled estrogen receptor 1 0.411 1.33 (+/-0.16) 1.47 (+/-0.1) 1.18 (+/-0.15)
Gria1 glutamate receptor, ionotropic, AMPA 1 0.421 0.98 (+/-0.12) 1.06 (+/-0.06) 0.93 (+/-0.08)
Gria2 glutamate receptor, ionotropic, AMPA 2 0.198 0.93 (+/-0.12) 1.22 (+/-0.11) 0.95 (+/-0.1)
Grik2 glutamate receptor, ionotropic, kainate 2 0.5 1.27 (+/-0.18) 1.30 (+/-0.14) 1.08 (+/-0.1)
Grin1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 0.822 1.07 (+/-0.11) 1.10 (+/-0.06) 1.01 (+/-0.08)
Grin2a glutamate receptor, ionotropic, N-methyl D-aspartate 2A 0.381 1.22 (+/-0.13) 1.47 (+/-0.11) 1.24 (+/-0.13)
Grin2b glutamate receptor, ionotropic, N-methyl D-aspartate 2B 0.943 1.10 (+/-0.16) 1.12 (+/-0.08) 1.06 (+/-0.11)
Grin2c glutamate receptor, ionotropic, N-methyl D-aspartate 2C 0.374 0.91 (+/-0.14) 1.07 (+/-0.07) 0.86 (+/-0.07)
Grin2d glutamate receptor, ionotropic, N-methyl D-aspartate 2D 0.824 1.00 (+/-0.11) 1.00 (+/-0.08) 0.93 (+/-0.08)
Igf1 insulin-like growth factor 1 0.298 0.96 (+/-0.16) 1.09 (+/-0.19) 0.74 (+/-0.12)
Igf1r insulin-like growth factor 1 receptor 0.183 1.08 (+/-0.11) 1.13 (+/-0.1) 0.89 (+/-0.07)
Kiss1 KiSS-1 metastasis-suppressor 0.827 0.45 (+/-0.07) 0.42 (+/-0.05) 0.40 (+/-0.05)
Kiss1r KISS1 receptor 0.537 1.08 (+/-0.11) 1.30 (+/-0.16) 1.12 (+/-0.14)
Lepr leptin receptor 0.936 1.13 (+/-0.17) 1.16 (+/-0.15) 1.09 (+/-0.1)
Mc3r melanocortin 3 receptor 0.751 0.96 (+/-0.14) 1.05 (+/-0.16) 0.90 (+/-0.11)
Mc4r melanocortin 4 receptor 0.335 1.35 (+/-0.33) 0.81 (+/-0.1) 1.14 (+/-0.19)
Oxt oxytocin, prepropeptide 0.091 0.76 (+/-0.14) 1.24 (+/-0.25) 0.52 (+/-0.07)
Oxtr oxytocin receptor 0.82 0.67 (+/-0.16) 0.82 (+/-0.18) 0.70 (+/-0.15)
Pdyn prodynorphin 0.446 0.77 (+/-0.14) 1.00 (+/-0.16) 0.77 (+/-0.11)
Per2 period homolog 2 0.159 0.98 (+/-0.11) 1.03 (+/-0.12) 0.78 (+/-0.06)
Pgr progesterone receptor 0.82 0.58 (+/-0.05) 0.58 (+/-0.05) 0.54 (+/-0.06)
Slc17a6 solute carrier family 17, member 6 0.057 0.87 (+/-0.12) 1.32 (+/-0.07) 1.01 (+/-0.14)
Srd5a1 steroid-5-alpha-reductase, alpha polypeptide 2 0.682 1.19 (+/-0.15) 1.27 (+/-0.12) 1.11 (+/-0.1)
Tac2 tachykinin 2 0.718 0.49 (+/-0.09) 0.43 (+/-0.05) 0.52 (+/-0.07)
Tgfa transforming growth factor, alpha 0.346 0.89 (+/-0.08) 1.05 (+/-0.09) 0.92 (+/-0.07)
Tgfb1 transforming growth factor, beta 1 0.105 0.98 (+/-0.05) 1.25 (+/-0.14) 1.01 (+/-0.08)
Thra thyroid hormone receptor, alpha 0.714 1.06 (+/-0.13) 1.12 (+/-0.07) 0.99 (+/-0.09)





Table 3.6: Effects of prenatal EDCs on somatic markers and hormones in male rats. 
Those genes with significant differences or trends in AVPV or ARC are shown. No 
significant effects of prenatal EDC treatment on somatic markers were detected. For 
serum hormones, only E2 was affected, with higher concentrations in both EB and A1221 
males. For gene expression, three significant effects were detected, one in AVPV and 2 in 
ARC, with differences between EB males and their DMSO counterparts. We also present 
data for two genes for which there were trends in the ARC. 
DISCUSSION 
 Endocrine disrupting chemicals have become a prototypical model for the “fetal 
basis of adult disease,” with prenatal exposures during critical developmental periods 
associated with adult dysfunctions related to reproductive, metabolic, thyroid, and many 
other target systems. However, little of this research has extended the “fetal basis” model 
to aging populations, and an even smaller subset on reproductive senescence. The current 
study sought to determine if gestational exposure to low doses of estrogenic EDCs would 
hasten reproductive aging in males and females through premature aging of 
neuroendocrine function, assayed here through a network of gene expression in three key 
hypothalamic regions. The basis for this work was the body of epidemiological evidence 
suggesting that there are correlations between exposures to EDCs and advancements in 
p-value Mean SEM Mean SEM Mean SEM
Body Wt (g) 0.969 562.5 (+/- 21.58) 556.44 (+/- 11.33) 558.9 (+/- 12.53)
Pituitary Wt (g) 0.364 0.014 (+/- 0.) 0.013 (+/- 0.001) 0.0132 (+/- 0.)
Adrenal Wt (g) 0.987 0.05 (+/- 0.002) 0.049 (+/- 0.002) 0.049 (+/- 0.002)
GSI 0.961 0.007 (+/- 0.) 0.008 (+/- 0.) 0.008 (+/- 0.)
Serum LH (ng/ml) 0.478 0.455 (+/- 0.054) 0.633 (+/- 0.196) 0.444 (+/- 0.029)
Serum T (ng/ml) 0.364 0.474 (+/- 0.058) 0.459 (+/- 0.139) 0.649 (+/- 0.125)
Serum E2 (pg/ml) 0.022 2.36 (+/- 0.264) 7.72 (+/- 2.968) 4.13 (+/- 0.589)
AVPV Avpr1a 0.05 0.751 (+/- 0.097) 1.25 (+/- 0.191) 0.932 (+/- 0.109)
AVPV Ahr 0.006 1.18 (+/- 0.14) 1.49 (+/- 0.182) 0.842 (+/- 0.058)
AVPV Bdnf 0.008 0.895 (+/- 0.129) 2.14 (+/- 0.353) 1.42 (+/- 0.257)
ARC Slc17a6 0.057 0.872 (+/- 0.119) 1.32 (+/- 0.073) 1.01 (+/- 0.139)





the timing of menopause in humans (Akkina et al., 2004; Cooper et al., 2002; Hatch et 
al., 2006; Knox et al., 2011). However, some of these results have been contradictory 
(Akkina et al., 2004; Cooper et al., 2002; Farr et al., 2006; Hatch et al., 2006; Knox et al., 
2011; Yu et al., 2000), possibly due to differences in exposure timing, dose, and type of 
EDC. Animal models may be more useful in determining the cause-and-effect links 
between early life EDCs and reproductive aging. Our laboratory recently found that 
perinatal exposure to the pesticide methoxychlor advanced reproductive senescence in 
Fischer female rats and altered gene expression and DNA methylation in the 
hypothalamus 16 months after the original exposure (Gore et al., 2011). Other rodent 
work shows that EDCs can cause irregular estrous cyclicity in females and accelerate the 
transition to persistent estrus by 9 months of age (Adewale et al., 2009; Armenti et al., 
2008; Dickerson et al., 2011b; Dickerson and Gore, 2007; Gellert, 1978a, b). Previous 
studies specifically investigating the effects of A1221 on the timing of reproductive aging 
in female rats (Gellert, 1978a, b; Gellert and Wilson, 1979) have produced inconsistent 
results and did not investigate molecular endpoints. While Gellert et al (Gellert and 
Wilson, 1979) investigated gestational exposure to A1221 on male fertility at 6 months of 
age, to our knowledge no study has investigated the long-term hypothalamic effects of 
A1221 on male rodents.  
 Based on the literature to date, our experimental design sought to address several 
novel points. First, we tested how ecologically-relevant exposures to estrogenic EDCs 
might affect reproductive physiology in males and females. There is a paucity of data on 




physiological changes in the animals throughout their first 9 months of life, representing 
a significant portion of a rat’s lifecycle, and associated them with molecular endpoints in 
brain regions important for reproductive function and physiology. Third, we performed 
cluster and network analyses to gain insights into the complex relationships caused by 
prenatal EDC exposure – this goes beyond the “gene by gene” or “hormone by hormone” 
approach and has been very informative about the big picture of bionetworks (Ojeda et 
al., 2010a; Walker et al., 2012). 
Reproductive physiology is altered in females exposed to A1221 in utero 
While we did not see a significant advancement of the timing of reproductive 
senescence or in the number of acyclic females by 9 months of age, we did observe a 
significant increase in the length of estrous cycles in A1221 females (Figure 3.2) 
throughout the life cycle. Elongated cycles are a common characteristic of reproductive 
aging in both primates and rodents before transitioning to acyclicity (Kermath and Gore, 
2012) and the appearance of such cycles earlier in life may be indicative of an aging 
phenotype. Additionally, we noted a marked decreased (albeit non-significant) in serum 
LH in cycling females exposed perinatally to A1221 (Figure 3.1A) when compared to 
their control counterparts. The pulsatile nature of LH release probably led to high 
variability in serum LH concentrations between individuals. In rodents, age-related 
decreases in LH release on proestrus presage reproductive decline, and are associated 
with decreased GnRH drive (Lloyd et al., 1994; Zuo et al., 1996). Further studies are 




Gestational exposure to A1221 alters cycle status specific expression of 
neuroendocrine genes in the ARC and ME, but not the AVPV, of female rats 
 The ARC plays a role in the regulation of GnRH pulsatility (Reviewed in 
(Navarro, 2012)), and in negative feedback of hormones on GnRH/LH release, processes 
that are subject to age-related decline (Weiss et al., 2004). This region had the greatest 
number of genes that were affected by EDC treatment interacting with cycle status. 
Interestingly, gene expression tended to be higher in acyclic than cycling rats in the 
control DMSO groups, whereas opposite effects were seen for the A1221 rats (gene 
expression was lower in acyclic than cyclic). EB rats tended to fall in the middle (Figure 
3.3). These genes fell into 4 functional categories: epigenetic processes, steroid hormone 
receptors, neuropeptide signaling, and glutamate signaling. While changes in 
hypothalamic sex steroid hormone feedback and glutamatergic signaling are thought to 
contribute to the transition to reproductive senescence (Reviewed in (Gore, 2001)), it 
should be noted that many of these genes are important for signaling cross-talk among 
neuroendocrine systems regulating reproduction, stress, and metabolism (e.g., Pdyn, 
Lepr, Mc3r and Oxt) (Onaka et al., 2012; Shimizu et al., 2007; Yosten and Samson, 
2010a, b). All of these axes undergo age related changes in rodents (Bowman et al., 2006; 
Santollo et al., 2012) and non-human primates (Reviewed in (Appt and Ethun, 2010)), 
and our data suggest that gestational exposure to A1221 causes lifelong alterations that 
may affect numerous neuroendocrine axes. Furthermore, our data provide insight into 
target gene candidates that may play roles in the transition from cyclicity to acyclicity.  
 In the ME, we found that levels of steroid hormone receptor genes for ERα and 




were affected by prenatal EDCs (Figure 3.4). In DMSO rats, acyclic females had lower 
expression of all four of these genes compared to cycling DMSO rats (notably, this is the 
opposite gene pattern from the ARC). Again, A1221 rats had completely different gene 
expression patterns by cycle status from the DMSO group. The ME is mainly composed 
of glial cells and axons projecting to the portal capillary system to release neuropeptides 
(Yin and Gore, 2010); the low occurrence of neuronal cell bodies in this region suggests 
that the gene expression results in this experiment are probably mainly from glial cells or 
local mRNA in axons (Reviewed in (Jung et al., 2012)). The few studies on reproductive 
aging investigating changes specifically in the ME revealed age-related changes: Direct 
stimulation of GnRH release from terminals with glutamate or glutamate agonists was 
decreased in middle aged females compared to young (Zuo et al., 1996), and the 
ultrastructural organization of the ME, and the relationship between glia and GnRH 
terminals in this region, was disrupted with age (Yin et al., 2009a; Yin et al., 2009b).  
 It was surprising that so few effects of aging or cycle status were found in AVPV. 
It is possible that nine months may be too early in reproductive aging to see an effect. In 
comparing results for the three hypothalamic regions, there are distinct regional 
differences in responses to prenatal EDCs, and in effects of cycle status. Overall, results 
from the ARC and ME indicate that patterns of gene expression between cyclic and 
acyclic rats seen in control treatments are obliterated or even reversed in A1221 rats. 
Although this requires further experimentation, we hypothesize that A1221 females begin 
the transition of reproductive aging earlier in life and that the overall process is altered. 




A1221 females cluster with the cycling DMSO females and vice versa in both the ARC 
and ME. The elongated cycles and lower serum levels of LH in A1221 cycling rats 
further support this idea. Finally, expression patterns of genes in the ARC and ME in 
cycling females exposed to A1221 are similar to the acyclic, and dissimilar to the cyclic, 
control rats.  
Our data must be interpreted in light of some limitations. All rats were euthanized 
at a single time of day, and it is possible that the treatment effects observed on gene 
expression are due to other influences such as a disruption of circadian rhythms or 
changes to other endocrine organs that feedback onto the hypothalamus. Although we 
were able to assay multiple genes, serum hormones, and somatic endpoints, several 
additional endpoints (e.g. expression and localization of proteins in the brain; release of 
neurotransmitters/ neuropeptides) would be extremely valuable information. Finally, the 
age of euthanasia (9 months) is fairly early in the aging process for the females and 
males, and later ages would be very informative. Nevertheless, even at 9 months, it is 
clear that there are distinct differences between the prenatal treatment groups in our aging 
population.  
Housing conditions may alter effects of treatment in males and females 
 In general, there were very few effects of treatment in males on somatic indices, 
serum hormones, and gene expression in the ARC and AVPV. Previous studies from our 
laboratory are consistent with this latter result, and showed that exposure to A1221 
during the critical period alters programming of the female hypothalamus to a much 




we have observed that exposure to A1221 on E16 and 18 delays the timing of puberty in 
males (Dickerson et al., 2011b). A sister study from our laboratory found that gene 
expression is altered specifically in the male ARC throughout adulthood (unpublished 
data). Again, the lack of effects of A1221 here may be due to the relatively early age at 
euthanasia (9 months).  
 We believe that the housing conditions of our rats may have had unexpected and 
potentially interesting influences on some outcomes, that merit further investigation. This 
experiment was part of a larger study in which littermates had been euthanized at earlier 
life ages for a companion experiment. At P90, rats for the current aging study were 
randomly paired with a new same-sex cage mate. Possible housing pairs were DMSO-
DMSO, DMSO-EB, EB-EB, DMSO-A1221, A1221-A1221, and EB-A1221, but because 
investigators were blind to treatment, some combinations were overrepresented and 
others were underrepresented (in fact, we never had any DMSO-DMSO pairings for 
either sex). While these data should be considered preliminary, an individual’s partner 
had effects on body weight, gene expression, and cycle status. For example, males 
housed with an EB treated cage mate weighed less than the EB cage mate, whereas those 
housed with a DMSO cage mate showed no differences in their weights (data not shown). 
Interestingly, genes associated with social behaviors were affected in AVPV and ARC of 
males and may relate to the housing conditions. There is some evidence that social 
environment can affect the timing of reproductive aging in male mice (Schmidt et al., 




effects of treatment may be exacerbated or masked by an interaction with social 
condition. 
In females, we noted that 69% of the cage mates had the same cycling status as 
their partners suggesting that cycling status may be sensitive to social condition in the 
aging females, as reported previously (Hermes et al., 2009; Hermes and McClintock, 
2008; Hermes et al., 2006). This is a plausible explanation for the high number of acyclic 
females treated with DMSO, as they were all housed with EB or A1221 partners. We had 
expected that the treated females (both EB and A1221) would have a greater number of 
acyclic females than our control group (Gellert, 1978b; Gore et al., 2011) and the 
similarities in acyclic and cyclic animals of all treatments may relate to the social pairing 
condition. 
Network analysis reveals region-specific changes between cycling and acyclic 
females 
 In order to generate new hypotheses about hypothalamic and peripheral changes 
during the transition of reproductive aging, we used Cytoscape (Kohl, 2011; Kohl et al., 
2011; O'Connell and Hofmann, 2012) to generate networks of hormones, genes and 
endocrine tissues in each of the regions of interest. The most striking difference between 
cyclic and acyclic networks was seen in the AVPV. This result was both interesting and 
surprising, as the gene-by-gene analysis did not reveal gene expression effects, whereas 
the network analysis gave a more holistic perspective on patterns of change with aging. 
In the cycling animals there were 3 “hubs” of negative correlations: serum estradiol (E2), 




significant correlations was substantially decreased, and virtually all negative 
relationships were with serum LH concentrations. Because the AVPV is necessary for the 
LH surge (Wiegand and Terasawa, 1982), it is not surprising that we saw stark 
differences between the cyclic and acyclic network. Moreover, it should be noted that the 
correlations observed in the cycling AVPV reveal some unexpected relationships. 
Notably, serum E2 and Pgr (progesterone receptor) were negatively correlated in contrast 
to other studies (Blaustein et al., 1988; Blaustein and Turcotte, 1989; Shughrue et al., 
1997). Most work on regulation of the progesterone receptor by E2 is conducted on 
models of ovariectomy +/- estradiol treatment. Our current study on intact females 
provides new information about changes in this relationship with aging. We recently 
published (Walker et al., 2012) a paper showing that during early postnatal development 
of intact female rats, the E2-Pgr connection also differs from the OVX model, suggesting 
that models of natural development and aging with a bionetwork approach is important in 
understanding physiological regulatory processes. 
 In the ARC, one of the more surprising findings was that the cycling animals had 
a hub of positive correlations with Gnrh1 and a negative hub with gonadal somatic index 
(ovary) weights. GnRH cell bodies of rats are primarily located in the AVPV but not the 
ARC of the rodent (King et al., 1982). However, these data provide intriguing evidence 
of local translation of Gnrh1 in the axons of the GnRH neurons and may be reflective of 
the ready, releasable pool of GnRH. While this has not been observed in GnRH neurons 
specifically, other neuroendocrine cells, e.g. oxytocin and vasopressin, use local 




2012). In the acyclic rat’s ARC, the hubs of positive correlations were Gnrhr, pituitary 
and adrenal weights whereas the negative hub is uterus weight. It is notable that many of 
the genes that were altered by treatment in the ARC are associated with the 2 positive 
hubs in the cyclic and acyclic networks suggesting these genes may have differing roles 
in the cyclic and acyclic ARC. Interestingly, two of these somatic endpoints (pituitary 
and uterus) are the same ones that show significant effects of status independent of 
treatment supporting the ARC’s role in the central regulation of reproductive aging. 
 In the ME, there were few differences in the number of correlations between 
cyclic and acyclic end points. Additionally, there do not appear to be distinct hubs as 
observed in the AVPV and the ARC. Many of the correlations were between genes and 
not peripheral changes, which was surprising since the ME is the region of final output of 
the GnRH system to the HPG axis. The reduced number of correlations found and lack of 
hubs in the ME networks compared to the AVPV and ARC may signify a different role in 
reproductive function. With the presence of numerous neurons in the AVPV and ARC, 
many of which modulate GnRH neuronal activation and release, the coordination of their 
activity may be aptly reflected in a network of gene expression. However, while changes 
in gene expression are still likely important at the site of the terminals in the ME, the 
coordination of regulatory inputs (or “network”) may be better demonstrated at the 
protein level, as many neuropeptides and transmitters are released there.  
SUMMARY AND CONCLUSIONS 
Numerous studies have indicated that gestational exposure to EDCs can disrupt 




characterize the long-term changes reproductive physiology and gene expression 
throughout the hypothalamus in an aging model in both males and females. First, we 
found very few effects in the males either expression or the somatic markers of aging.  In 
the females, however, animals exposed to A1221 underwent a different process of 
reproductive aging than their control counterparts. Additionally, we identified genes in 
both the ARC and ME as potential targets of EDCs as well as biomarkers for altered 
reproductive aging. Finally, we used bionetworks to identify relationships of genes, 
hormones, and somatic changes that can provide insight into the process of reproductive 







 Taken together, the experiments presented here provide a comprehensive 
developmental profile of neuroendocrine gene expression changes in the hypothalamus 
and serum hormone concentrations from the neonate through reproductive aging in males 
and females. Although each experiment did not look at every age, I was able to replicate 
previous work throughout all experiments. However, my studies were far more 
comprehensive in that they included animals of both sexes at a range of ages; littermates 
were distributed across different time points to avoid over-reliance of siblings at a single 
age; numerous genes could be measured within individuals; the hypothalamus was 
subdivided to provide better anatomical specificity; and serum hormones were measured 
in the same animals. This design allowed me to explore new possibilities regarding the 
mechanisms of sexual differentiation of the brain as well as functional differences in the 
regulation of reproductive physiology between brain regions.  
 In addition, my dissertation compared normative hypothalamic development to 
that of animals exposed to prenatal EDCs. This is important because few studies have 
investigated changes in genes and hormones in the same animals throughout development 
and there are vast differences in experimental design between these studies. This made it 
difficult to interpret any effects of EDCs as we did not have a consistent basis for 
comparison  
 In chapter 1, I investigated the relationships between hormones and gene 
expression in the hypothalamus of normally developing intact male and female rats 




relationships between genes and hormones in two regions of the hypothalamus. I also 
reported that there were surprisingly few sex differences in the POA and MBH, with only 
Esr1, Kiss1 and Tac2 being sexually dimorphic. The sex differences were specific to 
brain regions and observed at specific ages. This result was important because all three of 
these genes are necessary for reproductive function and are expression in the same 
neurons in the MBH. Until recently, it was thought that these genes were not sexually 
dimorphic in those neurons. However, our data and others reveal novel sex difference in 
the caudal hypothalamus. 
 In chapter 2, I investigated if gestational exposure to PCBs, a known class of 
endocrine disrupting chemicals, altered the development of the hypothalamus. Here, I 
further refined my hypothalamic dissection and used microdissected anteroventral 
periventricular nucleus (AVPV) and the arcuate nucleus (ARC) of males and females 
from the juvenile period (P15) through the pubertal process (P30 and P45) and into 
adulthood (P90). I noted significant treatment effects in the females of 21 genes in the 
AVPV, including the same three genes highlighted in Chapter 1. Additionally, the 
expression profiles of 9 genes in the female AVPV were masculinized in their expression. 
This result suggests that gestational exposure to estrogenic EDCs can alter the 
developmental process in a male typical pattern. These effects were associated with 
altered estrous cyclicity in adult females, indicating a functional consequence of the 
prenatal EDC exposures. In males, the timing of puberty was delayed by A1221 
treatment. I also observed alterations of adrenal development, slight effects on gonadal 




effects in the male AVPV, 6 genes were altered by treatment in the ARC, most notably 
Ar and Lepr. Taken together, these data suggest that ARC plays an important role in the 
timing of puberty in males, whereas the AVPV plays an important role in regulating the 
estrous cycle in females.  
 I believe it is important that two of the genes altered by treatment in the female 
AVPV, Per2 and Arntl, function as clock genes and regulate circadian expression of 
other genes. Recent publications suggest that Kiss1 is under circadian control in the 
female AVPV. My data are the first to show that clock gene expression is sexually 
dimorphic in the AVPV and can be programmed by gestational exposure to estrogenic 
EDCs. These data also provide the first evidence that sexually dimorphic expression of 
genes in the AVPV may be under circadian control and are dependent on the cycle status 
of the female, thereby highlighting the importance of including intact, cycling animals 
when investigating the neuroendocrine control of reproductive physiology.  
 In chapter 3, I extended my analysis of gestational exposure to EDCs to the other 
end of the life spectrum, by analyzing effects on reproductive senescence in aging 
females and males. Siblings of the animals from the experiment in chapter 3 were 
allowed to age until 9 months of age. While there were few treatment effects observed in 
males, the females exhibited disrupted estrous cycles, altered LH concentrations, and 
effects on expression of genes in the ARC and median eminence (ME). However, unlike 
the young animals, no effects of cycle status or treatment were observed in the AVPV. 
Additionally, there were no differences in the number of acyclic females in the treated 




changes in the brain during the transition to reproductive senescence, I generated 
bionetworks to represent changing relationships between genes, hormones and endocrine 
tissues in cycling and acyclic. From these bionetworks I was able to develop specific 
hypotheses about region-specific changes during reproductive aging. Overall, my data 
suggested that changes in expression of genes in the AVPV preceded the transition to 
reproductive senescence, and resulted in altered estrous cycles, even before females 
became acyclic. However, it is seemingly the ARC and ME that undergo changes 
resulting in acyclicity and infertility as there were a number of genes altered in the ARC 
and ME when comparing cyclic and acyclic expression profiles.  
 In the next sections, I will discuss why I think these results are biologically 
relevant, and discuss specific data that emphasize the points mentioned above. 
IMPLICATIONS OF THIS WORK 
 Taken together, my data provide evidence for three overarching themes in regard 
to reproductive neuroendocrinology: 1) intact animals do not display relationships in 
gene expression and hormones that have been traditionally reported. In fact, my results of 
developmental patterns of serum sex steroid hormones (E2, T, P4) bear little relationship 
to gene expression when compared to published studies investigating hormone regulation 
of gene expression in gonadectomized models. 2) Network analysis revealed that the 
AVPV relates to sexually dimorphic temporal regulation of GnRH/LH release, and the 
ARC to the preovulatory GnRH/LH surge and the timing of reproductive transitions. 
More specifically, females in my studies exposed to EDCs in utero were more likely to 




numerous genes exhibited a male-typical expression profiles from P15 – P90. However, 
the ARC was relatively unaffected. On the other hand, in both chapters 2 and 3 
reproductive transitions were affected by gestational exposure to EDCs. In males, the 
timing of puberty was delayed and in females the process of reproductive aging was 
altered. In both cases, the effects of EDCs on gene expression were observed in the ARC. 
3) I identified novel targets of endocrine disruption as well as several genes that are 
consistent targets of gestational exposure to EDCs. With respect to identifying new 
targets, to my knowledge, I am the first to report that Per2 and Arntl are sexually 
dimorphic in the AVPV and can be programmed via gestational exposure to estrogenic 
compounds. Additionally, Ar was consistently altered by gestational exposure to EDCs, 
in agreement with other studies from my laboratory (Dickerson et al., 2011b; Gore, 
2008). This suggests that Ar is a potent target of A1221, presumably through its 
estrogenic actions as similar effects were caused by EB, my estrogenic control. 
Intact animals do not display relationships in gene expression and hormones that 
have been traditionally reported 
In general, few of the predicted relationships between genes and serum hormone 
concentrations were observed in young animals or aging females. For example, as Pgr is 
well-established as being regulated by E2 (Lauber et al., 1991b, c; Quadros et al., 2002; 
Quadros and Wagner, 2008), I was expecting that this would be observed throughout my 
developmental studies. However, this was never the case in my intact rats. In the young 
animals, at no age was a significant positive correlation observed between serum E2 with 




AVPV of the 9mo old females, E2 was negatively correlated with Pgr as well as Ar and 
Esr1 (Chapter 3, Figure 3.6). These discrepancies were also observed for Kiss1 
expression, which is positively regulated by serum E2 in the AVPV and negatively 
regulated by serum E2 in the ARC (Reviewed in (Oakley et al., 2009)). However, in my 
developing animals Kiss1 expression was positively correlated with P4 in the POA after 
puberty (P45 and P60) and was often negatively correlated with serum T. In the MBH, 
Kiss1 was not significantly correlated with any serum hormone concentrations. 
Interestingly, the aging females, Kiss1 in the cyclic AVPV was positively correlated with 
Avp (a gene involved in circadian signaling from the SCN) and in the cyclic ARC was 
positively correlated with Gnrh. The one time I observed a predicted correlation with 
Kiss1 was in the ARC of acyclic females, in which Kiss1 and Tac2 were negatively 
correlated with serum E2. As a whole, these studies reveal novel and complex 
relationships between serum hormone concentrations and gene expression that are 
specific to age, sex and cycle status and brain region. They also highlight the necessity 
for further studies to include intact and cycling animals in experiments to enable a fuller 
understanding of reproductive neuroendocrinology. 
Effects of prenatal EDCs in the AVPV 
One of the most surprising findings of these studies was that Kiss1 expression 
was not sexually dimorphic in the AVPV in adult animals. Additionally, in my treated 
animals, Kiss1 expression was greater in the female AVPV when compared to the males 
on P90 (Chapter 2, Figure 2.1). I noted similar expression patterns of genes previously 




estrus but not proestrus (Esr1 (Zhou et al., 1995) and Pdyn (Simerly et al., 1996)). My 
females were euthanized during their predicted preovulatory GnRH/LH surge on 
proestrus (1 – 3 hours before lights out). These alterations in gene expression, along with 
notable changes in estrous cyclicity (especially the observation that treated animals had 
elongated periods of estrus and diestrus), suggest that the timing of the surge may be 
disrupted in the animals exposed to EB and A1221. My observation that the two clock 
genes on my array (Per2 and Arntl) were affected by treatment in a sexually dimorphic 
manner, with a masculinized pattern in females, is concordant with this as the results 
suggest a temporal misalignment of hypothalamic gene expression and reproductive 
physiology. Nevertheless, our females were still had LH surges and were fertile (data not 
shown). These data suggest that disruptions in the AVPV, even of genes known to be 
necessary for reproductive function can be overcome.  
Results from my aging study showed that the estrous cycles were elongated and 
more likely to be irregular, similar to what was observed for young adult females with 
prenatal EDC exposure. Therefore, I hypothesize that sexually dimorphic gene expression 
is reduced in the AVPV of females as they progress into reproductive senescence. I 
propose a model by which circadian genes in the AVPV such as Per2 and Arntl lose their 
sexually dimorphic expression due to the prenatal endocrine disruption (Conclusions, 
Figure 4.1). My finding of a marked reduction in sexually dimorphic expression of Per2 
and Arntl in the AVPV as females progressed from cyclic to acyclic supports this 
prediction. There is evidence that circadian responsiveness declines with aging in male 




reduction in morning E2 and P4 surges (Ahn et al., 2011) and the LH surge is delayed and 
attenuated in the aging female rodent (Scarbrough and Wise, 1990). Taken together, these 
data indicate that there is circadian component to reproductive aging that is masculinized 
by early life EDC exposures.  
 
Figure 4.1: Comparison of sexually dimorphic expression in the adult & aging AVPV. 
Cycling females are indicated in red, acyclic females are in blue (9mo only) and males 
are in black. Because both our treated and aged females had elongated cycles, we 
compared expression of Arntl, Per2 and Kiss1 to males in both ages to see if sexually 
dimorphic expression was decreased between cyclic and acyclic females. For all 3 genes, 
our DMSO acyclic females displayed similar expression to our young treated females and 
males. Serum LH is included as an indicator of the preovulatory surge. 
 
Effects of prenatal EDCs in the ARC 
 Another surprising finding replicated throughout my experiments was that Kiss1 
and Tac2 were sexually dimorphic in the ARC. Recent evidence suggests that the KNDy 









































Furthermore, Ruiz et al, reported that Tac2 is sexually dimorphic in the KNDy neurons in 
mice (Ruiz-Pino et al., 2012). The fact that the KNDy neurons were not disrupted by 
EDCs and our females were still having LH surges and estrus cycles suggests that the 
ARC may also play a role in the pre-ovulatory surge. I propose that synchrony between 
the AVPV and ARC is important for the precise regulation of the release of LH, which in 
turn results in regular estrous cycles and a precisely timed LH surge. However, 
dysregulation of the system does not lead to infertility but rather unpredictable timing of 
the LH surge. This is a plausible explanation for the differences previously observed in 
reproductive behaviors in females exposed to A1221. Our laboratory and others have 
reported that exposure to A1221 results in females being less receptive (Chung and 
Clemens, 1999) and requiring more trials before successfully mating (Steinberg et al., 
2008). If the LH surge was shifted or attenuated due to a decoupling of circadian signals 
from the AVPV and “pacemaking” signals from the ARC, the females may be “out of 
phase” with the males attempting to mate with them. 
 My results support the possibility that the timing of reproductive transitions 
involves the ARC. This is supported by my findings that males exposed to EDCs in utero 
went through puberty later than their control counterparts, and that the most robust effects 
on gene expression in males were observed in the ARC. However, it is difficult to know 
the causality, i.e., if peripheral changes preceded changes in gene expression, or vice 
versa. What can be said is that Ar and Lepr are not simply responding to changes in 




throughout development or treatment. However, there are age specific gene expression 
changes between treatment groups.  
 In the aging study, I noted that a majority of the effects of treatment on gene 
expression were in the ARC and ME of females, either cycling or acyclic. Again, it is 
difficult to determine if gene expression changes are initiating the timing of reproductive 
senescence or if they are occurring in response to peripheral changes. However, there 
were no differences in serum E2 between cyclic and acyclic females, suggesting that the 
gene expression differences were not in response to fluctuations in E2. Other hormones 
and peripheral factors may be involved, something that requires further study. While the 
exact role of the ARC in reproductive transitions is not well understood, my data provide 
intriguing evidence that the ARC is involved in this process. Future studies should 
address this question from the perspective of the AVPV and the ARC, together, as these 
two brain regions are likely to interact in the control of reproductive development and 
senescence. 
Novel targets of endocrine disruption, notably aspects of the circadian clock, and 
molecules that are consistent targets of gestational exposure to EDCs 
I identified several novel genes that were affected by gestational exposure to 
EDCs. Most notably were the 2 clock genes included on our array, Per2 and Arntl. 
Additionally, I found that Ar was consistently affected by treatment in several brain 
regions including the AVPV of my young females, the ARC of our young and aged 
males, and the ARC of the aging females. Interestingly, studies have reported sex 




regulating circadian behaviors. For example, AR protein expression in mice is greater in 
the male SCN when compared to the female. Additionally, gonadectomy reduces activity 
in the evening (ZT 12) in males but has no effect on female behavior, which can be 
restored with testosterone replacement (Iwahana et al., 2008). In gonadectomized but not 
intact or DHT treated male mice, light-induced mPER2 protein expression is decreased in 
the evening (ZT13.5), and light-induced mPER1 expression is increased late at night (ZT 
21) suggesting that the AR is involved in regulating clock genes in the SCN. It has been 
proposed that sex differences in Ar expression in the SCN are necessary to ensure activity 
coincides with the time of ovulation in females (Karatsoreos et al., 2011). This is 
supported by the finding that there are sex differences in PER2 protein expression in the 
SCN (to my knowledge other clock genes have not been investigated in the brain), 
although it should be noted that those differences are dependent on the estrus cycle. For 
example, peak Per2 gene expression in SCN explants from females is at ZT13.5 on 
proestrus and metestrus (Nakamura et al., 2010). PER2 protein expression in the SCN 
shows a similar peak at ZT 13. However, there are sex differences in the rate of decline 
after lights out. On proestrus and estrus, PER2 protein expression decreases rapidly and 
reaches a nadir by 6 hours after lights out. On metestrus and diestrus expression is similar 
to males with levels peaking at the time of lights out and remaining elevated for 6 hours. 
Interestingly, gonadectomy in both sexes results in an expression pattern that is similar to 
females in proestrus and estrus (Perrin et al., 2006).  
While previous studies have focused on the SCN, it should be noted that I saw 




(euthanized between ZT 9 – 11). In my animals, Arntl, Per2 and Ar expression in the 
treated females were similar to males throughout development. A similar finding was 
made for Gnrh1, which displays sex differences in circadian expression in the POA 
(Gore, 1998; Gore and Roberts, 1995). However, numerous other genes were not 
masculinized by treatment but instead displayed a female-typical expression pattern if the 
female was in diestrus rather than proestrus. For example, Kiss1 expression was sexually 
dimorphic in AVPV of treated animals (Chapter 2 Figure 2.1). Data from my aging study 
suggests that arginine vasopressin (Avp) is an important regulator of cyclicity in the 
AVPV as it is the only “hub” that is a gene in our bionetworks of the cycling females. 
Interestingly, Avp is one of the 2 main signaling molecules from the SCN thought to 
regulate circadian GnRH release, the other being vasoactive intestinal protein (Vip). 
Unfortunately, my PCR low-density array did not include Vip or its receptor. However, I 
did find that vasopressin receptor expression (Avpr1a) was altered by treatment in the 
female AVPV. Furthermore, expression was almost identical to that of Kiss1, with sex 
differences only observed in the treated animals.  
Thus, I hypothesize that gestational exposure to estrogenic endocrine disrupting 
chemicals results in the circadian clock being less sensitive to resetting by central and 
peripheral cues. This could lead to a phase shift in the LH surge and a decoupling of 
precise timing of activity, the preovulatory GnRH/LH surge, and reproductive behavior 
in females. Furthermore, this shift is similar to what is observed in middle-aged females 
undergoing the process of reproductive senescence. Further studies are necessary to 




throughout the day, and to perform studies in the absence of diurnal cues (e.g. in constant 
dark). Physiological and behavioral measures of circadian rhythmicity would need to be 
measured. Additionally, follow-up analysis should be conducted in the SCN, together 
with the AVPV and ARC, to add more comprehensive information about SCN and other 
central nervous system clocks. Analyses should include genes involved in circadian 
rhythms such as Vip and its receptor and a broader array of clock transcription factors. 
CONCLUDING REMARKS 
 Taken together, my dissertation provides novel insight into the mechanisms of 
basic neuroendocrinology, reproductive transitions and endocrine disruption. By 
approaching the subject of endocrine disruption from a developmental perspective, we 
were able to assess novel targets of EDCs and identify specific ages when exposure might 
be having the most profound effects. These may be useful as biomarkers of gestational 
EDCs exposure or may also be helpful in identify developmental time points when the 
effects of EDCs could be mediated. Finally, by comparing a disrupted phenotype to 
untreated and DMSO control profiles, I was able to develop new hypothesis regarding the 
functional roles of well characterized nuclei of the hypothalamus. Finally, in the human 
population, symptoms of gestational exposure to EDCs (Schug et al., 2011) closely 
resemble those identified in sleep deprived including increased risk of metabolic disorder 
(Penev, 2007), cancer (Davis et al., 2001) and infertility (Nurminen, 1998). Although 
further study is necessary, these data provide intriguing evidence for a novel mechanism 
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